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In January 2002, the New England Journal of Medicine published a 
paper entitled “Migraine-Current Understanding and Treatment,” 
written by several leading neurologists. The paper reviewed 
all the current treatment options for migraine headaches, and 
strongly emphasized triptans, a relatively new class of drugs 
developed by drug companies specifically to address migraines 
(Goadsby et. al., 2002). One of the most notable aspects of the 
paper was that it completely omitted the drug class antiemetics, 
which is increasingly used nationally and internationally, mostly 
among emergency medicine practitioners, to treat acute migraine 
headaches (Seguil & Lax, 2014). One factor for this omission may 
have been the varied perspectives which can often develop be-
tween members of different specialties of medicine, with neu-
rologists recommending one therapy and emergency medicine 
doctors recommending another (Newman, 2009). Nevertheless, 
it is likely that the authors were aware of the therapeutic history 
of antiemetics for migraine headaches, and they chose to omit 
it. In fact, the papers recommendations are completely consis-
tent with the guidelines published by the American Academy of 
Neurology (n.d.). The purpose of this review is to assess whether 
these influential omissions are in fact warranted by clinical obser-
vation and meta-analysis, or if antiemetics should be considered 
an efficacious treatment for acute migraines with the right clinical 
indications. Possible biases that could have caused conscious or 
subconscious influences on the recommendations of different 
groups will also be analyzed as a method of understandings them.
Methods
In order to assess antiemetics as an efficacious treatment option 
for acute migraines, a meta-analysis of the published literature 
was undertaken. Comparative studies between the effectiveness 
of triptans and antiemetics is the main focus. In assessing clinical 
value, both primary effectiveness and secondary side-effect prev-
alence were surveyed to accurately portray an overall picture of 
patient outcomes. Clinical trials were obtained using the National 
Institute of Health’s PubMed search engine, and only studies pub-
lished in reputable academic journals were included.  
Migraine Headaches
A migraine headache is defined as a headache that usually affects 
one specific area or side of the head and is frequently accompa-
nied by nausea, sensory sensitivity, and possible neuralgia (Ferrari, 
2013). Headaches accompanied by neuralgia have been recorded 
since ancient times, as far back as the ancient Egyptians (Miller, 
et. al. 2005). The difference between a normal headache and a 
migraine is often one of degree and thus cannot always be defini-
tively assessed; however, chronicity can be an important indicator 
of migraines. The first modern treatment for migraines was er-
gotamine (Woakes, 1868), which was originally hypothesized to 
slow the stimulation of sympathetic nervous pathways (although 
its mechanism is now contested). The pathogenesis of migraines 
was illuminated in the 1940s, when serotonin was isolated as a 
potent cause of migraines (Wolff, 1948). This discovery led to the 
serotonin-inhibiting class of migraine treatments, starting with 
methylsergide, which was first used in the middle of the 20th 
century (Sicuteri, 1959).  
This paper focuses on two modern therapies for migraine head-
aches: triptans, of which the prototype drug is sumatriptan, dis-
covered in 1988, and antiemetics, which are primarily anti-nau-
sea medications, including domperidone, metoclopramide, and 
prochlorperazine. These drugs are typically given together with 
an analgesic, usually aspirin. Other commonly used pain-relieving 
drugs, such as NSAIDs, caffeine, and codeine should be noted, but 
are not of specific interest to this discussion.
Triptans
Triptans were first used in the treatment of migraines during the 
1980’s, when interest surged in examining the role of serotonin 
(5-HT) in the pathogenesis and pathophysiology of migraines 
(Bateman, 2000). Triptans are a class of drugs that affect sero-
tonin receptors, commonly called 5-HT receptors, of which there 
are many subtypes. Triptans are 5-HT agonists, binding with high 
affinity to many 5-HT subtypes that cause potent vasoconstric-
tion of many intracranial blood vessels. They also affect various 
neurotransmitters and chemical mediators, but no specific ef-
fect has been conclusively tied to theiranti-neuralgic properties. 
Because of a variety of concerns regarding the effectiveness of 
the original triptans, such as variable bioavailability, variable ab-
sorption, and significant adverse effects, new classes of triptans 
have been continuously developed by drug companies. Some of 
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the most recent triptans typically prescribed for migraine head-
aches include almotriptan, frovatriptan, and avitriptan (Loder, 
2010). Although the mechanism of the therapy remains unclear, it 
is generally recognized in the United States as a first-line therapy 
for patients unresponsive to analgesics. Triptans provide relief of 
symptoms within the first 10-60 minutes of use, depending on 
route of entry (Loder). 
Antiemetics
Antiemetics are drugs that relieve symptoms of vomiting and 
nausea. They are usually used to treat motion sickness and to 
relieve the side effects of nausea-causing therapies. The use of 
antiemetics as a direct therapy for migraine headaches was a 
serendipitous discovery. Originally, antiemetics were used to 
allow sufferers of migraines to ingest drugs given to relieve the 
headaches. However, physicians soon began to notice that the 
symptoms of the migraine headaches were relieved before the 
primary therapy could be given. Thus antiemetics soon became 
the drug of choice, especially among emergency medicine prac-
titioners, to treat analgesic-resistant headaches (Newman, 2009). 
Comparative Studies
Unfortunately, and for possible reasons that will be addressed 
further, there are very few studies that directly compare the 
efficaciousness of triptans and antiemetics in the treatment of 
migraine headaches (Gupta et. al., 2002). However, a number of 
studies have been completed globally that directly contrast these 
two treatment options.
The first comparative study was published in 1995, comparing 
oral sumatriptan (a triptan) with lysine acetylsalicylate plus me-
topramide (an aspirin plus an antiemetic) in their effectiveness 
in treating migraines (Tfelt-Hanson et. al., 1995). This study was 
conducted between October 26, 1993 and July 18, 1994 at over 
68 medical centers in Belgium, Denmark, the Netherlands, and 
France, and included only patients with significant histories of 
migraine headaches. It was a randomized, double-blind study, 
which included follow-up for up to as eight weeks, as needed. 
Four hundred twenty-one patients participated in the study. The 
study showed that in numerous benchmarks for effectiveness, 
the two treatment options were virtually identical, including im-
provement in immediate headache severity, control of adverse 
effects, headache recurrence, and patient satisfaction. The authors 
concluded that “there is no difference in primary or secondary 
efficacy between LAS+MTC and oral sumatriptan…because of 
its high price physicians should consider whether the routine use 
of sumatriptan as the initial treatment of a migraine attack really 
is preferable to the use of cheaper drugs such as analgesics com-
bined with an antiemetic.” Indeed, in Europe and in many other 
countries, these recommendations are generally considered best 
practice (Newman, 2009).
A subsequent study was performed in three medical centers in 
France, with a total of 666 participating patients (Geraud et. al., 
2002). It was a multicenter, double-blind, randomized study, and 
follow up was performed until fifteen days after the last migraine 
attack took place.  Each patient was given one of the follow-
ing: acetylsalicylic acid plus metoclopramide, zolmitriptan, or a 
placebo. The patients were then requested to keep an hourly 
diary to record headache relief, overall pain relief, nausea lev-
els, any adverse effects, and overall satisfaction with the thera-
py. The study results seemed to be inconclusive initially, as the 
authors wrote: “Both treatments reduced migraine-associated 
nausea, vomiting, phonophobia and photophobia. There were no 
important inter-group differences with respect to the onset of 
meaningful migraine relief, the frequency of headache recurrence, 
the usage or efficacy of a second dose of medication or the use 
of escape medicine.” However, the authors preceded to perform 
what they called a “post hoc analysis,” in which they found cer-
tain benefits to triptan use, including a greater overall patient 
satisfaction, overall pain-free reporting (as opposed to headache 
pain), a greater efficacy in patients with “migraine associated with 
menses,” and the fact that triptan use was “unaffected by age, 
weight, or gender.” They thus concluded that “Although evalua-
tion using the primary end point in this study was inconclusive, 
other end points such as freedom from pain, now identified as 
more clinically relevant end points, showed zolmitriptan 2.5 mg 
to be significantly better that the standard analgesic-anti-emetic 
combination of acetylsalicylic acid and metoclopramide.” In sum-
mary, this study found slight benefits to triptan use, although it is 
important to note that for all the primary end points designated 
before the study was completed, the therapies were identical. 
Only after the data was collected did the authors find certain 
benchmarks that could be identified as benefits to triptan use. 
This is generally considered a far less objective method of gath-
ering data, as it allows the investigator considerable latitude in 
actively picking specific data sets. In what may be an important 
note, the study concludes with an acknowledgement that “this 
study was supported by AstraZeneca Pharmaceuticals.” 
A third study, performed in New York City, compared aggressive 
metoclopramide treatment, consisting of four infusions within 
the first two hours, to subcutaneous sumatriptan treatment of 
migraine headaches (Friedman et. al., 2005). Two hundred two 
patients participated in the trial. Patients were not followed after 
the initial twenty-four-hour period, which can be considered a 
weakness in their overall assessment of the therapies; in fact, only 
37 of the patients completed the twenty four-hour follow-up 
protocol. In addition, the patient population studied was almost 
completely comprised of individuals of Latino origin, making ex-
trapolations to general populations uncertain. Another concern is 
that the study excluded those suffering chronic migraines, which 
may be a population which reacts differently to specific therapies. 
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The study concluded that there were no significant differences 
between the two therapy options in reaching the primary end 
points of the study, including headache relief, nausea relief, and 
overall well-being. However, in their own post hoc analysis, the 
authors find certain benefits to metoclopramide use, including 
twenty-four-hour symptom relief. 
A fourth comparative evaluation was performed in Iran at the 
Isfahan University of Medical Sciences, comparing metoclopr-
amide to sumatriptan for migraine headache treatment (Talabi 
et. al., 2013). This study was performed on emergency room 
patients. One hundred twenty-one subjects were included in 
this randomized, double-blind study. Several introductory notes 
should be mentioned about this study. First, the command of the 
English language displayed by the authors is competent overall 
but nevertheless displays signs of possible grammatical and idi-
omatic peculiarities which may or may not result in important, 
altered connotations (for example, the authors wrote that their 
study included a “controlled study design and patient blindness”). 
Second, the study noted that “it is surprising that no subjects in 
both groups complained of adverse effects.” This is a significant 
deviation from other comparable studies, which may be a cause 
for concern. The authors attempt to explain this discrepancy as 
“a result of slow metoclopramide injection and the way the ques-
tion about these effects were phrased.” It also may be a reflection 
of cultural differences in the way side effects are described, or 
how often, or upon what level of acuteness, they are remarked 
upon.  The patients were all observed during the initial hour after 
they were treated. The results of this trial were that metoclopr-
amide was superior to sumatriptan in headache relief (Talabi). 
In summary, there are very few studies that directly compare 
triptans to antiemetics for acute migraine headache relief. The 
few that have been performed suggest that the therapies are rel-
atively similar in effectivity for all primary end points. 
Triptans vs Antiemetics: Other Differences 
The fact that triptans and antiemetics have been shown to have 
similar outcomes in treating migraines does not necessarily mean 
that they are equally sound treatment options. In fact, there are 
several reasons why triptans may be a less advisable treatment 
option. The first is adverse effects. Triptans are known to cause 
several negative effects in patients. The most common set of ad-
verse side effects, affecting almost half of all triptan users, is often 
referred to as triptan sensations, and includes upper chest pres-
sure or pain and epithelial flushing. Rare cardiovascular events 
have also been reported and triptans are thus contraindicated in 
those with possible cardiac disease. This stands in contrast to an-
tiemetics, and specifically to metoclopramide, which have minimal 
reported adverse effects. The second shortcoming of triptans is 
their often high price, with the average cost of a single triptan pill 
typically exceeding ten dollars, while a single dose of antiemetics 
can cost less than ten cents (Adelman et. al., 2004). The benefits 
of antiemetics are thus both in terms of adverse effects, which 
are minimal, and cost, as they are extremely cheap therapy to 
provide to patients. Therefore, if antiemetics can be shown to 
be comparably effective to triptans in specific clinical settings, 
which seems to be the case, they can plausibly be considered 
a superior therapy overall under those conditions. Thus it re-
mains puzzling how the 2002 review article in the New England 
Journal of Medicine completely omitted antiemetics in its review 
of migraine relief protocols, and why it is omitted from the rec-
ommendations of the American Academy of Neurology on the 
treatment of migraines. 
Medical Parochialism
Parochialism in research has been a phenomenon long noted and 
lamented by meta-researchers (March, 2005). It is often based 
on nationality, with different countries’ research communities 
favoring different approaches. These differences can have cultural, 
ideological, or experiential origins. Parochialism can also be of 
disciplinary origin. In the medical field, this has often been the 
case; for example, medical doctors and nurse practitioners often 
find themselves at odds over a variety of disciplinary differences 
(Phillips et. al., 2002). In the specific case of the triptan vs. anti-
emetic debate, the difference in recommendations may have aris-
en from the different perspectives that neurologists and emer-
gency medicine doctors have of migraine sufferers. Emergency 
medicine practitioners generally see patients who are in the midst 
of acute migraine attacks. Therefore, their perspective is geared 
toward therapies that are most efficacious at immediate migraine 
relief, and this may factor into their preference of antiemetics to 
triptans (Friedman et. al., 2014). Neurologists, on the other hand, 
see mostly patients who are chronic migraine sufferers, and may 
therefore strongly favor treatments that provide longer-lasting 
relief. Nevertheless, it must be emphasized that the review in 
the New England Journal of Medicine was a complete review of 
both acute and chronic migraine treatments, and thus explicitly 
included the medical protocols in which emergency medicine 
practitioners are most experienced. It is therefore quite possible 
that parochialism is at fault for the varying guidelines proposed to 
treat migraines, where one field’s inherent biases led it to ignore 
or be unfamiliar with the practices of other fields. (It should be 
noted, however, that the 2005 study that found that antiemetics 
were comparable to triptans was authored by emergency room 
doctors and was published in the journal Neurology.)
Pharmaceutical Funding
Surveying the comparative studies of triptans and antiemetics 
brings to the fore the often uncomfortable question of relation-
ships between for-profit companies and medical institutions and 
research facilities (Smith, 2003). Although many regulations have 
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been passed over the last few decades, which have helped pre-
vent the more egregious practices of pharmaceutical companies, 
many interactions remain that might possibly compromise clinical 
objectivity (Brody, 2005). It is certain that drug companies would 
favor the use of expensive, patented triptans over the cheap an-
tiemetic drugs, and it is thus distressing that a drug company was 
the primary funder of the single comparative study that found, in 
post hoc data examination, that triptans were a superior treat-
ment option. The other studies were free of any reportable con-
flict of interest, and came to different conclusions. In addition, the 
review article from the New England Journal of Medicine, which 
strongly focused on and recommended triptan use, closes with 
a fine-print disclosure that all the authors have been recipients 
of grant funding or have acted as consultants for many different 
drug companies, including all those that currently manufacture 
triptan medications (Newman, 2009). This fact may explain why 
the authors, consciously or not, were especially focused on trip-
tan therapy. Of course, this does not mean to slander the authors 
in any way or to impugn their professional reputation, but rather 
to bring into focus the problems associated with industry funding 
of scientific enterprises. Certainly, the fact that such funding is 
indispensable to many research projects cannot be ignored, but 
perhaps other remedies, such as the mandatory authorship of 
one author without reportable conflicts of interest, can be ad-
vanced to protect the integrity of these studies. 
Another important question regarding pharmaceutical company 
funding of medical research is the types of studies performed. 
For example, if a pharmaceutical company deems a therapy to 
be dangerous toward its bottom line, it may simply withdraw all 
funding for studies pursuing that therapy, leaving little incentive 
for researchers to pursue it. This may explain why so few studies 
have actually been performed comparing triptans directly with 
almost any other therapy, including antiemetics, and instead most 
research in the field consists of large studies, including thousands 
of patients (Ferrari et. al., 2002), which look solely at the benefits 
of triptans. 
Conclusion
A survey of comparative studies available shows that antiemet-
ics are as suitable for treating acute migraines as triptans. The 
omission of this documented treatment from prominent guide-
lines and publications is disconcerting, and may point to several 
fundamental weaknesses in the current research and application 
model. Medical parochialism and pharmaceutical funding likely 
amplified these flaws, and must be addressed as part of the solu-
tion going forward. 
References
Adelman, J.U., Adelman, L.C., Freeman, M.C., Von Seggern, R.L., 
Drake, J. Cost considerations of acute migraine treatment. Headache 
2004;44(3):271-285. doi:332283
Bateman DN. Triptans and migraine. The Lancet 2000;355(9207):860-1. 
doi:10.22938
Brody H. The Company We Keep: Why Physicians Should Refuse to 
See Pharmaceutical Representatives. Ann Fam Med 2005;3(1):82-85. 
doi:10.1370/afm.259.
Ferrari MD. Headache: the changing migraine brain. Lancet Neurol 
2013;12(1):6-8. doi:10.1016/S1474-4422(12)70290-9.
Ferrari M, Goadsby P, Roon K, Lipton R. Triptans (serotonin, 
5-HT1B/1D agonists) in migraine: detailed results and methods 
of a meta-analysis of 53 trials. Cephalalgia 2002;22(8):633-658. 
doi:10.1046/j.1468-2982.2002.00404.x.
Friedman BW, West J, Vinson DR, Minen MT, Restivo A, Gallagher EJ. 
Current management of migraine in US emergency departments: An 
analysis of the National Hospital Ambulatory Medical Care Survey. 
Cephalalgia 2014. doi:10.1177/0333102414539055.
Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopra-
mide vs sumatriptan for the emergency department treatment 
of migraines. Neurology 2005;64(3):463-468. doi:10.1212/01.
WNL.0000150904.28131.DD.
Geraud G, Compagnon A, Rossi A, COZAM Study Group. Zolmitriptan 
versus a combination of acetylsalicylic acid and metoclopramide in the 
acute oral treatment of migraine: a double-blind, randomised, three-at-
tack study. Eur. Neurol. 2002;47(2):88-98. doi:47959.
Goadsby PJ, Lipton RB, Ferrari MD. Migraine--current understanding 
and treatment. N. Engl. J. Med. 2002;346(4):257-270. doi:10.1056/
NEJMra010917.
Gupta R, Gupta S, Cady R, Dodick DW. Strategies in the treatment of 
migraine / In reply. Mayo Clinic Proceedings 2002;77(8):876; author reply 
876-7.
Lipton RB, Bigal ME, Goadsby PJ. Double-blind clinical trials of oral 
triptans vs other classes of acute migraine medication - a review. 
Cephalalgia 2004;24(5):321-332. doi:10.1111/j.1468-2982.2003.00690.x.
Loder E. Triptan therapy in migraine. N. Engl. J. Med. 2010;363(1):63-70. 
doi:10.1056/NEJMct0910887.
11
Treating Acute Migraines: Triptans vs. Antiemetics
March JG. Parochialism in the Evolution of a Research Community: The 
Case of Organization Studies. Management and Organization Review 
2005;1(1):5-22. doi:10.1111/j.1740-8784.2004.00002.x.
Miller NR, Walsh FB, Hoyt WF. Walsh and Hoyt’s Clinical Neuro-
Ophthalmology. Lippincott Williams & Wilkins; 2005.
Newman D. Hippocrates’ Shadow. Reprint edition. New York: Scribner; 
2009.
American Academy of Neurology. Pharmacologic Treatment of Episodic 
Migraine Prevention in Adults.  https://www.aan.com/Guidelines/Home/
GetGuidelineContent/541.
Phillips RL, Harper DC, Wakefield M, Green LA, Fryer GE. Can nurse 
practitioners and physicians beat parochialism into plowshares? Health 
Aff (Millwood) 2002;21(5):133-142. doi:10.1016/S0147-6736(95)91554
Saguil A, Lax JW. Acute migraine treatment in emergency settings. Am 
Fam Physician 2014;89(9):742-744. doi:22239
Sicuteri F. Prophylactic and Therapeutic Properties of 1-Methyl-Lysergic 
Acid Butanolamide in Migraine. International Archives of Allergy and 
Immunology 1959;15(4-5):300-307. doi:10.1159/000229055.
Smith R. Medical journals and pharmaceutical companies: uneasy bedfel-
lows. BMJ 2003;326(7400):1202-1205. doi:10.1136/bmj.326.7400.1202.
Talabi S, Masoumi B, Azizkhani R, Esmailian M. Metoclopramide versus 
sumatriptan for treatment of migraine headache: A randomized clinical 
trial. J Res Med Sci 2013;18(8):695-698. doi:3469954
Tfelt-Hansen P, Henry P, Mulder L., Scheldewaert R., Schoenen J, Chazot 
G. The effectiveness of combined oral lysine acetylsalicylate and meto-
clopramide compared with oral sumatriptan for migraine. The Lancet 
1995;346(8980):923-926. doi:10.1016/S0140-6736(95)91554-0.
Woakes E. On Ergot of Rye in the Treatment of Neuralgia. Br Med J 
1868;2(405):360-361.
Wolff H.G. Headache and Other Headache Pain. New York: Oxford 
University Press; 1948.
Introduction
In 490 BCE Pheidippides, a 40 year old courier ran 24.8 miles 
from Marathon to Athens to announce the Spartan victory over 
the Persians, and then dropped dead from what is believed to be 
cardiac arrest. This is the earliest mention of death due to aerobic 
activity (Trivax & McCullough, 2012). It was not until the 1970s 
that jogging would become a popular form of aerobic exercise. 
The many physical and physiological benefits of aerobic exercise 
caused this phenomenon to grow. In 2010, statistics indicated 
around 36 million people jog daily. In 2013, 541,000 people com-
pleted a marathon (which is an intense aerobic event of 26.2 
miles) in the United States alone (Schnohr, et.al. 2013 & Martin, 
2014).  It has been hypothesized that a person capable of com-
pleting a marathon is immune to coronary heart disease (Bassler, 
1974).  This hypothesis is not fully supported since a six year 
study from 1975-1980 showed that eleven men died in Rhode 
Island while running; the cause of death being coronary heart 
disease (Thompson et. al.  1982). In addition, a study conducted 
from 2000-2010, shows that out of 10.9 million people who have 
completed marathons or half-marathons, only 59 have suffered 
cardiac arrest, majority due to coronary heart disease. (Kim, et.al. 
2012). 
The World Health Organization endorses at least 150 minutes a 
week of moderate demanding aerobic activity (such as walking, 
water aerobics, and bicycling) or 75 minutes a week of vigor-
ous-intensity aerobic physical activity (such as jogging, running, 
and swimming laps) for significant health benefits (Prevention 
and Health Promotion, 2014). People may think that exercising 
vigorously for longer periods of time would increase the health 
benefits. However, it is unclear whether more intense exercise 
improves the efficiency of the cardiovascular health or if it over-
exerts the heart and thereby puts the individual’s health at risk. 
By examining the data and studying trends associated with ex-
treme exercise and productivity of the heart, this review will try 
to determine if prolonged vigorous exercise is detrimental to a 
person’s cardiovascular health.
Methods
This comprehensive review was written through the critical anal-
ysis of clinical research papers and peer reviewed journal articles. 
The necessary material was found using Touro College’s online 
databases, such as Pubmed, Medline and EBSCO. Google and 
Google Scholar were used to search specific keywords related 
to the topic.
Discussion
The Mechanism of Cardiac Contraction
Cardiac muscle contraction and relaxation has been studied 
on the cellular and molecular level. The overall mechanism for 
muscle contraction is known as excitation–contraction coupling. 
In excitation–contraction coupling, an electrical stimulus (action 
potential) transforms into a mechanical response (muscle con-
traction).  In cardiac muscle, excitation–contraction coupling 
occurs by a more specific mechanism of calcium-induced calcium 
release, a positive-feedback system where calcium induces the 
release of more calcium from intracellular Ca2+ supplies. The 
internal conduction system initiates an action potential that pro-
gresses along the t-tubules of the cardiomyocytes, resulting in 
the opening of voltage-gated L-type calcium channels. This allows 
extracellular calcium to flow into the sarcoplasmic reticulum 
causing a stimulation of the ryanodine receptors (RyR) of the 
sarcoplasmic reticulum which results in a bulk release of calcium 
into the cytoplasm.  Binding of the cytoplasm calcium to troponin 
C (a subunit of the troponin complex), results in conformational 
changes of the tropomyosin complex allowing for cross bridging 
to occur between the actin and myosin (excitation–contraction 
coupling mechanism). Contraction occurs as the actin filaments 
are pulled toward each other. All this transpires through the 
hydrolysis of ATP in the mitochondria mainly found around the 
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ryanodine receptors.  The cardiac muscle cell relaxes/repolarizes 
once there is not any calcium left in the cytosol; this is achieved 
through the different ion channels that sequester the calcium 
back into the sarcoplasmic reticulum, an ATP dependent action. 
The more intense the exercise, the more frequently this process 
happens and a variety of toxic molecules are produced (Bers, 
2001).
Biomarker Release 
The troponin complex comprises of three subunits of proteins: 
troponin I (TnI), troponin T (TnT), and troponin C (TnC).  Each 
of the three subunit proteins has specific interactions with the 
actin filaments that help regulate muscle contraction. Necrosis of 
myocardiocytes results in loss of membrane integrity, resulting in 
the release of cardiac troponin T and cardiac troponin I into the 
bloodstream.  Troponin T and troponin I are considered leakage 
markers since cardiac muscle has a different isoform than skeletal 
muscle does for each of these respective troponins. Usually, an 
increase in troponin T and troponin I in the blood is an early 
warning sign of a myocardial infarction.  It has been hypothesized 
that the elevated cardiac troponin markers found in the blood-
stream after vigorous exercise is from the cytosolic pool rather 
than from physically bound cardiac troponin (the breakdown of 
the myocyte). This means that cardiac muscle contraction is not 
affected by the increase in troponin levels in the bloodstream 
due to vigorous exercise since the damage to the membrane is 
reversible  (Wells & Sleeper, 2008).  A study examined the rela-
tionship between cardiac troponin T and left ventricle function 
in 52 runners who just completed a marathon. The 52 runners 
were screened with an echocardiogram to determine left ven-
tricle function and a blood sample assessing for cardiac troponin 
T before and after the race. The 99th percentile for cardiac tro-
ponin T in the serum assay of normal subjects is 0.01 micro-
grams per liter. The cardiac troponin T was not detected in all 
the participants before the race. However, significant increases of 
cardiac troponin T levels were observed after the race in all the 
marathon runners. Twenty runners had values above the acute 
myocardial infarction cut off of 0.05 micrograms per liter. The 
study did not find a link between these elevated levels of cardiac 
troponin T and left ventricle function. This supports the notion 
that the cardiac troponin T released into the bloodstream during 
extreme exercise is from the cytosolic pool (Whyte, et.al. 2005).
 A study of fourteen amateur runners who completed a marathon 
were tested pre and post marathon for myoglobin, creatine ki-
nase (both also biomarkers for detecting a myocardial infarction) 
and cardiac troponin T along with a cardiac magnetic resonance 
to detect myocardial necrosis.  The study was performed to de-
termine whether elevated biomarkers due to vigorous exercise 
had a relation to myocardial necrosis.  Before the race, myoglobin, 
creatine kinase, and cardiac troponin T serum levels were normal. 
Post marathon there was a significant increase in the assay serum 
levels of all the three biomarkers. If these results were found in 
a person who did not partake in vigorous exercise it would be 
cause for alarm.  When cardiac magnetic resonance imaging was 
done there was no evidence of myocardial edema on T2 imaging 
or delayed enhancement of the left ventricle myocardium. Within 
one week of the race, all the biomarker levels returned to nor-
mal. Some might say vigorous exercise is fine since there is not an 
immediate relationship found between elevated biomarker levels 
and cardiac function. However, constant vigorous exercise might 
affect cardiac function in the future depending on whether the 
increased biomarker levels are from the cytosolic pool or from 
physically bound cardiac troponin (Mousavi, et.al. 2009). These 
two studies provide some evidence to the above hypothesis 
however further studies must be conducted to understand the 
exact reason for the increase in biomarker levels.  
The Heart Rate Effect
The body’s cardiac output increases during aerobic activity, due 
to the greater demand for oxygenated blood that the body has 
during exercise. The two defining qualities of cardiac output is 
stroke volume (the amount of blood forced out of a ventricle 
during one contraction [mm/Hg]) and heart rate (the amount of 
times the heart contracts in one minute [beats/min]). The stroke 
volume is determined by three factors: the blood that fills the 
heart during diastole (preload), the force with which the blood 
leaves the heart during systole (afterload) and, the resistance of 
the aorta or pulmonary arteries. Cardiovascular exercise caus-
es more blood to be pumped out of a ventricle, resulting in an 
increased stroke volume. There is a maximum capacity that the 
stroke volume can increase to before it levels off. At this point, 
the heart rate responsible for the cardiac output pumps blood to 
the rest of the body (McArdle, et. al. 2006).
In a recent study, fifty healthy females ages 18 to 24 were ran-
domly selected to examine the benefits that moderate and vigor-
ous exercise training has on a person’s heart rate and blood pres-
sure (systolic and diastolic). Participant’s heart rate and blood 
pressure were measured before and after actively engaging in an 
exercise regimen. The exercise regimen included a thirty minute 
combination of walking (moderate exercise) and running (vig-
orous exercise) over a three month period. The heart rate and 
blood pressure was considerably lower after the three months 
of aerobic training (see Figure 1 on next page) (Munisekhar, et. al. 
2014). This data shows that moderate exercise training is benefi-
cial for improved cardiovascular health due to a decreased resting 
heart rate and blood pressure. In addition, there is reduced stress 
on the heart and artery walls. A slower heart rate also gives the 
coronary arteries more time to fill with blood and oxygenate all 
the heart cells  (Harvard, 2008).
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Long Term Exercise Conditioning 
To attain the physiological condition of “athlete’s heart” there 
must be a decrease in heart rate and an increase in hemodynamic 
demands, which modifies the stroke volume loading. As a result 
of increased hemodynamic demand there is a change in the left 
and right ventricle mass and volume; the result of which is car-
diac hypotrophy. Due to the limitation of imaging tools, this has 
been shown in the past to be predominately on the left ventricle. 
Echocardiography and MRI were used in order to study the effect 
that prolonged vigorous exercise has on both the right and left 
ventricles’ mass and volume.  Twenty-one healthy male endur-
ance athletes, with a history of exercise and a control group of 
twenty one untrained males were used in the study. In order 
to meet the criteria of an “athlete’s heart”, the heart volume of 
the twenty one endurance athletes had to be at least 13 ml/
kg. Results showed that in the hearts of endurance athletes, the 
mass of the left ventricle was 200 grams while in the control 
group the mass of the left ventricle was 148 grams. In the hearts 
of endurance athletes, the mass of the right ventricle was 77 
grams while in the control group the mass of the right ventricle 
was 56 grams. This is a significant increase in the mass of the left 
and right ventricles and reaches the criteria for hypertrophy. The 
left ventricle  and right ventricle end-diastolic volumes were also 
substantially increased in the endurance athletes compared to 
the control group (Figure 2) (Scharhag, et.al. 2002). This study 
shows that an “athlete’s heart” has a balanced enlargement of the 
left ventricle and right ventricle, which in turn indicates a benign 
balanced cardiac hypertrophy.
In another study echocardiography and electrocardiography was 
used to look at left ventricle hypertrophy remodeling in forty elite 
endurance male athletes after termination of systematic training 
(deconditioning). Of the forty endurance athletes, fifteen stopped 
all physical activity and the other twenty five changed from doing 
intense exercise to doing moderate exercise.  The forty athletes 
had left ventricle cavity enlargement of more than 60mm or wall 
thickness of more than 13mm at the beginning of the study.  After 
the average deconditioning period of six years, the 
dimensions of the left ventricle during end-diastolic 
shrunk by seven percent. The left ventricle cavity 
size still remained enlarged; more than 55mm in 
85 percent of the athletes and more than 60mm 
in 22 percent of them. The average wall thickness 
decreased by fifteen percent from 12mm at peak 
training to 10.1mm after deconditioning. There was 
not any difference between the fifteen that stopped 
all physical activity and the other twenty five that 
changed from intense to moderate exercise. The 
study showed that once there is substantial left 
ventricle dilation (hypertrophy), there is only a 
slight reversal in left ventricle hypertrophy, even 
after ceasing to do exercise for a long period of time (Pelliccia, 
et.al. 2006).
Myocardial Fibrosis
La Gerche et al. (2012) found that five of the participants (13%) 
who had greater prior exposure to vigorous exercise displayed 
delayed gadolinium enhancement (DGE) in their cardiac magnet-
ic resonance imaging baseline test. More specifically, they showed 
fibrosis and scarring in the interventricular septum. Another 
study which contained 102 healthy male runners between 50 
–72 years were matched with 102 control subjects who were 
non-runners. In order to be included in the experiment the run-
ners had to have completed at least five marathons in the past 
three years.  The results showed that 12% of marathon runners 
had myocardial fibrosis and patchy scarring, as demonstrated 
by delayed gadolinium enhancement with cardiac magnetic res-
onance imaging. This rate was three times higher than in the 
control group, who had a 4% occurrence of myocardial scarring. 
The study also did a 21 month follow up on all the participants 
and found the rate of coronary heart disease was higher in the 
runners with myocardial scarring and fibrosis then in the con-
trol group.   Even though the percentage of marathon runners 
with scarring or fibrosis is low, compared to the control group, 
the incidence of scarring is greatly higher. This author proposes 
that the development of myocardial scarring may be correlated 
Endurance Athletes Untrained Control
Comparison of volume and mass of both ventricles in endurance athlete’s vs 
untrained Control (Scharhag et�al� 2002�)
Figure 2
Figure 1
HEART RATE 
(BEATS/MIN)
DIASTOLIC BLOOD 
PRESSURE (mm/Hg)
SYSTOLIC BLOOD
PRESSURE (mm/Hg)
Before 
Training
After 
Training
Before 
Training
After 
Training
Before 
Training
After 
Training
Mean Mean Mean
Resting 78.1 68.1 66.2 62.15 99.6 95.1
Walking 126.2 106.58 76.65 67.75 115.88 102.5
Running 169.25 127.93 77.7 72.3 144.85 124.35
Mean heart rate, blood pressure (diastolic & systolic) of the 40 participants before and after 
their training: Modified from (Munisekhar, et. al. 2014).
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to prolonged engagement in vigorous exercise; in this case, the 
marathon running (Breuckmann, et.al. 2009).  
A study on myocardial fibrosis resulting from extreme training 
was performed on twelve lifelong veteran male endurance ath-
letes, twenty age-matched controls and seventeen younger male 
endurance athletes. Veteran male athletes had to have 35–52 
years of continuous intense training and younger male athletes 
had to have 11–31 years of  intense continuous training. Just as in 
the previous study, delayed gadolinium enhancement with cardiac 
magnetic resonance imagining was performed to evaluate myo-
cardial fibrosis. Results showed that in six of the twelve veteran 
athletes (50%), the existence of myocardial fibrosis and scarring 
was present. There was no sign of myocardial fibrosis found in 
the age-matched veteran controls or the younger athletes. The 
extensiveness of myocardial fibrosis in veteran athletes was not 
correlated to the age of the athlete, but rather to the amount of 
years spent training and to the amount of marathons completed. 
Even though the previous two studies were a small sample size, 
they still add validity to the correlation between extreme exer-
cise and myocardial fibrosis (Wilson, et.al. 2011).
Right Ventricle Dysfunction Immediately  
After Exercise 
Vigorous aerobic activity increases the average cardiac output of 5 
liters per minute to a maximum of 35 liters per minute (McArdle, 
et. al. 2006).  This increase puts a strain on the heart causing the 
right atrium (RA) and right ventricle (RV) to dilate. A one-time 
event will not have a negative impact since the heart will return 
to its normal size. However more consistent vigorous exercise 
can cause myocardial scaring due to the volume load and cardiac 
strain because of the chronic dilation of the right atrium and right 
ventricle. In fact, a study using cardiovascular magnetic resonance 
(CMR)  showed that running a marathon causes acute right atrium 
and right ventricle dilation and reduces the right ventricle ejec-
tion fraction (RVEF). The participants in the study were randomly 
selected; 25 healthy participants from a pool of 425 volunteers. 
Cardiovascular magnetic resonance imaging was conducted four 
weeks before and after the race. The mean age of the participants 
was 38 years and the mean time for completing a marathon was 
256 minutes. “Cardiovascular magnetic resonance showed before 
and after marathon left ventricular ejection fractions were com-
parable, 57.7 ± 4.1% and 58.7 ± 4.3%. Right atrial volume index 
increased from 46.7 ± 14.4 to 57.0 ± 14.5 ml/m2 . Also, right ven-
tricular end-systolic volume index increased from 47.4 ± 11.2 to 
57.0 ± 14.6 ml/m2 whereas the right ventricular ejection fraction 
dropped from 53.6 ± 7.1 to 45.5 ± 8.5%”. This data shows that 
marathon running causes a decrease in right ventricular ejection 
fraction due to a dilation of the right atrium and right ventricle. 
However, according to the study it does not appear to result in 
ischemic injury to any of the chambers (Trivax, et.al. 2010).
Forty healthy endurance athletes were studied following a vig-
orous event (duration of between 3-11 hours) to assess cardiac 
function at baseline, immediately post-race, and 1 week post-
race. The authors found a reduced right ventricular ejection 
fraction after the race, which was connected to the dilation of 
the right ventricle after the event. This follows the Frank–Starling 
mechanism, which states that an increase in the volume of blood 
stretches the ventricle causing the heart to contract more force-
fully. Thus, in these extreme conditions it causes a dysfunctional 
heart which is evident by the right ventricular ejection fraction. 
A greater dilation of the right ventricle caused a slight decrease 
in left ventricle volume (figure 3) (La Gerche, et.al. 2012).  This 
may be explained because the increase in ventricular load due 
to intense exercise is greater for the right ventricle then the left 
ventricle (La Gerche, et.al. 2010). The study also showed that the 
extent of right ventricle deformation is directly correlated to the 
event period.  A week after the event, all of the cardiac dysfunc-
tion returned to their baseline readings (La Gerche, et.al. 2012). 
There was a correlation found between a decrease in right ven-
tricular ejection fraction and ventricular arrhythmias (VA) in en-
durance athletes. This was a result of right ventricle dysfunction 
in 82 percent of the cases. The study performed right ventricle 
angiography on three groups: 22 athletes with ventricular ar-
rhythmias, 15 athletes without ventricular arrhythmias and 10 
control non-athletes. The study defines an athlete as one who 
has 6 hours a week of endurance exercise (running or cycling) 
for more than 5 years. Results showed that those athletes with 
ventricular arrhythmias showed a substantial decrease in right 
ventricular ejection fraction versus athlete without ventricular 
arrhythmias (49.1 ± 10.4 vs. 63.7 ± 6.4%). It was also revealed 
that the athletes who participated in vigorous exercise have 
Intense exercise effect on right and left ventricle�  The change in volume from 
baseline is showed on the left (La Gerche, et�al� 2012)�
Figure 3
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enlarged right ventricles while the control group right ventricles 
were normal, these findings are consistent with previous studies 
(Ector, et.al. 2007).
Mortality Rate
The positive effects of exercise on health are numerous. The 
greatest benefit is the overall decrease of the mortality rate due 
to physical activity. A 21 year study observed 55,157 adults from 
the age of 18 to 100 (mean age 44) to determine the correla-
tion of running with all-cause and cardiovascular mortality risk. 
Individuals with any health issues prior or present were excluded 
from the experiment. There was a questionnaire that was distrib-
uted to participants which asked specific questions regarding a 
person’s exercise training (figure 4). Of the 55,157 participants 
24% of them were involved in weekly running of some sort. 
The study found that runners had a 30% lower all-cause and 
45% lower cardiovascular mortality rate then compared with 
non-runners. The cardiovascular mortality life expectance de-
creased in non-runners by 4.1 years. These results were similar, 
as long as the weekly running time was kept under 175 min/week 
(less than 1840 MET -min/week).  Exercising more than 175 min/
week slightly increased the mortality rate but was still less than 
the non-runners mortality rate.  This was not only the case for 
time spent running but also for speed, frequency, and distance 
(Figure 3) below for the given data (Lee, et.al. 2014). 
In the Copenhagen heart study, similar results were found after 
it was adjusted to a comparable set of confounders found in the 
previous study. The authors reported with less than 150 minutes 
of exercise a week there was a decrease in all-cause mortality. 
However, exercise time greater than 150 min/week did not make 
a difference in all-cause mortality between runners and non-run-
ners. These results produced a U-curve with regard to jogging 
time versus mortality rate (figure 5) (Schnohr, et.al. 2013). One of 
the reasons may be because in this study there were only 1,878 
joggers which caused wide confidence intervals since there were 
not enough runners to equally distribute in all the different exer-
cise categories. On the other hand in the previous study by Lee 
et.al. there were approximately 13,000 joggers which allowed an 
equal distribution in the different dose running times.  
Another observational study was done by the British Regional 
Heart Study in 1978 on the decreased risk of coronary heart 
disease due to physical activity. There were a total of 7,735 male 
participants aged between 40 and 59. The male participants were 
randomly chosen from general practices in 24 British towns with-
out distinguishing whether they had pre-existing coronary heart 
disease. A typical questionnaire was conducted which asked ques-
tions on exercise and leisure activities (such as walking, weight 
lifting, and jogging). After eight years, results showed that the male 
participants without any pre-existing coronary heart disease who 
partook in moderate exercise (such as walking at 4 miles per hour) 
had decreased the risk of coronary heart disease by 50 percent, 
compared to those who were inactive. The participants with cor-
onary heart disease conditions in the past showed a comparable 
inverse relationship: decreased risk of coronary heart disease with 
increased  moderate exercise. However, those partaking in vigorous 
aerobic activity (such as jogging or running) had a higher rate of a 
heart attack than those participating in moderate exercise (Shaper, 
et.al. 1991). These three studies show that those who participate in 
weekly moderate exercise versus those who do not do any exer-
cise have less of a risk of developing coronary heart disease, and a 
lower all-cause and cardiovascular mortality rate. However these 
studies also show that there is an upper limit to these benefits 
and over exercising slightly reverses these positive effects and the 
mortality rate is similar to those who do not exercise. 
Animal Studies
In order to achieve a post-mortem look at the effect intense 
exercise training has on cardiovascular health, it is necessary to 
perform studies using animals. Rats were used to examine the 
long term intense exercise effect on cardiac function; more pre-
cisely fibrosis, which can induce cardiac arrhythmias. The Wister 
rats were separated for 16 weeks (this is equivalent to around 
10 years in humans) into exercise and sedentary control groups. 
After the 16 week experiment, some of the rats from the exercise 
group were held for another eight weeks without exercise. This 
was done in order to see if the effect that intense exercise has on 
the heart is reversible. At the end of the experiment, all of the rats 
were euthanized and their hearts were removed for dissection. 
The exercise rats were put on a treadmill for five days a week, at 
60 centimeters per second. In order to keep the rats running, a 
small shock was provided however, it was extremely low so that 
a stress response would not be elicited. Results showed that after 
16 weeks of training, the exercise rats developed left ventricle 
hypertrophy, and impaired diastolic function; which is related to 
the left atrium dilatation.  There was also right ventricle dilatation, 
Figure 4
Hazard ratio of all-cause mortality versus the amount of time spent exercising 
per week� Graph produces a U shaped curve with an optimal exercise time 
between 1-2�4 hours per week (Schnohr, et�al� 2013)� 
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impaired diastolic and systolic dysfunction.  All these symptoms 
are also found in humans with “athlete’s heart”. Right ventricle 
fibrosis was found in the histological sections. This can be due to 
the higher loading conditions on the right ventricle versus the 
left which is also consistent in humans.  TGF-β1, a fibrotic marker, 
was found in high levels in both atrium and right ventricle.  TGF-
β1 is a collagen stimulator that leads to development of fibrosis. 
Another component that was observed was the surge in colla-
gen-I [determines stiffness of cardiac muscle] protein expression 
in the right atria and ventricle, collagen-III [distensible] remained 
unchanged. This shows that the diastolic dysfunction of the right 
atria and ventricle could be due to the increased cardiac stiffness. 
Intense long term exercise effect on cardiac arrhythmias was 
evaluated in vivo, by attaching a modified catheter to the right 
ventricle apex. Inducible ventricle tachyarrhythmia was found in 
42% of the exercise rats compared to 6% of the control rats. A 
possible explanation for the higher prevalence of arrhythmias in 
exercise rats could be linked back to cardiac fibrosis.  After the 
eight week deconditioning period, all the exercise rats had almost 
all the cardiac remolding mentioned above revert to the control 
rats levels. (Benito, et.al. 2011)   There have been other animal 
studies conducted that show similar results to this one. Even 
though there are some similarities between cardiac remodeling 
in animals and humans, researchers cannot be certain that cardiac 
remodeling in both is exactly the same.
Conclusion
After intense exercise immediate testing resulted in dilatation of 
the right ventricle and atrium, reduced right ventricular ejection 
fraction, and elevated levels of biomarkers found in the blood. 
Even though there was a correlation found between reduced 
right ventricular ejection fraction and ventricle arrhythmias, the 
sample size was too small to fully determine the validity of the 
correlation. Further research needs to be conducted on the effect 
and mechanism of elevated biomarkers found in the bloodstream 
after vigorous exercise. Testing after many years of intense aero-
bic activity show that balanced cardiac hypertrophy is normally 
found in a person with the condition known as “athlete’s heart.” 
Even after many years of deconditioning, the heart does not re-
turn to its normal size. A result of cardiac hypertrophy is myo-
cardial fibrosis and scarring. The percent of myocardial fibrosis in 
those participating in prolonged vigorous activity is low; however, 
compared to the control group, the percent is significantly great-
er. Studies also show that while moderate exercise is beneficial 
to lowering a person’s all-cause mortality rate and cardiovascu-
lar mortality rate, intense exercise reverses this positive effect 
slightly. Humans share similar results found in dissections of rats 
that underwent exercise training. Though intense exercise does 
not have a positive effect on cardiovascular health, more studies 
involving a greater sample size have to be conducted to deter-
mine the extent to which vigorous exercise damages the heart. 
In addition to the negative effects that intense exercise has on the 
heart one has to consider the adverse effects that it has on the 
body and more specifically the skeletomuscular system.
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Introduction
There has been an increase in treating pregnant women with 
cancer and scientists suggest that the change in trend is due to 
older women conceiving. Reports indicate that cancer is diag-
nosed in approximately 1 in 1000-1500 pregnancies (Voulgaris, 
et al., 2011). If cancer treatment cannot be postponed until after 
birth, ethical concerns arise with regard to the health of the 
mother and fetus, and so the benefits and side-effects need to be 
discussed by patient, oncologist, and obstetrician. Factors that im-
pact treatment include cancer type and stage, gestational age and 
consequences of treatment on the mother and fetus. In addition, 
risks, treatments and, if necessary, the option of abortion must be 
determined. The goal is to determine if and at what gestational 
age treatment should be given, whether cytotoxic drugs admin-
istered to the mother impacts the development of the fetus and 
results in long-term risks for the child. 
Methods
Information and research was obtained through Ebsco, Proquest 
and Pubmed. Access was provided by Touro College library. Main 
key words included pregnancy, short-term, long-term, transpla-
cental, in utero, fetus, and chemotherapy.
Discussion
Transplacental Transfer
To first address the impact of transplacental transfer, it is essen-
tial to determine if there is drug transfer between the mother 
and the fetus, and if so, to what extent. A mouse model using 40 
pregnant mice was studied to determine the amount of trans-
placental transfer of chemotherapeutic agents, doxorubicin, epi-
rubicin, cytarabine, paclitaxel, carboplatin and vinblastine. Due to 
the difference of drug metabolism in mice, the drugs were given 
at proportionately higher dosages than when given to humans. 
Fetal and maternal blood was collected on day eighteen and a 
half, during the phase of fetal development. The mice were deliv-
ered by caesarean section ninety minutes (an arbitrary amount 
of time) after chemotherapeutic drugs were intravenously given 
to the mother. At this point in time, an increase in plasma levels 
ensured drug detection and was the first phase of distribution 
after the drugs were intravenously administered.  The drug lev-
els in the maternal and fetal plasma were detected using two 
methods. High performance liquid chromatography determined 
the amount of the five chemotherapy drugs and Atomic absorp-
tion spectrometry determined carboplatin levels, based on the 
amount of platinum in the blood.  
Plasma Drug Analysis 
Paclitaxel was found in maternal plasma, but was not detected 
in fetal plasma. It has a high molecular weight, is highly protein 
bound and is a substrate of P—glycoprotein (ATP-binding cas-
sette transporters) and multidrug resistance protein. P—glyco-
protein is found in fetal-derived epithelial cells which forms the 
maternal-fetal blood exchange border and protects the fetus. 
Vinblastine and anthracyclines, which includes epirubicin, a 
4′-epimer of doxorubicin, and doxorubicin, only presents as a 
small transfer ratio due to being P-glycoprotein substrate, which 
protects the fetus against xenobiotics’ harmful effects. Another 
factor is that it possesses pharmokinetic properties that contrast 
to the substances that cross the placenta. Thus, one can imply 
that vinblastine, anthacyclines and paclitaxel present a safe option 
for treatment when given in small dosages during the last two 
trimesters. 
However, both carboplatin and cytarabine have high transfer rates 
and can penetrate the membranes barriers since they are slightly 
bound and have a low molecular weight. Therefore, researchers 
recommended, if possible, avoiding these drugs (Calsteren, et al., 
2010; Van Calsteren et al., 2010)
The transplacental transfer is generally through passive diffusion 
and is typically penetrable. However, there are three factors that 
influence the maternal-fetal transfer.  They are: (1) maternal and 
fetal circulation concentration gradient, (2) the placental blood 
flow, and (3) chemotherapy’s drug properties.  The pharmok-
inetics of chemotherapy that favor transplacental transfer are 
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uncharged, low molecular weight, lipid soluble, and unbound or 
low protein bound compounds (Calsteren, et al., 2011).
Maternal- Fetal Transfer in a Baboon Model
The data obtained from the previous experiment, however, is 
limited in its clinical application due to the differences of human 
and mouse metabolism and permeability and formation of the 
placenta (Van Calsteren, et al., 2011). This elicited further inves-
tigation of the effects of maternal-fetal transfer of chemothera-
peutic agents given in second and third trimesters. Two studies, 
using the same subjects, examined the results of different che-
motherapeutic drugs on a group of nine pregnant baboons. Data 
more relevant to humans can be obtained from baboon models 
as compared to mice models due to the greater similarity of 
human and baboon embryological development, placental struc-
ture and function, reproductive physiology and endocrinology of 
pregnancy and drug metabolism. Based on the outcome, since 
only low levels were detected, the authors were reassured that 
the use of doxorubicin, epirubicin, vinblastine, taxanes (docetaxel 
and paclitaxel) and active metabolite of cyclophosphamide (4-
OHPC) were not damaging to the fetus. However, they were 
concerned with the results of trastuzumab and carboplatin since 
they were transferred in large or complete amounts. The study 
was limited since there was no record of long term results, and 
it was suggested that further research needed to be performed 
(Calsteren, et al., 2010).  Furthermore, other medical profession-
als contraindicate trastuzumab since it has been correlated with 
oligohydramnios, reduced production of amniotic fluid resulting 
from the drug binding to fetal renal receptors (Gziri, et al., 2012). 
Placental Perfusion Model
As it would be unethical to perform human testing on pregnant 
women to determine whether there is maternal-fetal transfer 
due to fetal risk of fetal blood sampling from the umbilical cord 
known as cordocentesis, Van Calsteren et al. (2011) suggested 
that they can be applied to a single cotyledon models that have 
separate fetal and maternal circulations. Unfortunately, some 
complications with this proposal included difficulties obtaining 
absolute physiological conditions in a perfusion system, tempo-
rary status of tissue viability, and the differences in data between 
in vivo and placenta perfusion model with some drugs (Myllynen, 
Vhakangas, 2002; Van Calsteren, et al., 2011).
An attempt was made, however, to examine the effects of ma-
ternal-fetal transfer of taxanes (paclitaxel and docetaxel) to de-
termine whether it can be a viable treatment option. The single 
cotyledons were taken from twelve placentas from uneventful 
pregnancies with each test group containing six models. The test 
groups were further divided into two groups of three, with one 
group containing high concentration of albumin (30 g/L) and the 
other group with low concentration of albumin (2 g/L). In the 
intervillous space two catheters were inserted to begin the per-
fusion and the twelve placentas were perfused for ninety min-
utes.  The results indicated that taxanes have a low transplacental 
transfer due to their chemical properties and added that there 
was no difference in amount of drug transfer between paclitaxel 
and docetaxel. Furthermore, the outcome between the groups of 
high and low levels of albumin reinforced the theory that protein 
levels affect the maternal-fetal transfer. This was supported with 
the observation of less transfer of both docetaxel and paclitaxel 
with high levels of albumin. Although this reinforced previous 
studies of placental transfer, sample size was too small and fur-
ther investigation should be performed (Berveiller, et al., 2012). 
Factors and Effects of Chemotherapeutic Drugs
Based on research that positively indicated transplacental trans-
fers of chemotherapeutic drugs, studies were initiated to deter-
mine the drug effect on the developing fetus. There are four main 
drugs that are typically administered to pregnant cancer patients. 
They are:  anthracyclines (e.g., doxorubicin, epirubicin), plati-
num-based antineoplastics (e.g., cisplatin, carboplatin), cyclophos-
phamide and taxanes (e.g., paclitaxel, docetaxel). Anthracyclines 
result in cardiotoxicity and inhibit topoisomerase, interfering 
with DNA replication. Platinum based antineoplastics result in 
neurotoxicity and ototoxicity if given at high doses. It also allows 
for apoptosis to occur since it binds to and causes crosslinking of 
DNA. The effect of cyclophosphamide is permanent infertility if 
given at high dosage. Lastly, taxanes disrupt the microtubule func-
tion in cell division thereby inhibiting mitosis (Vandenbroucke, et 
al., 2014). The overall similarity between them is that they halt 
normal cell proliferation cycles which results in interrupting cru-
cial cell processes. Studies on somatic cell mutations report that 
some adverse effects of chemotherapy are gene mutations, chro-
mosomal breaks and rearrangements, and aneuploidy (Arnon, et 
al., 2001).
The impact of chemotherapy on the fetus can vary due to phys-
iologic changes in the pregnant patient. Some examples that may 
occur include an increase in glomerular filtration, which increases 
the amount of elimination or drug excreted by the kidney, and an 
increase of drug metabolization in the liver, which might impact 
the presence of active drugs. Additionally, there is an increase in 
entero-hepatic circulation in pregnant women. This causes active 
metabolites to return to the liver and then colon after being 
secreted from bile into the colon and reabsorbed by enterocytes. 
The circulation prolongs the drug exposure since it lengthens 
the time needed to eliminate the drug from the body because it 
returns to the blood stream. The amount of active drugs available 
can decrease due to an increase in protein binding which results 
in a greater impact of cytotoxic drugs. However, plasma levels 
of cytotoxic drugs may be reduced as a result of an increase in 
plasma concentration (Amant, et al., 2008). The third space that 
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develops in pregnant women resulting from an increase of amni-
otic fluid can also impact the distribution volume of chemother-
apy, causing a slow release of drug which results in an increase 
of fetal chemotherapy exposure (Williams, Schilsky, 2000). Other 
factors that impact the maternal chemotherapy on the fetus are 
metabolic activity and excretion of the placenta, increase of body 
fat of the pregnant patient and pH difference between maternal 
and fetal fluids (Gedeon, Koren, 2006). When creating a treat-
ment plan, these physiologic changes must be considered.
Various other factors can also result in teratogenic risks to the 
fetus. Although the placenta can excrete fetal waste products and 
assist in fetal drug elimination, some antineoplastic agents may 
not be eliminated from the fetus if drugs are administered close 
to delivery time. Additionally, due to the fetus’s immature liver 
and kidney, the fetal metabolism and excretion of the chemo-
therapeutic drugs may be abnormal. This can result in an increase 
of chemotherapy exposure and acute toxicity (Williams, Schilsky, 
2000).
Administration Variables
The effect on the fetus is not only dependent on drug type and 
performance, but is also based on dose, route and gestational 
age. Studies have proven higher toxicity can develop from short 
infusions, topically applied cytotoxic agents and intraperitoneal 
administration.¬ Drugs given orally may be absorbed less due 
to a decrease of elimination from the stomach and intravenous 
administration can result in fetal risks. As mentioned previously, 
prolonged drug elimination from the mother also impacts the 
toxicity on the fetus (Wiebe, et al., 1994).
Chemotherapy Exposure- Fertilization/
Implantation
To determine the effect of chemotherapy on the developing 
embryo and fetus, observations were performed during the 
three stages of pregnancy. The three phases of fetal develop-
ment are fertilization/implantation, organogenesis, and the fetal 
phase. Chemotherapy is cytotoxic, thereby inhibiting cell growth. 
Therefore, exposure during the first ten days of pregnancy, the 
stage of fertilization/implantation, results in an all-or-nothing phe-
nomenon. Cells are omnipotent and may develop into the three 
different embryological layers, ectoderm, mesoderm and endo-
derm. However, their ability to develop normally is dependent 
on the impact of maternal chemotherapy. If there is a sufficient 
amount of cells, the embryo will develop normally, but a miscar-
riage can occur if too many cells are destroyed by the chemo-
therapeutic drug (Reed, et al., 2010). 
Chemotherapy Exposure- Organogenesis
During the first trimester, it is highly inadvisable to treat the 
mother with cytotoxic drugs.  Voulgaris et al. reports (2011) that 
there is a 10-20% chance of teratogenicity, fetal malformation, 
occurring if agents are administered in the first trimester. An in-
crease of embryonic death can occur if there is damage to the 
embryo in the first month of gestation resulting from chemother-
apy exposure (Voulgaris, et al., 2011).  Spontaneous abortion and 
major malformations are also possible risks that can occur.  The 
fetus is more susceptible to malformations two to eight weeks 
after conception, the period of organogenesis. Specifically, the 
heart, neural tube, and limbs are more vulnerable, preceding the 
palate and ears of the fetus. If chemotherapy exposure continues 
after eight weeks, the eyes, genitalia, hematopoietic and central 
nervous system still remain at risk (Cardonick, Iacobucci, 2004). 
This strongly reinforces that maternal chemotherapy should be 
avoided in the first trimester.
Chemotherapy Exposure- Fetal Phase of 
Development
Based on observations of the fetus exposed to maternal che-
motherapy during the final two trimesters, researchers have 
suggested that these exposed fetuses did not exhibit more 
congenital malformations than fetuses from untreated mothers. 
Nevertheless, intrauterine growth restriction, low birth weight 
and neonatal myelosuppression have been detected in neonates 
exposed to chemotherapy in the second and third trimester 
(Cardonick, Iacobucci, 2004; Van Calsteren, et al., 2011). From 
week eleven until delivery, functional damage will frequently 
occur as a result of cell death.  In addition, some organs may later 
develop structural anomalies. For instance, the fetus can develop 
neuropsychological impairment since the central nervous system 
is progressing throughout gestation (Vandenbroucke, et al., 2014). 
Short-term Effects -Obstetric and Neonatal 
Outcomes
One study reported on 62 patients who were treated predom-
inantly in the last two trimesters with chemotherapy alone or 
combined with other treatments, such as radiotherapy. These 
patients were part of a sample of 180 pregnant women who re-
ceived various treatments for cancer.  The results were analyzed 
to determine the fetal risks of treated and untreated mothers 
diagnosed with cancer.
Regarding patients treated with chemotherapy, there was a sig-
nificant increase in preterm labor, but not in the rate of preterm 
premature rupture of membranes (PPROM) when compared to 
neonates not exposed to maternal chemotherapy.  However, the 
only incidents of preterm labor and PPROM that occurred in the 
180 cases analyzed involved patients treated with chemotherapy. 
Preterm labor can occur from the activation of hypothalamic-pi-
tuitary-adrenal axis of either the mother or fetus resulting from 
physical or psychological stress. Scientists propose that PPROM 
can result from apoptosis in amnion epithelial and chorion 
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trophoblast layers of the membranes after maternal chemother-
apy exposure (Van Calsteren, et al., 2010).
The risks of preterm labor include intraventricular hemorrhage, 
bradycardia, apnea, respiratory insufficiency, necrotizing entero-
colitis, sepsis, seizures, hypoglycemia, and feeding problems (Van 
Calsteren, et al., 2010).  Additionally, Johnson (2007) reported 
that preterm births are associated with a decrease in IQ scores, 
cognitive delay, behavioral problems and higher risk for psychiat-
ric disorders, primarily ADHD. Preterm labor in this research was 
preventable since several of the neonatal issues were iatrogenic. 
Therefore, researchers suggested that patients that can delay 
treatment until after delivery should do so to avoid prematurity 
(Van Calsteren, et al., 2010).  
Data of small-for-gestational-age children was available for only 
175 neonates. Regarding those treated with cytotoxic treatments 
(chemotherapy and/or radiotherapy), 16 of 66 children were 
small- for- gestational age as opposed to 10 of 109 children who 
were not exposed to maternal chemotherapy/radiotherapy. 
The malformation outcome in comparison to normal pregnan-
cies reveals that there was no significant increase in rate. The 
range of physical abnormalities of neonates exposed to maternal 
chemotherapy was still within normal range, with 2 of 66 (3.0%) 
inflicted with major malformations and 5 of 66 (7.5%) affected 
with minor malformations. The average rate of major and minor 
malformations was 4.1% to 6.9% and 6.5% to 35.8%, respectively. 
This suggests that the concern of malformation defects due to 
chemotherapy is not applicable and should not deter patients 
from avoiding treatment (Van Calsteren, et al., 2010).   
Another fetal risk that may occur is transient neonatal myelosu-
pression (TNM).  Elburg et al. (2008) defined TNM as “leukopenia 
and/or neutropenia combined with anemia and/or thrombocy-
topenia, during the first weeks of life in newborns exposed to 
maternal chemotherapy during pregnancy.” The disease is rare, 
potentially life-threatening and may not necessarily develop 
right after birth. Additionally, it may pose a risk for developing 
infections. The development of TNM may result from a short gap 
between chemotherapy administration and birth, maternal neu-
tropenia at delivery, type of chemotherapy and maternal disease 
and dosage given. Treatments for TNM include thrombocyte and/
or erythrocyte transfusions, bedside isolation, erythropoietin, 
and recombinant human granulocyte colony stimulating factors 
(G-CSF).   In a study of fifteen neonates diagnosed with TNM, 
only one died due to infection resulting from TNM. However, 
the other fourteen neonates’ physical and neurological devel-
opments were normal by the age of one and their TNM was 
resolved between two to ten weeks after birth.  Generally, there 
is no difference detected in short term outcomes and survival 
rates between neonates exposed to chemotherapy that develop 
TNM and those not diagnosed with TNM. Researchers stated 
that this is true as long as the disease is recognized and aggressive 
treatment is given. However, the long-term consequences are still 
unknown (Udink ten Cate, et al., 2009).  
 Another study performed by Aviles et al. (1991) consisted of 
43 infants exposed to maternal chemotherapy. The infants were 
examined from age three through nineteen years old and it was 
observed that only eight were pancytopenic at birth, which char-
acterizes them as being deficient in red and white blood cells 
and platelets. However, the mothers of these neonates were 
treated with chemotherapy in the last three weeks prior to de-
livery which disputes the suggestion that a short gap between 
chemotherapy administration and delivery results in TNM.  There 
were no congenital anomalies and neurological abnormalities re-
ported and like the findings of the Udink ten Cate et al. (2009) 
study, the TNM resolved 2-10 weeks after birth. In addition, in a 
study of 62 patients, two children suffered postnatal hematolog-
ic toxicity (leukopenia and pancytopenia) when born ten days 
after maternal chemotherapy administration for acute lymphatic 
leukemia and required hematologic growth factors as treatment 
(Calsteren, et al., 2010). This study supports the theory, unlike 
Aviles et al. (1991) that a short interval between the chemother-
apy administration and delivery can result in hematologic toxicity. 
As seen with these results, hematologic toxicity can present a 
slight concern for pregnant women with cancer, yet the risks are 
minimal if proper treatment is given.
Cardonick and Iacobucci (2004) have studied the impact of che-
motherapy given after the first trimester on 376 fetuses. Of the 
376, nineteen of the fetuses and four of the neonates died, 28 
neonates were born with intrauterine growth restriction and 18 
were born prematurely (iatrogenic cases excluded). Additionally, 
two were diagnosed with transient neonatal cardiomyopathy due 
to maternal idarubicin treatment, fifteen neonates developed 
transient neonatal myelosuppression. Eleven malformations were 
also reported with the majority resulting from chemotherapy 
exposure in the first trimester.
Another study was performed which was composed of 61 pa-
tients receiving chemotherapy during the second and third tri-
mesters. Of the 61 patients, 32 were treated with neoadjuvant 
chemotherapy and 2 received adjuvant chemotherapy. The 61 
neonates that were exposed to maternal chemotherapy were 
examined and compared to 60 neonates who were born prema-
turely and were not exposed to maternal chemotherapy. Results 
suggested that there were no differences in birth weight, admis-
sions to the NICU, and neonatal survival. No malformations were 
reported in either group. Nonetheless, one contrast between the 
groups was the considerable difference in Apgar score, which 
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tests the future neurobehavioral development first at one minute 
after birth, then five minutes after and after ten minutes after 
birth. The results favored the group of children not exposed to 
chemotherapy at one and five minutes, but there were no sig-
nificant difference at ten minutes. Although it reflects positive 
short-term outcomes, it’s limited in long-term follow up on these 
children and researchers suggest further studies need to be per-
formed (Abdel-Hady, et al., 2012). 
Fetal cardiotoxicity was also researched to determine whether 
it can develop from maternal chemotherapy and pose a threat 
to neonates. One study consisted of ten pregnant patients treat-
ed with anthracyclines in the last two trimesters to investigate 
whether these drugs, which are thought to cause fetal cardiotox-
icity, can result in fetal cardiac abnormality. The results indicated 
that one fetus was diagnosed with fetal supraventricular tachy-
cardia, but researchers believed it was unrelated to maternal che-
motherapy.  Additionally, differences in myocardial performance 
index and in the tricuspid inflow pattern were detected, but were 
considered clinically insignificant. The neurological development 
and weight, height, and clinical examination of the fetuses in the 
study group were within normal limits. Significant cardiac abnor-
mality and intrauterine growth restriction were not detected, al-
though low birth weight was observed. Although the researchers 
gathered data systematically, the study was small and therefore 
limited (Gziri, et al., 2012). 
Long Term Effects
A concern of maternal chemotherapy is the long-term cardiotoxic 
effects on the fetus. A study used tissue Doppler and strain imaging 
to identify any specific changes in cardiac performances that might 
result from chemotherapeutic drug. The study focused on children 
exposed to anthracylines, a drug shown to cause cardiomyopathy 
and cardiac dysfunction.  The children’s ages ranged from 1-9 years 
old, with the mean age being 1.7 years old. Those exposed to anth-
racyclines were observed to have minor changes in left ventricular 
(LV) wall thickness that might have occurred from the effect of 
anthracycline’s toxicity. Anthracycline is known to lead to loss of 
cardiac muscle. There was also indication that there might be a 
lower, but normal ejection fraction and left ventricular ejectional 
fractional shortening, which is not clinically important since there 
is no change in functionality. Since there were no differences in tis-
sue Doppler and strain imaging between the control group and pa-
tients, researchers indicated that there was no change in myocardi-
al function. They stated that changes recorded could have resulted 
from the fact that the majority of the neonates born were preterm. 
Overall, their observation showed that there was no significant 
change between the 62 patients and 62 age gender-matched con-
trols. Researchers recommended further research to observe any 
future irregularities and suggested performing further studies with 
larger patient groups with proper follow up (Gziri, et. al., 2013).
Further research was performed to assess the neurodevelop-
ment, cardiac function, and general health of 70 children who 
were exposed to chemotherapy in utero. Seventy children from 
68 pregnancies (two twin pregnancies) were assessed at age 18 
months and at ages 5–6, 8–9, 11–12, 14–15, or 18 years.  The me-
dian gestational age at birth was 35.7 weeks, with a median fol-
low-up period of 22.3 months. Most of the children had normal 
cognitive development. However, children who were born pre-
maturely had lower cognitive development scores albeit within 
normal range of cognition.   Moreover, for each additional month 
of gestation, the IQ score increased by an average 11.6 points. 
Therefore, iatrogenic preterm delivery is not suggested since it 
significantly impacts the cognitive development. 
Additionally, because the CNS continues to develop after the 
first trimester, the possibility that maternal chemotherapy may 
adversely affect neurological development is a serious concern 
(Gziri, et al., 2012). However, only one set of twins of 70 children 
observed experienced severe neurodevelopmental delay. This 
cannot be completely attributed to the exposure to a chemo-
therapeutic drug (Amant, et al., 2012). The cortex of the fetal 
brain develops surface sulci and gyri at 14 weeks gestational age 
and doesn’t remain the original smooth cerebral surface. The for-
mation of polymicrogyria, in which the cerebral cortex develops 
abnormally before birth in the deeper layers and excessive gyri 
form, removes some of the probability that chemotherapy expo-
sure after 15 weeks instigated the developmental delay observed 
in the twins (Amant, et al., 2012; Barkovich, et al., 2010). Yet, the 
researchers did acknowledge that although the neurodevelop-
ment was normal in the overall researched group, subtle changes 
could occur and further research on longer follow-ups should 
be conducted.
Nonetheless, the average results of the children’s behavior, gen-
eral health, hearing, and growth were within the normal range, 
along with their cardiac dimensions and functioning. No increase 
in CNS morbidity was recorded. Although there were no con-
genital cardiac abnormalities detected, further study was recom-
mended on the cardiac function since there were clinically small, 
but statistically significant changes in ejection fraction, fractional 
shortening and diastolic variables. They did detect, however, a 
higher incidence of disharmonic intelligence profiles. The results 
of the Wechsler test depicted a discrepancy between verbal 
and performance IQ values. This was seen in 39% of patients in 
comparison to 15% in the normal population. The discrepancy 
has been associated with several neurological disorders, learning 
problems and behavioral issues. 
The study was limited due to the small sample size, short fol-
low-up periods, and lack of children born at the same gestational 
age and similarly assessed, who were not prenatally exposed to 
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chemotherapy. Additionally, researchers could not predict if sec-
ondary malignancy and infertility would have developed due to 
time constraint of the experiment. Only one twin, who also had 
congenital malformation, was diagnosed with secondary malig-
nancy and suffered from papillary thyroid cancer at age eleven 
and neuroblastoma at age fourteen. 
Nonetheless, the researchers suggested that chemotherapy not 
be administered after 35 weeks since this can trigger sponta-
neous labor. Delivery, they stated, should be arranged to be no 
less than three weeks after the last chemotherapy cycle. This en-
sures that the bone marrow recuperates properly, prevents the 
development of fetal and maternal sepsis and hemorrhage and 
hematological toxicity. As mentioned, preterm delivery should be 
avoided due to the impact on cognitive development. Preterm 
neonates are limited in their capacity to metabolize and elimi-
nate drugs since they have immature liver and kidneys. Therefore, 
if delivery can be postponed, the fetus can excrete the drug 
through the placenta instead.
The positive outcome led the researchers to conclude that there 
are three factors that may reduce the risks associated with ma-
ternal chemotherapy. First, is that maternal chemotherapy admin-
istration should be given after the first trimester, as this avoids 
the period of increased susceptibility of the fetus to toxicity. 
Secondly, they believe that the fetal blood brain barrier protects 
the brain from drug diffusion with tight junctions and decreas-
es rates of transcytosis and expression of specialized influx and 
efflux transporters, such as P-glycoprotein. Furthermore, vascu-
lar permeability and CNS immune cell infiltration is decreased 
through the inhibition of pericytes. Lastly, they suggest that the 
fetus is protected since the plasma filters the chemotherapeutic 
drugs (Amant, et al., 2012).
The most reassuring study which demonstrated the safe use of 
maternal chemotherapy was the observation on the long-term 
effect on 84 children/adults with a follow-up period of 6-29 years. 
The mothers of these children were diagnosed with hematologi-
cal malignancies, and were treated with intense chemotherapeutic 
agents given in adequate doses. The treatments, however, varied 
in which trimester the dosage was administered. Observations of 
the children/adults reported that the height, weight, birth and cy-
togenetic material were normal and that there was no evidence 
of cellular damage. Additionally, educational performance and 
neurological and psychological evaluations were on par with the 
general public. Furthermore, sixteen of patients were married, 
with twelve children born in total, who also did not suffer from 
any abnormalities. Although many doctors disagree, research-
ers in this study suggest that treatment can be given in the first 
trimester due to their positive results (Aviles, Neri, 2001). This 
gives positive encouragement to pregnant cancer patients since 
it provides concrete evidence that the fetus can escape harm and 
develop normally into a healthy accomplishing adult.
Conclusion
Overall, transplacental transfer of cytotoxic drug is not detect-
ed in all of the treatments and its impact varies based on the 
physiologic changes in pregnant women and the pharmokinetics 
of drugs administered. Many emphasize that chemotherapeutic 
agents should certainly be delayed and only be given after the 
first trimester since the fetus is highly vulnerable to teratogenic-
ity. When given in the final two trimesters, risks can still persist. 
However, this should not prevent the mother from seeking treat-
ments due to insignificant short-term and long-term effects. 
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Introduction
Carcinoma of the prostate, more commonly known as prostate 
cancer, is a malignant tumor that develops on the prostate –a 
male organ that wraps around the urethra. Prostate cancer can 
occur in many different forms, such as carcinoid, small-cell tu-
mors, and ductal carcinoma, however, these types are extremely 
rare and little is known about which treatment most effectively 
eliminates them. The vast majority of cases are adenocarcinoma, 
a tumor that originates in the gland cells. Prostatic adenocarcino-
ma is observed in over 95 percent of patients (National Cancer 
Institute 2014) and affects 15 percent of men predominantly 
above the age of 66, making it the most common cancer among 
American males (SEER 2014). Fortunately, prostate cancer tends 
to grow extremely slowly, and early treatment can often yield 
high survival rates. The most common treatment interventions 
for prostate cancer include surgery or radiation therapy. Within 
radiation therapy there are two methods, external beam radia-
tion therapy (EBRT) and internal radiation therapy. The latter, also 
referred to as brachytherapy, involves the placement of radioac-
tive pellets within the prostate gland that release a highly con-
centrated dose of radiation to eliminate the cancerous growth. 
External beam radiation therapy is employed by using a linear 
accelerator to accelerate electrons close to the speed of light 
and strike them against a metal plate. On impact, high-energy, 
ionizing photons are produced, which travel towards the targeted 
cancerous cells. The high amount of energy in the photons can 
irreparably damage vital structures in the cell such as DNA, RNA, 
or protein. Photons are able to directly harm the cancerous cells’ 
DNA by energizing its electrons and pulling them out of their 
orbits. This produces free radicals, causing irreversible damage by 
altering the chemical structure of the nucleotides. Ionizing radi-
ation can also delete, fragment, and translocate the nucleotides. 
Radiation can also indirectly harm DNA when photons collide 
with a cell’s water molecules and energize its electrons. When 
a water molecule’s excited electrons bounce out of their orbits 
it produces a hydroxyl ion (OH-). The hydroxyl ion is then able 
to extract a hydrogen atom from the deoxyribose part of the 
DNA, ruining the nucleotide’s chemical configuration. Direct or 
indirect radiation damage to a cancerous cell’s DNA is usually 
lethal. This is because the uncontrollable growth of the prostate 
cancer involves the mutation of the tumor suppressor gene TP53 
(Wang et al. 1997). The protein that TP53 codes for is not only 
responsible for regulating the cell cycle, it is also responsible 
initiating DNA repair. As a result, cancerous cells are ineffective 
at repairing radiated DNA, and the cell’s ability to proliferate is 
practically destroyed. Damaging 1000 nucleotides in DNA only 
takes one cobalt grey equivalent –the unit measure of radiation 
used during treatment. 
Although external beam is an effective form of treatment, it also 
delivers radiation to surrounding healthy tissue. This is because 
before the advent of image guided treatment, physicians had to 
target the entire prostate to ensure that the entire tumor was 
radiated. Additionally, since the dose of radiation is gradually re-
duced as the beam passes through the patient, tissue directly in 
front of the tumor must be radiated to the prescribed dose. This 
leaves a track of radiation damage as the photons enter the body 
until it reaches the tumor. Furthermore, photons are massless 
particles and are not stopped or slowed down when they impact 
body tissue. This causes healthy tissue behind the tumor to re-
ceive radiation when photons travel past the tumor. Radiation to 
nearby healthy tissue often causes gastrointestinal and genitouri-
nary toxicity, which can impair the patient’s quality of life. 
Advances in radiotherapy have greatly reduced these problems. 
The advent of three-dimensional conformal radiotherapy (3D-
CRT) helps radiation oncologists treat prostate cancer more ef-
fectively. This sophisticated computer program creates a three-di-
mensional map to conform the radiation beam to the shape of 
the cancer and its surrounding normal tissues. Concentrating the 
beam more accurately to the cancerous area reduces the expo-
sure of normal tissue to radiation, further reducing side effects 
after treatment. More recent advances in high precision target-
ing have led to intensity-modulated radiotherapy (IMRT), where 
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there is an even more effective manipulation of the radiation 
beam. The beam in IMRT is divided into multiple ‘beamlets’, aimed 
at the target from different directions. The ‘beamlets’’ shape and 
intensity are adjusted to avoid radiating nearby healthy tissue. By 
taking advantage of intensity-modulated ‘beamlets’, IMRT is able 
to deliver higher doses of radiation to the prostate. This arguably 
ensures greater eradication of cancerous cells while sparing even 
more healthy tissue than 3D-CRT. Additional advances include 
image-guided radiotherapy, which provides more accuracy to the 
targeted area in the event that patients or the organs inside them 
move during treatment. 
Despite all the improvements in radiotherapy healthy tissue be-
hind the tumor is still getting bombarded with radiation. Proton 
therapy is able to stop this. Proton therapy involves the ther-
apeutic use of protons to radiate the DNA of cancerous cells. 
Protons are positively charged heavy particles, approximately 
1800 times the mass of an electron. Therefore, protons need a 
particle accelerator to strip hydrogen atoms of their electrons, 
accelerate them to nearly the speed of light, and shoot them into 
tumors. Particle accelerators, either cyclotrons or synchrotrons, 
require an enormous amount of space, which makes the cost 
of a particle accelerator exceed 100 million dollars (National 
Association for Proton Therapy 2010). Upon entering the body, 
protons slow down due to their heavy weight and their attrac-
tion to the electrons in the body’s cells. Consequently, physicians 
must program the particle accelerators to provide the protons 
with enough energy to reach the cancerous cells. After traveling 
the specified distance protons stop abruptly, depositing most 
of their energy at the targeted cells, sparing harmful radiation 
to the healthy cells behind the tumor. This biologic phenome-
non, of depositing high dose and energy of the beam within the 
tumor while having minimal energy deposited beyond the tumor 
is known as the Bragg Peak Effect. During radiation treatment, 
physicians modify the Bragg peak and extend its distance to cover 
the entire depth of the tumor, ensuring that the entire tumor 
is radiated. Extending the distance of the Bragg Peak is accom-
plished by treating the tumor to different energies, which sends 
multiple sprays of protons to different depths of the tumor. This 
manipulation of the proton beam is called the Spread-Out Bragg 
Peak. Additionally, protons do not deposit much radiation when 
they enter the body. Taking advantage of the Bragg Peak Effect 
and the low entrance dose, proton therapy should theoretically 
achieve less exposure of radiation to normal tissue. This is be-
lieved to lead to higher prescribed doses, reduced complications 
of therapy, and greater efficacy in eradication of the tumor than 
any other form of radiotherapy. 
Methods
Literature for this article was obtained using the Touro College 
Online library, in particular PubMed.
Discussion
Over the past decade, intensity-modulated radiotherapy has be-
come the standard form of radiation treatment for prostate can-
cer, accounting for more than 80% of all radiotherapy (Nguyen 
2011). Although IMRT is the most common method of radiation 
treatment, new forms of treatment are still emerging, most no-
tably proton beam therapy. Proton therapy is currently being 
implemented at various cancer centers across America because 
of the excitement over the radiological advantages protons seem 
to offer. Even though there is a lot of enthusiasm over PBT, no 
factual evidence to prove protons are better than photons has 
been found. The lack of evidence in conjunction with the enor-
mous cost of delivering the treatment is compelling physicians 
to determine if protons are more beneficial. To date there has 
been no clinical study that establishes that protons have a major 
advantage in cancer cure rates. This is because it is difficult to 
conduct cure rate trials, since such differences take many years to 
manifest. Therefore, the initial studies on proton therapy focus on 
treatment related toxicity and quality of life (Pearson et al. 2007). 
The organs most frequently affected by radiation toxicity after 
treatments are the bladder and rectum.
Dosimetric Analysis
A dosimetric analysis is the estimated measurement of ionizing 
radiation from the dose that is absorbed by nearby organs and 
is projected before treatment is delivered. This analysis helps 
physicians determine if there will be toxicity to nearby healthy 
tissue, which can downgrade the patient’s quality of life. A study 
comparing the dosimetry of intensity-modulated radiotherapy 
and proton therapy was conducted to discover if protons spare 
more healthy tissue than photons on the bladder and rectum. Ten 
Figure 1
The graph compares the Bragg peaks of IMRT vs� Proton beam therapy� 
Protons, unlike photons, are clearly seen to delivery most of the radiation at 
the targeted cell� 
(Mohan et al� 2013)
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patients were planned with both three dimensional conformal 
proton therapy and intensity-modulated radiotherapy. The pre-
scribed dose for both treatments was 79.2 cobalt gray-equivalent 
(CGE) to the prostate gland. The study concluded that protons 
reduce the area of nearby healthy tissue that inadvertently re-
ceives low to medium, but not high doses of radiation. In contrast, 
intensity-modulated radiotherapy spreads more low and medi-
um doses of radiation over a larger area of the pelvis (Table 1) 
(Trofimov et al. 2007). IMRT likely ‘bathes’ the pelvis with low to 
medium doses of radiation because it uses multiple ‘beamlets’ to 
target the tumor from different directions. As a result, there are 
more entry points into the patient’s body as radiation is shot 
from the linear accelerator to the tumor.
More significant results were reported by a study from the 
University of Florida. The study also used 10 patients to compare 
proton beam therapy treatment with intensity-modulated radio-
therapy, but with a prescribed dose of 78 CGE (Table 1) (Vargas et 
al. 2008). The difference in results between the study by Trofimov 
et al, in comparison to Vargas et al, can most probably be attribut-
ed to the difference in beam margins and arrangement. To be 
certain the cancerous growth was completely radiated, Trofimov 
et al, added a 10 mm margin around the clinical target volume, 
Vargas et al, only added 5 mm by 8 mm. By minimizing the mar-
gins, Vargas was able to better conform the beam to the tumor. 
When IMRT was delivered both studies used 7 beams, 52° apart 
from each other. However, for proton therapy, only Vargas et al 
optimized the beams. Beam angle optimization means physicians 
determine the ‘beamlet’ angles and intensities, so that the beams 
strike the tumor while sparing as much normal tissue as possible. 
Two steps are taken when determining the correct beam angle 
and intensity. “First, the physicians through their experience and 
intuition decide the arrangement of the beams. Secondly, based 
on the orientation of the beams and the shape of the cancer, 
computer software optimizes the beam intensities.” (Bertsimas 
et al. 2013). 
A clinical investigation conducted by Chera et al, did not use 
beam angle optimization, but used the same prescribed dose and 
similar margins to Vargas et al (Table 1).  Chera et al, concluded 
that the, “use of PBT significantly reduced the dose to normal 
tissues in the pelvis while maintaining adequate target coverage 
compared with IMRT” (Chera et al. 2009). Although the abso-
lute difference between the two treatments was greater in the 
study by Chera et al, Vargas et al, managed to spare slightly more 
healthy tissue.  One can conclude that beam margins play a more 
important role in limiting radiation from healthy tissue than beam 
arrangement. 
In a recent study about the dosimetric impact on anatomical 
movements, Zhang et al, noted that the proton beam is affected 
by compensators that shape the beam at the end of the nozzle. 
As a result, protons experience more scatter than photons and 
minimizing the margins is extremely crucial. Although a dosim-
etric analysis was not the main focus of their study, Zhang et al 
reported that, “The proton therapy plan was better at sparing the 
rectum at doses of less than 50 Gy. However, above 50 Gy, IMRT 
was better at sparing the rectum” (Zhang et al. 2007). Clearly, all 
studies confirm that proton therapy reduces the amount of low 
to medium radiation unintentionally delivered to nearby healthy 
tissue. Yet, IMRT can sometimes yield better conformity to the 
target area in cases where high doses are delivered.
Author Dosimetric Value Bladder Rectum Absolute DifferenceBladder / Rectum
Trofimov
30% CGE 44.5%(IMRT) / 32.8%(PBT) 65.3%(IMRT) / 43.8%(PBT) 11.7% / 21.5%
70% CGE 11.4%(IMRT) / 17.3%(PBT) 9.7%(IMRT) / 10.3%(PBT) 5.9% / 0.6%
Vargas
30% CGE 42.8%(IMRT) / 27.7%(PBT) 55.4%(IMRT) / 20.7%(PBT) 15.1% / 34.7%
78% CGE — 5%(IMRT) / 2.9%(PBT) - / 2.1%
Chera
30% CGE 73.1%(IMRT) / 29.3%(PBT) 71.8%(IMRT) / 22.5%(PBT) 43.8% / 49.3%
70% CGE 9.7%(IMRT) / 9.8%(PBT) 11.5%(IMRT)  / 7.9%(PBT) 0.1% / 3.6%
Table  1
Dosimetric Analysis Comparing IMRT Versus PBT (Pearlstein et� al  2013)
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Toxicity and Quality of Life
Radiation poisoning of healthy tissue caused by protons can ir-
ritate the bladder, cause frequent urination, rectal bleeding, and 
sexual dysfunction. The question is, does toxicity to surrounding 
normal tissue result from the combined low and medium dose 
areas or the high dose area? A clinical investigation compared the 
rate of second cancers between IMRT and 3D-CRT. The study 
found that IMRT almost doubles the amount of second malig-
nancies from 1% to 1.75%. This is because IMRT increases the 
amount of low dose radiation absorbed by surrounding healthy 
tissue (Hall et al. 2003). With this information it should follow 
that proton therapy, which substantially reduces low to medium 
unintentionally absorbed radiation should have significantly lower 
toxicity rates than IMRT. 
A study was launched to discover if proton therapy causes less 
toxicity to nearby organs than intensity-modulated and three-di-
mensional conformal radiotherapy. There were 95 proton thera-
py patients, 153 IMRT patients, and 123 3D-CRT patients. Every 
patient’s bowel and urinary functions were assessed 3, 12, and 24 
months after treatment. The Expanded Prostate Cancer Index 
Composite (EPIC) was used to grade patients that received IMRT. 
Patients that received PBT or 3D-CRT were evaluated with the 
Prostate Cancer Symptom Indices, a similar scale to EPIC. In 
both tests scoring lower signifies lower quality of life. At three 
months following treatment, patients who received 3D-CRT or 
IMRT scored lower on the indices. They reported symptoms of 
urinary irritation, obstruction, incontinence, and a decrease in 
bowel quality of life. Proton therapy patients only reported min-
imal bowel and urinary morbidity. At 12 months all groups were 
equal on the indices when they reported decreased bowel quality 
of life. Only proton therapy patients reported a slight decrease 
in quality of urinary functions, such as irritation and obstruction, 
in comparison to the other groups. By 24 months all groups 
reported minor but clinically meaningful decrements in bowel 
and urinary functions quality of life. Proton therapy had a slight 
advantage for toxicities after 3 months and IMRT and 3D-CRT 
only had a slight advantage for urinary toxicities at 12 months. All 
groups had the same level of toxicity 24 months later. However, 
there are problems with this study. Firstly, each group received a 
slightly different dose to the prostate: 75.6 to 79.2 CGE for the 
IMRT patients, and 74.0 to 82.0 CGE for PBT patients. Different 
doses of radiation could have caused the different patterns of 
toxicity reported by the patients. Also, treatment was delivered 
according to each center’s preferred practice and planning target 
volume margins were not explicitly mandated (Gray et al. 2013). 
Another study on whether PBT can control the incidence of rec-
tal toxicity only comprised of patients receiving the same dose, 
74 CGE. Patients were followed up with after treatment to col-
lect data on the toxicities at 1 month and once every 3 months 
for the first two years and once every 6 months thereafter. The 
rectal toxicities observed included anal pain at defecation and 
rectal bleeding. The bladder toxicities were urinary frequency, 
painful urination, and urinary retention. The patients were graded 
with the Common Toxicity Criteria 4.0, a scale created by the 
National Cancer Institute Grade 1 toxicity usually means minor 
toxicity. Grade 2 means symptoms requiring medications and 
grade 3 means symptoms requiring minor corrective surgery. The 
results revealed that PBT can achieve a low occurrence of grade 
2 rectal toxicities and no major late toxicity was seen. (Nihei et al. 
2011). The study by Nihei et al, takes care of some of the issues of 
the trial by Gray et al, that were mentioned earlier. Each patient 
had the same dose of radiation. In both studies a low amount of 
rectal toxicity is seen early on.
More significant results were found by a study conducted by 
Mendenhall et al. The authors used image-guided proton therapy 
to target the cancerous tissue. They discovered low amounts of 
grade 2 genitourinary and gastrointestinal toxicities (Mendenhall 
et al. 2012). These toxicity results do appear more favorable than 
results commonly reported with IMRT. There was a high inci-
dence of grade 1 and 2, and some patients experienced grade 3 
toxicity. (Valeriani et al. 2014). Even more surprising was the fact 
that Valeriani et al, used image-guided IMRT and the prescribed 
dose was much lower, 68 CGE. The image guided radiation and 
the low amount of radiation should have curtailed the amount of 
toxicity that was reported. 
Only one study reported overall worse gastrointestinal toxic-
ity rates for protons than photons. The study used data from 
Surveillance, Epidemiology, and End Results (SEER), a Medicare 
linked database. Sheets et al, analyzed patient reported outcomes 
based on billing claims for diagnoses and procedures from six-
teen cancer registries. There were 684 patients treated with 
proton therapy and 6666 with IMRT. The authors observed that, 
“proton therapy–treated patients were more likely to receive a 
diagnosis of gastrointestinal morbidity and undergo gastrointes-
tinal procedures” (Sheets et al. 2012). However, this investigation 
did not report information on the prescribed dose and target 
margins. If the dose and margins differed between the two groups 
it could have caused a difference in toxicity rates. Another issue 
with this study is that Sheets et al, used claims for colonoscopy 
to measure gastrointestinal toxicity rates. This would be an im-
precise surrogate for any population. This is the same population 
that might also be more concerned about colonoscopy screening, 
and therefore would receive more gastrointestinal procedures. 
This study should not be used to relay any important morbidity 
information to inquiring patients. The few studies on quality of 
life have only shown modest advantages associated with proton 
therapy in comparison with other forms of radiotherapy.
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Problems with Scatter Beam Proton Therapy
Theoretically, protons should be the superior form of radiation 
treatment because of the Bragg Peak Effect. However, this phe-
nomenon also makes the protons extremely sensitive to uncer-
tainties during treatment. If a physician is unsure how deeply 
situated the tumor is, protons will not destroy the cancerous 
cells if it is not given even energy to reach that area. In contrast, 
photons continue to deposit a substantial amount of radiation 
as they transverse the entire body. As a result, physicians end 
up programming the Spread-Out Bragg Peak to extend deeper 
into the body, irradiating nearby healthy tissue. Additionally, the 
Spread-Out Bragg Peak requires multiple shots of protons to be 
passed through the body to completely radiate the entire depth 
of the tumor. This causes the tissue in the front of the prostate 
to be exposed to many doses of radiation. Additional concerns 
have recently been raised that organ toxicity can also be a result 
of secondary neutrons. Secondary neutrons are created when 
protons collide with the collimator –a metal piece that shapes 
the beam. The collimator is made out of brass and when struck 
by protons it sends off secondary neutrons. Low secondary neu-
tron radiation can cause patients receiving treatment to develop 
a high chance for contracting second malignancies (Brenner et al. 
2008). These neutrons could be stopping PBT from having better 
toxicity results. Although there are simple fixes to reduce the 
amount of neutrons, such as using a material with a low mass 
number, these techniques do not substantially curtail the amount 
of neutrons (Gould 2009). 
Pencil Beam Scanning
Recently, a newer method of delivery has been added to pro-
ton therapy. The older method, Scatter beam uses thick beams 
of passively scattered protons. The beams are shaped through 
slits in metal plates that form a relatively large beam as it exits 
the particle accelerator. The latest improvement to proton beam 
therapy is pencil beam scanning. Also known as spot scanning, this 
method is more accurate version of proton therapy. Pencil beam 
employs an extremely narrow beam that is brushed from side to 
side, ‘painting’ the dose on the tumor spot by spot. Because no 
apertures are needed, the protons do not collide with any metal 
and secondary neutrons are not produced with the collimator. 
The beam targets each spot on the tumor with a specific dose 
of radiation. Pencil beam scanning can even adjust the Spread-out 
Bragg Peak for every individual cancerous cell. “Scattered beam 
and pencil beam can be compared to a painter spraying with a 
spray can versus an airbrush. Instead of needing a stencil to mas-
ter the shape, the proton beam is made ultra fine to define the 
contours and landscape of a tumor” (MD Anderson 2009). With 
pencil beam protons are turned into an intensity-modulated type 
of treatment. This is projected to give protons more conformation 
to the cancer and its surrounding healthy tissues. Recently, a small 
number of cancer centers that deliver proton therapy introduced 
this new technology (Weisenbaugh 2014). To date, it is premature 
to determine if pencil beam is the most optimal method to use 
in the fight against prostate cancer. Only one study concluded 
that there is no toxicity or quality of life differences between 
passively scattered and pencil beam. The clinical investigation was 
comprised of 226 men who received passively scattered proton 
therapy and 65 men who received pencil beam proton therapy. 
Both groups reported similar gastrointestinal toxicity results, 
grade 2, throughout the 24-month trial. Genitourinary toxicity 
was also grade 2 and occurred mostly in the first 12 months 
following treatment. Yet, the authors acknowledged that, “Future 
comparative analyses between spot-scanning and passively scat-
tered are warranted in a larger cohort” (Pugh et al. 2013). 
Conclusion
Proton beam therapy can cure prostatic adenocarcinoma as effi-
ciently as IMRT. If proton therapy would not be extremely expen-
sive this therapy would be less controversial. Protons would have 
been regarded as another type of treatment used to eradicate 
cancerous cells. However, because proton therapy is consider-
ably more expensive it draws criticism to the fact that it only 
has a meager benefit over IMRT. PBT is slightly more effective 
in curtailing the amount of low to medium dose of radiation to 
the nearby organs. However, this only translates into a modest 
advantage in early toxicity over intensity-modulated radiother-
apy. Currently, there is no clinical evidence that proves scatter 
beam proton therapy is a significantly better form of treatment 
than IMRT. However, since there are limited centers that deliver 
proton therapy and relatively few patients that received it, more 
studies need to be conducted to solidify this claim. Although 
scatter beam might not be so advantageous in comparison to 
intensity-modulated radiotherapy, pencil beam proton therapy is 
theorized to turn protons into the ultimate form of treatment. 
More clinical trials need to be conducted to find out if pencil 
beam technology gives proton therapy the edge in the battle 
against prostate cancer.
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Introduction
Scarring, both as a component and complication of, wound heal-
ing affects millions of US citizens every year at a cost of more 
than 7 billion dollars (Wilgus, et al. 2003). In addition to esthetic 
concerns, scar formation is also implicated clinically in fibrotic 
diseases that some reports suggest are responsible for up to 45% 
of deaths in the industrial world (Wynn, 2008).  Despite such a 
heavy toll on the healthcare system, current treatment options 
are limited. Further research is needed to understand the under-
lying causes and mechanisms of scar formation so that effective 
treatments and even methods of prevention can be developed. 
Cellular response to tissue damage and the consequent forma-
tion of fibrotic tissue is a complex process that is still not very 
well understood. Current paradigms include the contribution of 
such varied cells as epithelial cells, macrophages, T-cells and, of 
course, fibroblasts. Initial response to tissue wounds involves the 
rapid recruitment of clotting factors and immune inflammatory 
moderators to stem blood loss and reduce potential infection 
by pathogenic microbes. Later, the relatively extended process of 
wound healing begins. Injured epithelial cells undergo a process 
of reprogramming, initiation, and propagation of mesenchymal 
pathways that includes the ubiquitous TGF-β related pathways. 
Macrophages also contribute to the inflammatory response and 
secrete profibrotic cytokines as well as growth factors, including 
TGF-β, that recruit and activate fibroblasts. Fibroblasts accumu-
late and ultimately produce and deposit new extracellular matrix 
and collagen that replaces normal tissue architecture. It is this 
deposition that characterizes scar formation and clinical fibrosis.
Interestingly, the development of scar tissue differs greatly be-
tween adult and embryonic wounds. Contrary to the normal 
fibrotic result in adult wounds, fetal wounds have been shown to 
exhibit scarless healing. Many cellular and molecular differences, 
including differences in key inflammatory mediators and various 
cytokines and growth factors, have been studied and documented 
to attempt to explain this phenomenon. 
In addition to expected scarring as a result of injury, there exist 
two clinical examples of atypical wound healing that result in ab-
normal scar formation. The etiology of hypertrophic scars and 
keloids is not well-understood, and although important differ-
ences between them have been detailed, both clearly involve the 
deposition of excessive amounts of collagen even as compared 
to normal scarring. 
Such anomalous results, from the scarless healing of fetal wounds 
to the excessive scarring of keloid and hypertrophic scars, may 
serve as paradigms for understanding the mechanisms behind the 
wound healing and scarring processes and the ability to prevent 
undesired outcomes.
Methods
Literature searches were chiefly performed using the PubMed 
database. After relevant literature was found, related articles 
were accessed using the Related Citations feature on the PubMed 
website. Additionally, references in these articles were retrieved 
and then served as additional points of reference for further re-
search. Review articles relevant to the research topic were help-
ful in providing references to source material. The Touro College 
Online Library and Google Scholar proved to be valuable for 
finding and accessing the necessary relevant articles. Moreover, 
conversation with plastic surgeons led to additional searches for 
source material on the website of the Plastic and Reconstructive 
Surgery journal.
Discussion
The formation of scar tissue in the process of wound healing is 
both a positive construct that effectively patches breaks in dam-
aged tissue and a negative consequence that can have dire effects. 
Scar tissue production is intended to increase the tensile the 
strength of wounds but never surpasses 70% of the strength of 
the original undamaged tissue (Wilgus, et al. 2003). Scar tissue 
also can impede tissue function, restricting mobility in joints and 
impairing normal growth in the case of external injuries involving 
the skin. The issue is even more problematic in the case of scar 
deposition as a result of internal organ damage. In such cases, 
scars can dramatically reduce function of vital organs as with 
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victims of myocardial infarctions whereby normal heart tissue is 
replaced with nonfunctional scar tissue. However, the problem 
of scar formation is perhaps greatest with respect to its role in 
devastating fibrotic diseases where scar tissue often times fatally 
overtakes normal tissue function.
Scars are essentially large deposits of extracellular matrix and 
collagen that are deposited by activated fibroblasts in response 
to tissue damage. After an injury, inflammatory mediators are 
immediately recruited and activated. Numerous cell types are 
involved in this response which includes the production and 
excretion of various growth factors and cytokines such as the 
well-studied TGF-β, IL-6, IL-8 and others.
Tissue injury involves disruption of capillaries and immediate-
ly triggers activation of platelets which begin a clotting cas-
cade. Inflammatory events follow with recruitment of neutro-
phils which secrete a variety of growth factors and cytokines. 
Monocytes arrive to facilitate changes in the wound matrix and 
macrophages release factors that activate fibroblasts to begin 
adding hyaluronate and glycoproteins such as fibronectin to the 
extracellular matrix (ECM). Gradually, these fibroblasts shift to 
producing proteoglycans and collagen which are then deposited 
at the wound site. Over the course of several days, macrophages 
and fibroblasts work to remodel the matrix and thus convert the 
granulation tissue into scar tissue (Harty, 2003). 
Studies comparing scarless fetal wounds to adult wounds have 
found significant differences in the levels of proinflammatory cy-
tokines such as IL-6 and IL-8. Liechty et al. (1998) grafted adult 
and fetal skin subcutaneously into SCID mice, wounded the site 
and subsequently excised the wound after varying lengths of time. 
The presence of IL-8 was confirmed using reverse transcription 
polymerase chain reaction (RT-PCR). Their results showed that 
fetal fibroblasts produced significantly less IL-8 at baseline (50 
+/- 6 pg/mL versus 450 +/- 115 pg/mL, P < 0.001). IL-8 mRNA 
was detected in unstimulated adult fibroblasts but not in fetal 
fibroblasts and much less IL-8 mRNA was detected in stimulated 
fetal fibroblasts than in adult fibroblasts. IL-8 mRNA was detect-
ed 4 hours after wounding in both fetal and adult wounds but by 
12 hours no IL-8 mRNA was detected in fetal wounds, whereas 
IL-8 mRNA persisted for up to 72 hours in adult wounds.
In a similar experiment, Liechty et al. (2000a) excised incisional 
wounds and examined them for IL-6 mRNA quantification by RT-
PCR. As with IL-8, fetal fibroblasts produced less IL-6 protein and 
mRNA at all points examined (P < 0.01 vs adult). IL-6 mRNA was 
detected 4 hours after wounding in both fetal and adult wounds. 
By 12 hours there was no IL-6 mRNA in the fetal wounds but the 
adult wounds had IL-6 mRNA persisting to 72 hours. In this ex-
periment, another set of grafts had 5 micrograms of IL-6 injected 
at wounding and the wound subsequently harvested at 7 days for 
analysis. The wounds with administered IL-6 resulted in scar for-
mation. Since these cytokines are responsible for the recruitment 
and activation of various leukocytes including macrophages, the 
diminished inflammatory response by fetal tissues may explain 
the lack of cellular recruitment and inflammation in fetal wound 
healing and further suggests that the inflammatory response 
plays a key role in the process of scar formation.
One well studied growth factor, TGF-β, exists as three known 
isoforms and is involved in many aspects of wound healing, from 
the immediate inflammatory response to matrix deposition 
(Adzick & Lorenz, 1994). In response to tissue injury, macro-
phages release TGF-β which stimulates the deposition of collagen 
and other matrix components by fibroblasts, thus implicating it in 
the etiology of fibrosis. Specifically, the TGF-β1 and TGF-β2 iso-
forms have been directly implicated in the fibrotic response and 
formation of scar tissue. Whitby and Ferguson (1991) detected 
both TGF-β1 and TGF-β2 isoforms with immunolocalization in 
adult wounds but not in fetal wounds. In a pioneer study, Shah et 
al. (1992) studied the effect of reduced levels of TGF-β in adult 
rodent wounds by using various neutralizing agents. The results 
of that experiment indicated inhibited fibrosis and scar forma-
tion. In another similar experiment, Shah et al. (1994) injected a 
polyclonal neutralizing antibody to TGF-β1, 2 into full-thickness 
cutaneous wounds of adult rodents just prior to wounding or 
within 24 hours of wounding and repeated daily for two days 
post-wounding. The effect was successful reduction in scarring. 
Numerous similar studies have been performed that confirm 
these results with more or less comparable data (Singer, et al. 
2009; Shah, et al. 2000). Conversely, up-regulation of these TGF-β 
isoforms via exogenous application resulted in excessive scar 
formation in a number of animal models (Lin, et al. 1995; Wang, 
et al. 1999; Lanning, et al. 1999). Thus direct evidence exists that 
increased levels of TGF-β1 and TGF-β2 play an important role in 
the fibrotic response and suggests that manipulation of TGF-β 
levels may provide an efficient strategy of reducing scar formation.
The culpability of TGF-β in the formation of scar tissue is fur-
ther supported by studies that have investigated the cellular and 
molecular differences abnormal scar formation such as keloid 
and hypertrophic scars. Experimental evidence suggests that 
upregulation of TGF-β is necessary for the excessive scarring 
characteristic of these pathologies (Lee, et al. 1999; Campaner, 
et al. 2006). Wang et al. (2000) compared the levels of TGF-β1 
mRNA in hypertrophic scar tissue and normal skin and found 
that hypertrophic scar tissues expressed five-fold more TGF-β1 
mRNA than normal skin per unit of wet weight. TGF-β1 mRNA 
expression in 5 pairs of fibroblast cultures derived from hyper-
trophic scar tissue also was found to be significantly elevated as 
compared to those derived from normal cells (116 +/- 6 vs. 97 
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+/- 7, p = 0.017). Additionally, Schmid (1998) demonstrated by 
immunohistochemistry and in situ hybridization, that hypertro-
phic scars exhibit unresolved persistent overexpression of TGF-β 
receptors by fibroblasts leading to overproduction of matrix pro-
tein and subsequent fibrosis. 
However, although the TGF-β1 and TGF-β2 isoforms have been 
implicated in scar formation, a third isoform has been shown to 
reduce scarring. Whitby and Ferguson (1991) demonstrated that 
fetal wounds express low levels of TGF-β1 and TGF-β2 but high 
levels of the third isoform, TGF-β3 (Table 1).
This implied that the ratio of TGF-β isoforms in wounded tissue 
may be the key to understanding the mechanism of wound heal-
ing and whether or not a scar forms. Shah et al. (1995) confirmed 
this hypothesis when they demonstrated that pan-neutralization 
of all three known TGF-β isoforms in linear incisions made on 
rats did not improve scarring, while exogenous application of 
TGF-β3 resulted in marked improvement in scarring and even 
scarless healing. Numerous studies have exploited this therapeu-
tic approach of increasing the relative ratio of TGF-β3 to TGF-β1 
and TGF-β2 with novel pharmaceutical agents (Ferguson, O’Kane, 
2004) (Figure 1).
The first clinical application of human recombinant TGF-β3, 
avotermin (Juvista; Renovo, UK) administered as an intradermal 
injection at the time of surgery, had shown promise in reduc-
ing scarring in controlled, double-blind, randomized phase I/
II clinical studies (Durani, et al. 2008). So et al. (2011) studied 
sixty patients (35 men and 25 women; age, 19 to 78 years; 53 
Caucasians; scar length, 5 to 21 cm) who received intradermal 
Table 1
TGF-β Isoform Scarless Fetal Healing
Scar-forming 
Adult Healing
TGF-β1 low/absent high
TGF-β2 low/absent high
TGF-β3 high low
Summary of relative TGF-β isoform differences in scarless fetal wound healing 
and scar-forming adult wound healing� (Ferguson, O’Kane, 2004)�
Figure 1
(a) Placebo-treated incisional rat wound compared with (b) scarless healing in TGF-β3-treated wound 84 days post-wounding (Ferguson, O’Kane, 2004)�
(b)
no visible scar
histological score - 0.5
(a)
normal scar
histological score - 4
macroscopic: black
dots indicate ends of incision
improved dermal organization 
similar to normal skin
scar: dense abnormally 
organized dermis
histologyhistology
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avotermin (200 ng/100 μl/linear cm wound margin) and placebo 
to wounds immediately after scar revision surgery and again 24 
hours later. Primary efficacy was measured as a total scar score 
derived from a visual analogue scale and scored by a lay panel 
from standardized photographs from 1 to 7 months following 
treatment. Profilometry showed a greater reduction in scar sur-
face area from baseline with avotermin treatment compared with 
placebo and histologic analysis showed collagen organization that 
more closely resembled normal skin. However, an earlier study 
of dermal ulcers on the ears of female rabbits had demonstrat-
ed only that exogenous topical TGF-β3 had accelerated wound 
healing but with no improvement in scar morphology and prom-
inence. Wu et al. (1997) showed that the use of TGF-β3 (0.3-0.75 
microgram per wound) increased granulation tissue formation 
by more than 100% (P < .005) but no significant difference in the 
hypertrophic index was noted as compared with controls. In fact, 
phase III trials of avotermin failed to meet primary and secondary 
endpoints, suggesting that the difference between scarless and 
scar-forming wound healing is perhaps more complex than simply 
altering the ratio of TGF-β isoforms (Penn, et al. 2012) .
Interestingly, a number of studies have demonstrated that even 
in fetal wounds, exogenously applied TGF-β can induce fibrosis. 
McCallion and Ferguson (1996) applied exogenous TGF-β1 to 
fetal wounds and observed a profound fibrotic response with 
scar formation. Krummel et al. (1988) showed that the addition 
of TGF-β to polyvinyl alcohol sponges implanted in fetal rabbits 
produced fibrosis. Sullivan et al. (1995) also examined human scar-
less fetal wounds transplanted subcutaneously into adult nude 
mice. Immunohistochemistry performed on the wounds did not 
show TGF-β staining. In a second part of the study, a slow-release 
disk with varying amounts of TGF-β1 was placed beneath the 
fetal skin graft at the time of wounding. Marked scarring in these 
fetal grafts was observed fourteen days post-wounding with the 
size of the scar proportional to the amount of TGF-β1 applied. 
These data suggest that the cellular mechanism of scar formation 
characteristic of adult wound healing is present in fetal wounds. 
The absence of scar formation in fetal wounds thus implies active 
suppression of these inflammatory mediators that have been im-
plicated in scar formation.
The concept of immune inflammatory suppression as the mech-
anism of scarless healing has been investigated further by testing 
with the known anti-inflammatory cytokine IL-10. IL-10 deacti-
vates macrophages and inhibits expression of both IL-6 and IL-8. 
Liechty et al. (2000b) hypothesized that the diminished levels of 
IL-6 and IL-8 they had revealed in a previous study were in fact 
due to the effects of IL-10. They developed a new syngeneic mu-
rine model of fetal wound repair in which 15-day-gestation skin 
from either normal or transgenic IL-10 knockout mice was graft-
ed to the back of the same strain adult mice. Incisions were made 
in the grafts after 5 days, which were then harvested at 1 week 
and analyzed for inflammatory response and scar formation. The 
normal fetal skin grafts showed minimal inflammation and were 
histologically consistent with scarless healing. The IL-10 knockout 
fetal skin grafts, in contrast, displayed significant inflammation and 
scar formation. Thus, the anti-inflammatory effects of IL-10 are 
necessary for active suppression of the inflammatory response 
leading to the observed paucity of macrophages, less TGF-β re-
lease, and consequently, less scarring.
The impact of IL-10-induced immune suppression is a key fac-
tor in scarless wound healing. Yamamoto et al. (2001) performed 
Northern blot analysis to show that IL-10 differentially regulates 
collagen deposition by downregulation of TGF-β1-induced col-
lagen mRNA. In a phase II randomized controlled clinical trial, 
Kieran et al. (2013) demonstrated that exogenous IL-10 applied 
to human incisional wounds reduced scarring and generally im-
proved scar appearance.
In a recent study, Wise et al. (2014) studied the effects of a pu-
rified IL-10 homolog derived from orf virus (ovIL-10). Orf virus 
infections induce persistent skin lesions that are reminiscent of 
sustained wound healing, yet surprisingly resolve with minimal 
scarring (Gurel 2002), and genetic studies have discovered that 
orf virus encodes for a variety of factors that allow it to subvert 
host immune responses, including an IL-10 homolog (Fleming 
2007). Wise et al. made excisional wounds in mice and divided 
them into four groups. The first three groups were treated with 
either recombinant murine IL-10 (mIL-10) or ovIL-10 in a buff-
ered saline solution (PBS), or PBS alone, while the fourth group 
received no treatment. The wounds were biopsied at varying 
times and analyzed. Histological analysis revealed that wounds 
treated with ovIL-10 exhibited accelerated healing as evident 
by increased wound reepithelialization as compared to controls. 
Reduction in visible scarring was also evident and quantitative 
PCR confirmed decreased levels of key proinflammtory medi-
ators. Thus supporting evidence exists that limiting the inflam-
matory response in wound healing can improve the quality of 
wound repair.
TGF-β is an upstream regulator of the cyclooxygenase (COX) 
pathway (Wilgus, et al. 2004). COX enzymes catalyze the con-
version of membrane phospholipid-derived arachidonic acid into 
prostaglandins which are known mediators of the inflammatory 
response. Western blot analysis and immunohistochemistry of 
biopsied hypertrophic and keloid scar lesions revealed significant 
overexpression of COX-1 and COX-2 isoforms, respectively, in 
comparison to normal dermal tissue which further suggests a sig-
nificant role these enzymes play in the pathogenesis of these ab-
normal scarring processes (Rossiello, et al. 2009). Indeed, TGF-β 
was shown to induce prostaglandin production in cultured 
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fibroblasts via COX-1 overexpression (Diaz, et al. 1998).
The significance of COXs in the etiology of pathological scarring 
such as keloids and hypertrophic scars has led to the investiga-
tion of its role in wound healing in general. Wilgus et al. (2003) 
examined the role of COX inhibitors in reducing scar formation. 
Celecoxib belongs to the family of nonsteroidal anti-inflammato-
ry drugs (NSAIDs) which target the COX enzymes. Specifically, 
celecoxib selectively targets COX-2 and prevents its enzymatic 
activity and subsequent production of prostaglandins including 
prostaglandin E2 (PGE2). Wilgus et al. made full-thickness inci-
sions in mice and closed the wounds with stainless steel wound 
clips to mimic surgical wounds. The staples were removed after 
5 days. The wounds were treated topically immediately after 
wounding and for up to 14 days daily with either 200 µl of the 
vehicle control (K-Y Jelly; Ortho Pharmaceutical Corp., Raritan, 
NJ) or with 1 mg of celecoxib capsules (Celebrex®, Searle, St. 
Louis, MO) dissolved in 200 μl of vehicle such that 200 μl con-
tained 1 mg of the drug. 
Skin sections were excised and analyzed. Immunohistochemical 
analysis using an antibody specific for the neutrophil surface 
marker Ly-6G, revealed a stark contrast between vehicle-treated 
and celcoxib-treated wounds. While a major inflammatory re-
sponse, manifested as a massive infiltration of neutrophils, was 
observed in the vehicle-treated wounds in comparison to un-
wounded tissue, wounds treated with celecoxib were virtually 
devoid of neutrophils.
Additionally, Biotrak enzyme immunoassays (EIA; Amersham-
Pharmacia, Piscataway, NJ) were used to quantify the concentra-
tion of PGE2. An approximately 50% decrease in wound PGE2 
levels was observed in wounds treated with celecoxib (p < 0.05). 
Levels of TGF-β1 were examined by Western blot analysis which 
revealed significantly lower levels in celecoxib-treated wounds 
compared to vehicle-treated wounds. These data were substanti-
ated by the observation of reduced scarring later on.
Wilgus et al. (2003) also reported that PGE2 promotes fibroblast 
proliferation and collagen synthesis consistent with known find-
ings (Lupulescu 1975) as well as their data showing decreased 
scar tissue deposition in treatment with celecoxib. This seems to 
be corroborated by the fact that lower levels of the proinflam-
matory fibrogenic TGF-β1 were detected. A similar result was 
presented by Miyajima et al. (2001) who also showed the ability 
of COX-2 inhibitors to reduce TGF-β levels and thus fibrosis.
The demonstrated effect of treatment with topical celecoxib in 
reducing scar formation in adult wound healing led Wilgus et al. 
(2004) to examine the role of COX-2 in scarless fetal wound 
repair. Incisions were made in the dorsum of fetal mice at either 
15 (E15) or 18 (E18) days after the detection of a vaginal plug 
using microsurgical scissors. These time points represent the ages 
at which either scarless or fibrotic healing occurs. Normal E15 
and E18 skin were harvested as controls along with the wounded 
samples at varying times for examination. Immunohistochemical 
staining at 24 hours post-wounding demonstrated COX-2 pro-
tein expression only in wounded E18 skin but not in E15 skin. 
Western blot was also used to detect COX-2 protein and the 
levels were analyzed by image analysis software. Levels of COX-2 
protein as well as PGE2 were higher in wounds introduced at E18 
compared to those at E15, implying that COX-2 is involved in the 
process of scar tissue formation.
It is thought that one mechanism by which PGE2 contributes to 
scar deposition is by increasing the rate of fibroblast prolifera-
tion. Indeed, Wilgus et al. showed that exogenous PGE2 applied 
to fetal fibroblast cultures resulted in statistically significant (p 
< 0.05 compared to untreated cells) dose dependent increased 
proliferation.
However, conflicting data suggest that fibroblasts from other or-
gans do not respond in the same way to increased PGE2 levels. 
For example, PGE2 reduces proliferation and collagen synthe-
sis by lung fibroblasts. This suggests that PGE2 can have varied 
effects perhaps resulting from differences in the expression or 
activity of various PGE2 receptors (Wilgus 2004).
Thus, the mechanism of PGE2-induced scarring could involve a 
number of plausible options. PGE2 could be contributing to the 
inflammatory response which has already been implicated in scar 
formation. Alternatively, PGE2 could be promoting scar depo-
sition through increases in the profibrotic TGF-β. Lastly, PGE2 
could be directly encouraging scar formation by stimulating fi-
broblast proliferation. 
Of note, however, is that although keloid and hypertrophic scars 
were found to express high levels of COX proteins, Yeh et al. 
(2006) found that fibroblasts derived from keloid patients exhib-
ited diminished capacity to produce PGE2, in line with the studies 
that identified PGE2 as an antifibrotic agent. In this experiment, 
fibroblast cultures were stimulated using the proinflammatory 
cytokine IL-1 which is known to activate fibroblasts and induce 
the formation/release of COX pathway products such as PGE2 
(Elias, et al. 1987). The effects of PGE2 on the synthesis of colla-
gen were determined using enzyme-linked immunosorbant assay 
(ELISA) kits. According to these data, the excessive deposition of 
collagen characteristic of keloids may in fact be due to decreased 
levels of PGE2 rather than increased.
The conflicting and perhaps confounding data surrounding PGE2 
and its effect on fibroblast proliferation and collagen synthesis 
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necessitate further investigation into the exact mechanisms by 
which this enzyme affects the healing process. Such contradictory 
data does not now lend to sufficient understanding that can lead 
to exploitation and development of therapeutic clinical applica-
tions in the treatment or prevention of scarring. In fact, some 
have suggested that the use of NSAIDs and COX-2 inhibitors 
may even exacerbate wound scarring because of their ability to 
decrease PGE2 production (Su, et al. 2010).
Until such time as the role of PGE2 and its effect on wound 
healing becomes better understood, a more promising approach 
to treatment and/or prevention of scarring would seem to be 
manipulation of the various TGF-β isoforms, which perhaps play a 
more direct role in the process of scar formation .
Already, clinical trials that manipulated the ratio of TGF-β iso-
forms have proven efficacy in the controlling scarring, although 
not without some failure. Further investigation into the exact 
role the various isoforms of TGF-β play in the process of wound 
healing can hopefully lead to the development of better targeted 
therapies to reduce scarring and perhaps even cure the numer-
ous fibrotic diseases. 
Conclusion
In this review, the underlying mechanisms of scar formation in 
wound healing were explored. The various TGF-β isoforms (and 
their ratio) seem to play a vital role by regulating the inflammato-
ry response although the process is undoubtedly more complex. 
The role of COX and PGE2 remains unclear with contradictory 
evidence pointing either to a reduction in scarring or perhaps 
exacerbation of the problem. The focus of potential therapeutic 
agents should for now remain dedicated to TGF-β as past studies 
have already proven potential in reducing scarring, while the other 
options reviewed here remain clouded in uncertainty. Research 
has further investigated the effects of interactions between cell 
adhesion molecules such as integrins and cadherins and the vari-
ous TGF-β isoforms in an effort to explore targeted therapeutic 
agents (Eslami, et al. 2009; Agarwal, 2014). Additionally, research 
has explored TGF-β as a potential target for anti-scarring gene 
therapy (Liu, et al. 2004). These and other efforts show promise in 
the development of successful clinical means of controlling scar-
ring and perhaps even fibrotic disease.
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Introduction
Alzheimer’s disease is a neurodegenerative disease that causes 
severe memory loss and ultimately death. The first part of the 
brain affected by Alzheimer’s disease is the hippocampus, a region 
of the brain associated with memory. Memory loss is usually the 
first symptom of Alzheimer’s disease. As the disease progresses 
the degeneration spreads to other parts of the brain leading to 
the loss of other cognitive skills such as language skills and the 
ability to plan. Eventually, damage to the basal nucleus of Meynert 
leads to a sharp drop in the amount of the neurotransmitter 
acetycholine present in the brain, leading to further deficiencies 
(Peterson, 2002). Approximately ten percent of the population 
over the age of 65 and fifty percent of those above 85 suffer 
from Alzheimer’s disease (Carlson, 2011). Currently, there is no 
medication that can cure Alzheimer’s disease or stop its progres-
sion. Patients suffering from Alzheimer’s disease are treated with 
medications that alleviate the symptoms. Acetylcholinesterase 
inhibitors are prescribed to alleviate the cognitive symptoms. 
Anxiolytics and antipsychotics may be prescribed to treat be-
havioral symptoms. These drugs, however, may worsen cognitive 
deficiencies. Ultimately, the inexorable progression of Alzheimer’s 
disease leads to death (Peterson, 2002).
Although the cause of Alzheimer’s disease has not been defini-
tively determined, two pathological conditions have been linked 
to Alzheimer’s disease, amyloid plaques and neurofibrillary tan-
gles. The amyloid plaques are extracellular deposits of the pro-
tein beta amyloid (sometimes referred to as amyloid beta). These 
plaques are surrounded by degenerating neurons and activated 
microglia, the phagocytotic cells of the central nervous system. 
Activated microglia are a sign of inflammation or immune re-
sponse. The neurofibrillary tangles are intracellular accumula-
tions of hyperphosphorylated tau proteins. These tangles disrupt 
transport within the neurons eventually killing the cell and leaving 
behind the tangle of filaments (Carlson, 2011). 
Alzheimer’s disease is split into two categories: early onset, also 
called familial, and late onset, also called sporadic. Alzheimer’s 
disease occurring before the age of 65 is considered familial 
whereas Alzheimer’s disease occurring after the age of 65 is con-
sidered sporadic. Familial Alzheimer’s shows a clear pattern of 
inheritance. In different families the disease is caused by different 
genetic mutations. Three genetic mutations have been identified: 
a mutation in the amyloid precursor protein gene (APP) gene, a 
mutation in the presenilin 1 (PS1) and a mutation in the prese-
nilin 2 (PS2) gene. All three of these mutations have been shown 
to increase the relative amount of amyloid beta 42 in the brain. 
Amyloid beta 42 is “stickier” than the wild type variant, amyloid 
beta 40. Consequently, amyloid beta 42 is more likely to con-
glomerate and form plaques. Sporadic or late onset Alzheimer’s 
disease does not show any clear pattern of inheritance. However, 
a variant of the apolipoprotien E gene, apolipoprotein epsilon 
4, has been linked to increased occurrence and earlier age of 
onset of Alzheimer’s disease. Apolipoprotein E is a carrier protein 
for cholesterol. The epsilon 4 variant of this protein has been 
linked to an increase in the amount of amyloid beta in the brain. 
The mechanism behind this relationship is unknown. Researchers 
suspect that apolipoprotein E is involved in the clearance of am-
yloid beta from the brain and that the epsilon 4 variant is not as 
effective the epsilon 2 or epsilon 3 variants in clearing amyloid 
beta (Peterson, 2002). 
Researchers have recently begun to examine the role of diet in 
the etiology of this disease (Heude et al 2003, Kalmijn et al 1997, 
Engelhart et al 2002, Luchsinger et al 2002, Morris et al 2003 
and Laitnen et-al 2006). Diet is a particularly interesting field for 
research because dietary interventions are relatively cheap and 
easy to initiate. This research hopes to provide the public with 
a cost effective method for preventing Alzheimer’s disease, or 
at least delaying its onset. Dietary fats in particular have been 
the focus of much research. The central nervous system has a 
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very high concentration of lipids, second only to adipose tissue. 
Additionally, lack of essential fatty acids has been shown to be a 
limiting factor in brain development (Winocur and Greenwood, 
1993). It follows that intake of fatty acids would have a significant 
impact on the health of the brain later in life. The link between 
apolipoprotien E and Alzheimer’s disease also suggests a role for 
lipid metabolism in the etiology of Alzheimer’s disease. 
Dietary fatty acids are ingested as triglycerides, groups of three 
fatty acids attached by an ester bond to a glycerol backbone. 
In the small intestine, these triglycerides are broken down to 
monoglycerides and fatty acids by the enzyme lipase. After being 
absorbed by the epithelial cells of the small intestine, they are 
recombined to form triglycerides. Because triglycerides are not 
water soluble, they cannot be transported through the blood 
stream without a carrier. Instead, they are combined with pro-
teins to form lipoproteins. Lipoproteins are spherical particles 
with an outer shell of proteins, phospholipids and cholesterol 
surrounding an inner core of triglycerides. There are a number of 
different types of lipoproteins, each with a different composition 
and a different function. The lipoprotein formed in the epithelial 
cells of the intestine is called a chylomicron. The chylomicron 
passes from the intestinal epithelial cells to the lacteal, and is 
delivered to the blood stream via the lymph system (Tortora and 
Derrickson 2006).
Studies have shown that rats raised on a diet high in saturated 
fat were impaired on behavioral tests (Winocur and Greenwood 
1993). Changes in the morphology of the hippocampus consis-
tent with a loss of dendritic integrity and immune response were 
also observed (Granholm et al 2008). Additionally, animals that 
were fed a diet high in saturated fat were found to have higher 
concentrations of the protein amyloid beta (Galloway et al 2007), 
the main component of amyloid plaques, and compromised blood 
brain barrier integrity (Farrall and Wardlaw 2009, Taketchi et al 
2010, Taketchi et al 2013a, Taketchi et al 2013b, and Freeman and 
Granholm 2012). In humans, however, the link between saturated 
fats and Alzheimer’s is not as clear. A number of studies have been 
conducted, and they have yielded conflicting results. This paper 
will review and elucidate the relevant research with the goal of 
answering the following two questions: Is there a definitive link 
between high intake of saturated fat and incidence of Alzheimer’s 
disease? If yes, what is the mechanism of this relationship, and 
does this suggest any possible interventions other than diet 
modification?
Methods
A literature search was conducted using pubmed.gov. The follow-
ing search terms were used: Alzheimer’s disease AND saturated 
fat, Alzheimer’s disease AND dietary fat, Alzheimer’s disease AND 
amyloid beta, Alzheimer’s disease AND blood brain barrier, and 
Alzheimer’s disease AND statins. To exclude irrelevant papers the 
search terms were restricted to the title and abstract. Of the 
papers that were found using these search terms, relevant papers 
were selected based on their abstract. Additional sources of in-
formation were found in the reference sections of these papers.
Discussion
Saturated Fat and Amyloid Beta 
In 1992 Hardy and Higgins proposed that the deposition of am-
yloid plaques is the initiating event in Alzheimer’s disease. This 
hypothesis, called the amyloid cascade hypothesis, suggests that 
an influx of calcium caused by the toxic effects of amyloid plaques 
leads to hyperphosphorylation of the tau proteins which then 
form neurofibrillary tangles and kill the neurons. A number of 
findings support this theory. Firstly, it has been observed that mu-
tations of the gene encoding the tau protein lead to Parkinson’s-
like symptoms, but did not lead to the deposition of amyloid 
plaques. Secondly, it has been observed that mice expressing mu-
tant variations of both amyloid beta and tau protein experience 
increased formation of tau protein tangles when compared to 
mice expressing only the mutant version of tau protein, while the 
number of amyloid plaques is the same. Both of these observa-
tions indicate that the deposition of amyloid plaques leads to the 
formation of tau protein tangles, but not the other way around. 
The discovery that familial Alzheimer’s disease is caused by a ge-
netic mutation in the amyloid precursor protein also supports 
the amyloid cascade hypothesis. It seems likely that both famil-
ial and sporadic Alzheimer’s disease share an underlying cause 
(Hardy and Selkoe, 2002). 
It has been shown that the degree of dementia is correlated with 
the amount of amyloid beta present in the brain (Naslund et. al. 
2000). However, there is no evidence of increased production 
of the amyloid beta protein in the brains’ of Alzheimer’s disease 
patients, indicating that the observed increase is caused by de-
creased clearance of amyloid beta from the brain or increased 
uptake of this protein from circulation (Pallebage-Gamarallage et. 
al. 2009). Using iodine-125 labeled amyloid beta, researchers have 
shown showed that amyloid beta from circulation does indeed 
cross the blood brain barrier (Mackic et. al. 2002) This suggests 
that factors which increase the levels of circulating amyloid beta 
may increase the level of amyloid beta in the brain, and lead to 
the formation of plaques. 
The protein amyloid beta is involved in the metabolism of lipids. 
In vivo, it is associated with chylomicrons and lipoprotein B, and 
it increases the uptake of triglyceride rich lipoproteins (TRLs) 
by fat rich organs (James et. al. 2003). Consistent with this, it has 
been found that a diet high in saturated fat increases the levels 
of amyloid beta in enterocytes (Galloway et. al. 2007). The link 
between lipid metabolism and the deposition of amyloid plaques 
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in the brain is further strengthened by the finding that high serum 
cholesterol induced by high cholesterol feeding is correlated with 
increased levels of amyloid beta in the brain, as well as increases 
in the number and size of amyloid plaques (Refolo, 2000). These 
studies investigated the effect of cholesterol only, but not the 
effect of saturated fat.
The link between saturated fat and amyloid plaques suggests that 
reducing intake of saturated fat would reduce the incidence of 
Alzheimer’s disease. However, it must be noted, that a ketogenic 
diet, a diet very low in carbohydrate content and very high in fat 
content, has been shown to lower the amount of amyloid beta 
in a rat’s brain (Van der Auwera et. al. 2005). This indicates that 
the increase in amyloid beta observed in rats fed a high saturated 
fat diet is not simply because of the high fat content. Rather, it 
is the result of a synergistic effect between saturated fats and 
carbohydrates. 
Saturated Fat and Blood Brain Barrier 
Dysfunction
Saturated fat may also have a detrimental effect on the health of 
the brain by disrupting the blood brain barrier. The blood brain 
barrier was discovered more than 100 years ago by Paul Ehrlich 
when he observed that blue dye injected into an animal’s blood 
stream will not reach the spinal cord or the brain. The blood 
brain barrier is formed by the endothelial cells of the blood 
vessels in the central nervous system. In most capillaries there 
are gaps between the endothelial cells that allow substances to 
diffuse in and out of the blood. In contrast, the endothelial cells in 
the central nervous system are tightly packed, and held together 
by tight junctions. This prevents many substances that normally 
diffuse out of the blood stream from diffusing into the central 
nervous system (Carlson, 2011).
A disruption of the blood brain barrier can lead to Alzheimer’s 
disease through two distinct pathways. As previously mentioned, 
there is evidence that the increase in the amount of amyloid beta 
in the brains of Alzheimer’s patients may be due to an influx of 
amyloid beta from circulation. We previously explored the pos-
sibility that this is because intake of certain lipids increases the 
amount of amyloid beta present in the blood. Another possibility 
is that the influx of amyloid beta is due to the breakdown of the 
blood brain barrier. In addition to affecting the level of amyloid 
beta in the brain, a breakdown of the blood brain barrier would 
allow toxins to enter the brain, possibly leading to Alzheimer’s 
disease through a completely different pathway.  
There are a number of methods by which blood brain barrier 
integrity can be assessed. The levels of plasma derived proteins 
in the brain can be measured, with a greater amount indicat-
ing influx through the blood brain barrier. Similarly, the levels of 
cerebrospinal fluid derived proteins in the plasma can also be 
measured to determine efflux through the blood brain barrier. 
Immunoflourescent antibodies can be used to detect the pres-
ence of tight junction proteins and other proteins integral to the 
maintenance of the blood brain barrier.  Imaging techniques such 
as contrast CT, contrast MRI, and positron emission topography 
(PET) have also been used. 
Whether blood brain barrier dysfunction is linked to Alzheimer’s 
disease has been debated for many years. A number of experi-
ments have been performed using both biochemical and imaging 
techniques. A meta-analysis of sixteen studies found that there 
was a statistically significant link. There was, however, great het-
erogeneity among the results of individual studies (Farrall and 
Wardlaw, 2009). 
To examine the effects of saturated fat on the blood brain barrier, 
researchers examined the brains of mice fed a diet high in satu-
rated fat, high in unsaturated fat and a control group fed standard 
laboratory chow. Immunoglobin G (IgG), and apolipoprotien B 
(a hepatically derived lipoprotein) were used to measure influx. 
The cerebrospinal fluid protein, S100B was used to detect efflux. 
After three months, the mice were euthanized, and the relative 
abundance of occludin, a tight junction protein, was also assessed. 
It was observed that levels of immunoglobin G and apolipopro-
tien B were greatly elevated in the brains of mice in the saturated 
fat group, indicating increased influx of proteins and lipoproteins. 
The increased presence of apolipoprotein B, a lipoprotein that is 
associated with amyloid beta in enterocytes, supports the the-
ory that blood brain barrier dysfunction can cause Alzheimer’s 
disease by increasing the influx of amyloid beta. Plasma levels of 
S100B were also greatly elevated indicating efflux from the cere-
brospinal fluid into the brain. Finally, levels of occludin were found 
to be lower in the saturated fat group, indicating a breakdown of 
the tight junctions that form the blood brain barrier. The effects 
of the high saturated fat diet were exacerbated when the mice 
were examined after six months of feeding (Taketchi et. al. 2010 
and Taketchi et. al. 2013a). 
Another experiment examined the effect of a high saturate fat/
high cholesterol diet on three blood brain barrier proteins. The 
proteins investigated were endothelial barrier protein and the 
tight junction proteins occludin, and ZO-1. Using immunofloures-
cent antibodies the high saturated fat/high cholesterol fed rats 
were found to have markedly less endothelial barrier protein 
in the cortex and the CA-1 region of the hippocampus. When 
analyzed by western blot, a hippocampal homogenate of the ex-
perimental rats was found to have more occludin and the same 
amount of ZO-1 as that of the control rats. However, immu-
noflourescent imaging showed that the localization of occludin 
was markedly different in the two groups. In the control group 
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occludin was found to be present mostly in the walls of blood 
vessels, as would be expected for a blood brain barrier protein. 
In contrast, the blood vessels of the experimental group stained 
very weakly for occludin, while there was a strong signal in axon 
fibers and granule cells of the dentate gyrus. It may be that the 
increased level of occludin detected in the brain of the experi-
mental group was because expression of occludin had been up-
regulated in response to blood brain barrier damage (Freeman 
and Granholm, 2012). 
Saturated Fat and Cognitive Decline in Animals
The evidence linking saturated fat to increased production of 
amyloid beta and blood brain barrier dysfunction suggests a link 
between saturated fat and Alzheimer’s disease. Indeed, a link 
between saturated fat and cognition has been observed in rats. 
Researchers found that rats fed a diet high in saturated fat per-
formed worse on memory tests than rats fed a diet that had 
unsaturated fat as its main fat component (Winocur and Gordon 
1993). Again, it must be noted that rats fed a ketogenic diet did 
not experience any cognitive decline, despite the extremely high 
saturated fat content in their diets. This is consistent with the 
finding that a ketogenic diet reduces the levels of amyloid beta in 
the brain (Van der Auwera et al 2005). 
In addition to memory impairment, researchers found that a 
diet high in cholesterol and saturated fat significantly altered the 
morphology of the hippocampus, one of the areas of the brain 
responsible for memory and learning. After being fed a diet high 
in saturated fat and cholesterol, sections of the hippocampus 
were tested for Map2, an integral membrane protein that is con-
sidered a marker for dendrites, and Iba1 a marker for microglia. 
Compared to the control group, rats fed a diet high in saturated 
fat had significantly less Map2 and considerably more Iba1, in-
dicating a loss of dendritic integrity and activation of microglia, 
both hallmarks of Alzheimer’s disease (Granholm et al 2008).
Saturated Fat and Alzheimer’s Disease
A link between saturated fat and Alzheimer’s disease cannot be 
definitively asserted unless there is evidence of such a link in 
humans. A number of epidemiologic studies have been conduct-
ed to determine the link between dietary fats and Alzheimer’s 
disease (Heude et. al. 2003, Kalmijn et. al. 1997, Engelhart et. al. 
2002, Luchsinger et. al. 2002, Morris et. al. 2003, and Laitnen et. 
al. 2006). Although the information gleaned from these studies is 
enlightening, the results must be approached with caution. All of 
these studies rely on self reporting. Because participants do not 
know how much fat they have ingested, researchers use food 
frequency questionnaires that ask participants about their dietary 
habits. This information is used to estimate their intake of various 
micronutrients. This method is an estimate at best. As with all 
studies relying on self reporting there is an inherent inaccuracy. 
Additionally, responses on a questionnaire reflect only the re-
spondent’s current diet, but offer no information about their di-
etary habits in the past. Discrepancies among these studies can 
arise from differences in the questionnaires used, length of follow 
up time, the age of the population being studied, and the ethnicity 
of the population.  
In the Rotterdam study, 7,983 residents of a suburb of Rotterdam 
over the age of 55 were administered questionnaires that were 
followed up by clinical examinations. After a two year follow 
up, researchers found a statistically significant link between in-
creased intake of saturated fat and incidence of Alzheimer’s dis-
ease (Kalmijn et. al. 1997). Interestingly, the link was significant 
even after eliminating patients with cerebrovascular disease, in-
dicating that the mechanism mediating this link is not vascular in 
nature. However, a six year follow up of the same group showed 
no significant link between saturated fat intake and Alzheimer’s 
disease (Engelhart et. al. 2002). An examination of the methods 
used in the two studies does not reveal an obvious reason for 
this discrepancy. Both studies used the same method of assessing 
dietary intake of fats, and both adjusted their results for similar 
confounding variables. The authors of the second study do not 
address the discrepancy directly, but they do suggest that the 
longer follow up may introduce selective survival. For instance, 
it may be that subjects who live longer are less susceptible to 
the detrimental effects of a high fat diet leading to a longer life 
span, and a lower incidence of dementia as well (Engelhart et. al. 
2002). It may also be that saturated fat lowers the age of onset 
of Alzheimer’s disease, but does not increase overall incidence.
Using data from the Washington Heights-Inwood Columbia Aging 
Project (WHICAP), researchers found a link between total intake 
of fat and increased incidence of Alzheimer’s disease. Saturated 
fat alone was linked to increased incidence of Alzheimer’s disease; 
however, the hazard ratio was slightly lower than that of total fat 
intake and was less than that of monounsaturated fats, indicating 
that saturated fat is not more harmful than other fats. Although 
increased intake of saturated fat overall was linked to increased 
incidence of Alzheimer’s disease, no difference was found be-
tween those reporting moderately high intake and those re-
porting very high intake. When the data was analyzed using only 
people who had tested positive for the apolipoprotien E epsilon 
4 allele (both homozygous and heterozygous) the link between 
total fat intake and Alzheimer’s disease was much stronger and 
successively greater intake of saturated fat indicated successively 
greater risk of Alzheimer’s disease (Luchsinger et al 2002).
Another study using data from the Chicago Aging Project and a 
median follow up of 3.9 years found a strong link between satu-
rated fat and Alzheimer’s disease. Participants in the top fifth of 
saturated fat intake were 70% more likely to develop Alzheimer’s 
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disease. This is in contrast to other fats, some of which seemed to 
lower the risk of Alzheimer’s disease. Adjusting for confounding 
variables led to 120% increase in risk. In contrast to the findings 
of Luchsinger et al (2002), this study found that the link between 
saturated fat and Alzheimer’s disease was not any stronger in par-
ticipants possessing the apolipoprotein E epsilon 4 allele (Morris 
et al 2003). 
The previous studies focused on elderly people and had a follow 
up between two and seven years. A short follow up can poten-
tially underestimate the link because of the possibility of sub-
clinical dementia (i.e. the patients who were discovered to have 
dementia might have had subclinical dementia at baseline, and 
the poor diet is a symptom rather than a cause of the disease). 
In contrast, Laitnen et al (2006) studied the link between fat in-
take at midlife and the incidence of Alzheimer’s disease later in 
life. In this study participants of the CAIDE study who had been 
examined in either 1972, 77, 82, or 87 were called for reexamina-
tion in 1998. The mean follow up was 21 years. This study found 
that participants with moderate fat intake (second quartile) had 
a lower risk of Alzheimer’s disease than either low fat or high 
fat intake. When broken down to specific fats, high polyunsat-
urated fats and monounsaturated fats were correlated with a 
decreased risk of Alzheimer’s disease, while high intake of satu-
rated fats was correlated with a higher incidence of Alzheimer’s 
disease. Only the data for polyunsaturated fats and saturated 
fats yielded results that were statically significant. When adjusted 
for the Apolipoprotien E epsilon 4 allele, the results were sim-
ilar; suggesting that effect of saturated fat is not related to the 
Apolipoprotein E epsilon 4 allele. It is noteworthy that this study 
calculated relative intake of fatty acids based only on intake of 
different types of dairy, excluding two major sources of dietary 
fatty acids, meat and fish.
As previously mentioned, studies that rely on self reporting food 
frequency questionnaires are inherently inaccurate.  To address 
this problem, researchers studied the link between erythrocyte 
membrane content and cognitive decline. This study found a sig-
nificant link between saturated fatty acid content in erythrocytes 
and cognitive decline. Interestingly, the results for polyunsaturat-
ed fatty acids were mixed; n-6 polunsaturated fatty acids were 
linked to cognitive decline while n-3 polyunsaturated fatty acids 
seemed to protect against decline. This study investigated only 
the link between fatty acids and general cognitive decline. A link 
between membrane composition and Alzheimer’s disease specif-
ically was not investigated (Heude et al 2003). 
Lipid-Lowering Pharmaceuticals
The link between saturated fatty acids and Alzheimer’s disease sug-
gests that drugs that lower plasma lipids may prevent Alzheimer’s 
disease, or slow its progression. Probucol is a lipid-lowering agent 
with anti-inflammatory and antioxidant properties that has been 
used to treat cardiovascular disease (Santos, 2012). Experiments 
with mice have shown that Probucol ameliorates the detrimental 
effects of a diet high in saturated fat. It was previously mentioned 
that mice fed a diet high in saturated fat and cholesterol were 
found to have a greater abundance of the protein amyloid beta in 
enterocytes. When Probucol was added to their diet, the levels 
of enterocytic amyloid beta in the saturated fat group were com-
parable to those in the control group (Pallebage-Gamaramllage 
et al 2012). 
It was also found that Probucol prevented the damage to the 
blood brain barrier normally associated with a high saturated 
fat diet. Mice were randomly assigned either to a control diet, a 
diet high in saturated fat, a diet high in cholesterol, or a high sat-
urated fat/high cholesterol diet with Probucol for three months. 
Consistent with previous experiments the mice in the high satu-
rated fat and high cholesterol diets were found to have damage 
to the blood brain barrier as measured by the concentrations of 
immunoglobin G and apolipoprotien B in the brain, and the con-
centration of S100B in the blood plasma. High saturated fat and 
high cholesterol mice were also found to have a greater abun-
dance of activated microglia, a sign of inflammation. However in 
mice treated with Probucol the levels of immunoglobin G, apoli-
poprotein B and S100B were comparable to that of the control 
group. There was also no evidence of inflammation in mice treat-
ed with Probucol (Taketchi et al 2013a). 
When the experiment was repeated and mice were kept on the 
high saturated fat diets for 12 months the effect of the high satu-
rated fat diet on blood brain barrier permeability and enterocytic 
abundance of amyloid beta was even more pronounced. Yet, de-
spite the long term exposure to saturated fat, the group treated 
with Probucol was not effected (Taketchi et al 2014). In addition 
to preventing damage to the blood brain barrier and lowering en-
teroctyic accumulation of amyloid beta, Probucol was also found 
to increase synaptic density in mice (Poirier, 2008). 
A pilot study examined the effect of Probucol on 12 patients with 
mild-to-moderate Alzheimer’s disease. A clinical assessment after 
six months of treatment found that Probucol led to a stabilization 
of symptoms (Poirier, 2008). This was a small scale study that 
did not include a control group. A long term controlled study is 
needed to definitively determine whether Probucol is an effective 
treatment for Alzheimer’s disease and whether its effect is long 
lasting. 
It is possible that the positive effects of Probucol are not related 
to lipid metabolism. Probucol was found to attenuate the effects 
of an injection of amyloid beta in mice. Mice injected with amyloid 
beta exhibited cognitive decline, and a histological examination of 
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their brains shows decreased synaptic density (as measured by 
the presence of the presynaptic protein synaptophysin) and in-
creased acetylcholinesterase activity. Injection with amyloid beta 
does not increase plasma cholesterol. Treatment with Probucol 
for 15 days attenuated the effects of the amyloid beta injection. 
This is despite the fact that the pathological conditions observed 
in these mice were not due to increased lipid intake or dysfunc-
tional lipid metabolism. This suggests that Probucol may directly 
affect the pathway responsible for Alzheimer’s disease patholo-
gy in addition to its positive effect on lipid metabolism (Poirier, 
2008). 
Statins (HMGCoA reductase inhibitors) are another group of 
lipid lowering agents prescribed to treat cardiovascular disease. 
Similar to Probucol, statins also have anti inflammatory proper-
ties. In an experiment similar to that performed with Probucol 
it was shown that treatment with statins will reverse the blood 
brain barrier damage caused by a high saturated fat diet. Mice 
were fed either a low fat diet or a diet high in saturated fat. 
Consistent with previous experiments the mice fed a diet high 
in saturated fat were found to have significantly higher levels if 
immunoglobin G and apoliprotien B in the brain parenchyma, 
an indication of blood brain barrier damage. Treatment for two 
weeks with Atorvastatin, a lipid soluble statin, led to a decrease 
in the amount of immunoglobin G present in the brain. Treatment 
with pravastatin, a water soluble statin did not lead to any re-
duction after two weeks. After eight weeks of treatment it was 
found that both atorvastatin and pravastatin completely negated 
the effects of the high saturated fat diet (Pallebage-Gamarallage 
et al 2012). Unlike other studies, this study tested the effect of 
the experimental compound after the mice had been on the sat-
urated fat diet for an extended period of time. The effectiveness 
of the compounds after the effects of the saturated fat diet had 
presumably set in suggests that statins may be effective at re-
versing damage to the blood brain barrier as opposed to simply 
preventing it. 
 An analysis of data obtained from the General Practice Research 
Database in the UK revealed that individuals who had been pre-
scribed statins had a significantly reduced incidence of Alzheimer’s 
disease. This was true even for individuals who had taken statins 
in the past, but were no longer taking these drugs. Interestingly, 
use of other lipid lowering agents was not correlated with a 
lower risk of Alzheimer’s disease (Jick et al 2000). Another study 
used data from the databases of three different U.S. hospitals. This 
study also found a statistically significant relationship between 
use of lovastatin (Mevacor) or pravastatin sodium (Pravachol), 
and a lower incidence of Alzheimer’s disease. Simvastatin (Zocor), 
a different statin, was not correlated with decreased incidence of 
Alzheimer’s disease in this study (Wolozin et al 2000).  
Ibuprofen, a non-steroid anti inflammatory drug (NSAID) that 
does not have any lipid lowering properties was also tested 
alongside simvastatin and pravastatin in the previously described 
experiment. After two weeks of treatment Ibuprofen was found 
to be as effective as simvastatin, and eight weeks of treatment 
completely reversed the effects of the high saturated fat diet 
(Pallebage-Gamarallage et al 2012). Antioxidants are another 
group of compounds that have been found to ameliorate the 
effect of saturated fat. Inflammation is caused by reactive oxy-
gen species (ROS). Anti oxidants combat the effects of reactive 
oxygen species and prevent inflammation. Four compounds were 
tested: aged garlic extract, alpha-lipoic acid, niacin, and nicotin-
amide. Mice were fed either a low fat diet a high saturated fat 
diet or a high saturated fat diet containing one of the four com-
pounds. All four compounds were found to prevent the blood 
brain barrier dysfunction and inflammation caused by a high satu-
rated fat diet (Takechi et al 2013b). These studies suggest that the 
protective property of statins and Probucol that was observed 
in humans and mice may be related to their anti inflammatory 
properties and not their lipid lowering properties.
Conclusion
Saturated fat is clearly linked to an increase in amyloid beta and 
to blood brain barrier dysfunction in animals. Although not de-
finitive, epidemiologic evidence seems to indicate that increased 
intake of saturated fat is a risk factor for Alzheimer’s disease. 
Based on the evidence presented, it is reasonable to suggest lim-
iting intake of saturated fat as part of an effort decrease the risk 
of Alzheimer’s disease. In particular those with the apolipopro-
tein E epsilon 4 allele should limit their intake of saturated fat. 
However, it must be noted that saturated fat is only one among 
many micronutrients that make up our diet. Saturated fat alone is 
not responsible for inflammation, blood brain barrier dysfunction, 
or deposition of amyloid plaques. In fact, we have cited evidence 
that a ketogenic diet, which is high in saturated fat, reduces the 
amount of amyloid beta in the brain. When designing a diet low 
in saturated fat one needs to ensure that saturated fat is not 
replaced with an equally unhealthy substitute. Furthermore, there 
is no evidence that limiting saturated fat intake after the onset 
of Alzheimer’s disease will reverse or even slow the disease’s 
progression. At best, limiting intake of saturated fat throughout 
the course of one’s life will lower the incidence of Alzheimer’s 
disease and delay its onset, but it will not cure it.
The use of Probucol, statins, and other anti-inflammatory med-
ications in the treatment of Alzheimer’s disease is strongly sup-
ported by the evidence cited. Anti inflammatory medication 
has been shown to reverse damage to the blood bran barrier 
caused by saturated fat. Probucol has been shown to lower en-
terocytic accumulation of amyloid beta and to slow the progres-
sion of Alzheimer’s disease. Use of statins has also been linked 
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to a decreased risk for Alzheimer’s disease. Further research is 
needed to determine which of these drugs is most effective, and 
whether these drugs can be effective in the long term.  
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Introduction
A big problem facing the world today is the rise of obesity. 
According to the CDC, approximately one third of the American 
adult population is obese. Obesity is characterized by a Body 
Mass Index (BMI), of 30 or higher, while healthy weight BMI is in 
the range of 18.5-24.9 (CDC, 2012). One possible con-sequence 
of obesity is the development of type 2 diabetes. Diabetes is a 
disease characterized by elevated glucose levels as a result of 
insufficient insulin production or a malfunctioning insulin system. 
Of the Americans population 29.1 million or 9.3%, had diabetes 
in 2012. This number was an increase from 2010 when the statis-
tics were 25.8 million and 8.3% (American Diabetes Association, 
2014). In type 1 diabetes mellitus, the β cells of the pancreas that 
are responsible for producing insulin are destroyed. In the ab-
sence of insulin, these individuals are at risk for hyperglycemia, or 
dangerously elevated blood glucose levels. Type 2 diabetes usually 
has a later onset. People with type 2 diabetes experience insulin 
resistance so that the insulin does not help glucose enter the 
body cells. Eventually the body stops producing insulin altogether 
(CDC, 2014). Most cases of diabetes, 90-95% are type 2 diabetes. 
Statistics show that 90% of cases of type 2 diabetes in western 
countries can be attributed to excess weight gain or obesity. 
Improving glucose tolerance while losing weight is the aim of 
new treatments for diabetes. Examining the effects the hormone 
ghrelin has on glucose metabolism can be a valuable therapeutic 
option (Rudolph, et al. 2007). Ghrelin is a 28 amino acid peptide 
hormone that plays a role in many different body functions. It is 
the endogenous ligand for the growth hormone secretagogue 
receptor (GHS-R) and has been proven to increase growth hor-
mone secretion. Additionally, ghrelin is known as an orexigenic, or 
appetite-stimulating hormone, and is also responsible for energy 
bal-ance. It is produced predominantly in the stomach but is also 
produced in other places including the pancreas. One important 
function ghrelin serves is the ability to control insulin release 
from β cells of the pancreas. In the presence of ghrelin, insulin 
secretion is reduced, and blood glucose concentration increases. 
Research shows the effect of ghrelin on pancreatic islet β-cells. 
Ghrelin suppresses insulin secretion from β-cells by interfering 
with the K and Ca2+ channels that are stimulated by glucose 
metabolism. Obese individuals and diabetics have lower levels of 
plasma ghrelin than lean individuals. It is reasonable to suggest 
that this may be a regulated response in order to minimize the 
ghrelin activity that reinforces obesity. Subsequent research im-
plicated possible regulation of ghrelin to treat obesity and diabe-
tes. Since insulin levels are decreased in the presence of ghrelin, 
investigation of techniques to reduce or diminish the effects of 
ghrelin is in effect. Various treatment options that have under-
gone research and experimentation show posi-tive outcomes 
in regard to treating diabetes and obesity. Many techniques that 
influence ghrelin’s role in decreased insulin secretion are still in 
the experimental phase but may eventually be effective to treat 
diabetes and obesity. Ghrelin’s effects on insulin sensitivity are 
also being explored. Can regulation of ghrelin serve as a possible 
treatment option for diabetes and obesity?
Methods
The research obtained about ghrelin’s effects on the metabolism 
of diabetics and obese individuals was collected from a variety 
of sources. The majority of articles were collected using Touro’s 
library to access databases such as Pubmed, ProQuest and more. 
Additionally, other articles were found by searching Google 
scholar for relevant journals on the topic. After reviewing numer-
ous articles on ghrelin’s effects on obesity and diabetes, evidence 
was compiled to answer the research question. 
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Discussion
Ghrelin and its forms:
Ghrelin is a 28-peptide amino acid that is produced mainly in the 
stomach. This hormone is responsible for signaling hunger and 
maintaining an energy balance. Acylated ghrelin, or acyl ghrelin, 
the active form of ghrelin consists of noctanoylation on the 
third serine. This form of ghrelin is able to bind to the GHS-R1a, 
enabling it to have a biological effect in areas such as growth 
hormone secre-tion and glucose metabolism. However, most of 
our plasma circulating ghrelin is unacylated ghrelin, or des acyl 
ghrelin, which has been discovered to have biological effects as 
well (Kiewiet, et al. 2009). 
The effects of each form of ghrelin on insulin concentration and 
sensitivity has been studied. Acylated ghrelin (AG), the active 
form of ghrelin has been found to be responsible for decreased 
insulin levels, while unacylated ghrelin’s (UAG) affects are being 
studied. It has been noted that ghrelin levels have a preprandial 
increase and a postprandial decrease indicating its role as an ap-
petite stimulant (Kiewiet, et al. 2009). The hormone insulin acts 
in the opposite way, so investigators seek to explain the rela-
tionship between the two. Some studies examined the effects of 
AG and UAG on the insulin metabolism. Findings were that AG 
stimulated glucose release by hepatocytes, while UAG inhibited 
these effects. In addition, in an experiment done with adult-onset 
growth hormone-deficient patients, AG was found to decrease 
insulin sensitivity, and coinjection of UAG countered the effect. 
Thus, the circulating plasma ghrelin’s two forms act in contrasting 
ways (Ukkola, 2009).  An experiment was conducted in order to 
isolate the actions of AG and UAG. Subjects were administered 
a combination of AG and UAG and then each form of ghrelin on 
its own. The subject group consisted of 8 morbidly obese female 
Caucasians. The mean age was 45.4± 10.3 in the range of 28-62 
years old. The average BMI of the subjects was 42.4± 4.8 kg/m2 . 
This experiment was a repeated measures design in which each 
of the 8 subjects received all the experimental conditions with 
a two-week break in between. Ghrelin was administered after 
overnight fasting conditions after a saline infusion. The three ex-
periments were: administration of 200 µg of UAG on its own, 
administration of 100 µg of AG together with 100 µg UAG, and 
a placebo. Subjects were then given a 595 kcal breakfast, a similar 
lunch three hours later, and then they were free to eat what they 
pleased until midnight. Blood samples were collected to measure 
the total ghrelin, glucose, and insulin concentrations. After the 
first hour of administration, while subjects were fasting, admin-
istration of UAG on its own did not change insulin levels or glu-
cose concentrations, nor did it differ from the placebo. Receiving 
the combination of UAG and AG resulted in significantly de-
creased insulin levels as compared to UAG administration alone 
and the placebo (58.2 ± 6.3% insulin concentration when AG and 
UAG were administered combined, compared to 91.8 ± 3.0%, 
the insulin concentration when UAG was administered alone). 
This experiment tested for insulin sensitivity using the glucose 
to insulin ratio. The results indicated an almost 50% decrease in 
insulin levels and almost no change in glucose concentration. This 
demonstrated the effect of UAG to improve insulin sensitivity 
when administered along with the AG that lowered the insulin 
levels. Also, subjects with a smaller AG:UAG ratio possessed 
increased insulin sensitivity indicating the combination effect of 
coinjection of AG and UAG. This may lead to a possible treatment 
for diabetes  for many diabetics have problems with insulin sensi-
tivity. However, further research is needed to exactly determine 
insulin sensitivity, for the glucose-insulin ratio does not consider 
secretion, distribution and degradation of insulin (Kiewiet, et al. 
2009). 
However, a recent study tested the effect of AG in combination 
with UAG on insulin and glucose metabolism. Healthy volunteers 
were given pharmacological doses of AG and UAG as a bolus 
and at 210-minute intervals under fasting conditions and intra-
venous glucose administration. However, The UAG did nothing 
to plasma insulin levels after AG decreased them. This study did 
not examine but encourages further study on insulin sensitivity 
following AG and UAG administration (Barazzoni, 2014). Previous 
research tested the effects of ghrelin on inulin sensitivity by using 
the insulin-glucose ratio. Although the insulin levels stayed the 
same, the glucose levels decreased indicating greater insulin sen-
sitivity (Kiewiet, et al. 2009). Although this may not give the most 
reliable results because it does not consider other factors that 
can contribute to insulin sensitivity, it is a start in observing the 
effect that UAG has on insulin sensitivity. Nevertheless, further 
research is needed to confirm this relationship.
Insulin Sensitivity
Although it may be hypothesized that obese individuals have 
Figure 1
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elevated ghrelin levels contributing to their obesity, on the con-
trary, obese individuals have lower ghrelin concentrations than 
normal.  According to a study obese patients’ plasma active 
ghrelin levels compared to lean subjects were 180 ± 18 vs. 411 
± 57 pg/ml. Serum total ghrelin levels differed from 3650 ±408 
in obese patients and 5263 ±643 pg/ml in lean subjects. Ghrelin 
levels were correlated with insulin resistance that was calculated 
using the HOMA approach which is: insulin (micro-units/milliliter) 
× blood glucose (milllimoles/liter)/ 22.5 (Marzullo, et al. 2003). 
Similarly, in a different study, lower ghrelin levels were found in 
obese subjects. This study, shows the correlation between body 
fat and circulating ghrelin levels after obese and lean subjects 
were fed a weight maintaining diet and abstained from exercise 
two days. The results indicated that the obese subjects’ ghrelin 
levels were 32% lower than the lean subjects’. Additionally, a 
negative correlation was found between ghrelin concentration 
and body fat  (r = -.45). Insulin was also negatively correlated to 
ghrelin concentration (r = -.45) (Tscöp, et al. 2001). Since ghrelin 
is responsible for energy balance and homeostasis, this study is 
consistent with present knowledge. Obese individuals have stable 
energy levels so the body lowers the ghrelin response. However, 
although the circulating ghrelin levels are minimized, its effects on 
insulin and body fat are still present. 
Studying children with type 1 diabetes mellitus (T1DM) indicated 
lower levels of total ghrelin in comparison to healthy subjects. 
Also, higher levels of AG contributed to lower insulin levels and 
greater insulin resistance. Therefore, a possible way the body 
protects diabetics from hyperglycemia can be the decreased con-
centration of circulating ghrelin. Insulin therapy after four months 
elevated ghrelin levels in twenty children with T1DM (Ukkola, 
2009). This can indicate the body considering lower ghrelin levels 
unnecessary due to the insulin therapy.
Although we can understand how insulin resistance is a problem 
in diabetic patients, obesity can contribute to insulin resistance as 
well. One way in which obesity contributes to insulin resistance 
is through the immune system’s activation by obesity. Adipose 
tissue macrophages produce pro-inflammatory cytokines that 
can lead to insulin resistance by blocking insulin action in adipose 
tissue, skeletal muscle, and liver. Therefore, ghrelin as a possible 
therapeutic option can improve both diabetics and obese individ-
uals’ health (Ota, 2014). 
Ghrelin’s Metabolic Effects
An experiment examined ghrelin levels in lean, obese, diabetic 
and nondiabetic subjects. Blood samples were collected after 
overnight fasting and again after monitored eating. Compared 
to normal weight subjects, mean plasma ghrelin concentrations 
were 225% for those with anorexia nervosa and 68% for obese 
subjects. A negative correlation exists between BMI and plasma 
ghrelin concentration. The body maintains homeostasis by de-
creasing ghrelin levels in the presence of positive energy balance. 
When the body has excess energy from nutrition, the ghrelin lev-
els are decreased to postpone hunger. This justifies the postpran-
dial, or after eating a meal, decrease of ghrelin levels (Shiiya, et al. 
2002). Ghrelin’s effects on feeding and energy balance refer to 
the ghrelin produced in the stomach; however, the pancreas also 
produces ghrelin contributing to glucose metabolism. Ghrelin 
is an insulinostatic hormone, meaning it controls the release of 
insulin. Ghrelin levels were compared from the pancreatic vein 
that leaves the pancreas and the pancreatic artery that brings 
new blood to the pancreas. Results showed 8 times the amount 
of ghrelin levels in the pancreatic vein, indicating the pancreas 
produces that ghrelin (Yada, et al. 2014). The GHS-R1a, the ghrelin 
receptor, is located on pancreatic islet cells. Ghrelin binds to the 
receptor and decreases insulin release from the cell and elevates 
blood glucose concentrations. When glucose concentrations rise 
from 2.8 mM to 8.3 mM, insulin release from β cells is stimulated. 
The intensification of Ca2+ concentrations, stimulated by glucose 
metabolism is a crucial step in insulin secretion. However, insulin 
release is weakened when ghrelin is exogenously administered at 
a high concentration of 10 nM. Ghrelin suppresses the peaks of 
Ca2+ by increasing amplitudes of Kv currents that block the in-
flux of Ca2+ ions into the cell thereby slowing down the process 
of glucose-induced insulin release (Yada, et al. 2008). 
 
Research has proven that ghrelin’s effect on the Kv channels re-
sult from decreased cAMP levels. cAMP, cyclic AMP (adenosine 
monophosphate) signaling plays one of the most vital roles in in-
sulin secretion from beta cells (Kashima,et al. 2001). Ghrelin uses 
G-protein Gαi2 to obstruct the cAMP response to glucose me-
tabolism. cAMP activates PKA, protein- kinase-A, and suppresses 
Kv currents in islet cells. Since the insulinostatic effect of ghrelin 
Figure 2
The binding of ghrelin to GHS-R reduces cAMP expression and in-
creases the K+ current. This slows down the influx of Ca2+ into the 
cell, leading to a decreased insulin secretion response to glucose 
metabolism� (Yada, et al� 2014)
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occurs through the cAMP pathway, one possible way to minimize 
it is by presenting cAMP analogues along with ghrelin. One mole-
cule used in testing the effects of cAMP analogs on insulin secre-
tion is 6-Phe-cAMP. In the presence of cAMP analogs, ghrelin has 
no effect on insulin secretion. Hence, by reinstating the cAMP 
activation pathway in the presence of ghrelin, diabetics can expe-
rience enhanced insulin secretion (Dezaki, et al. 2011). This study 
demonstrates a new remedial approach to reducing ghrelin’s ef-
fects. cAMP analogs may aid diabetes by enhancing insulin secre-
tion in pancreas islet. 
Ghrelin Antagonism
Since type 2 diabetics do not have enough insulin, anti-ghrelin 
treatments can enhance insulin secretion. In obesity, insulin resis-
tance is a problem, so eliminating ghrelin can produce a positive 
effect on hyperglycemia. Ghrelin’s affects on insulin and glucose 
metabolism, food intake, and body weight all need to be assessed 
in order to determine if antagonism of ghrelin can relieve symp-
toms of diabetics and obese individuals. One popular method 
used to remove ghrelin’s affects is by antagonism of the GHS-R. 
If the receptor does not accept ghrelin, it has no effect on the 
pancreatic islets. In an experiment using fasted mice, ghrelin re-
ceptor antagonists [D-Lys3]-GHRP-6 enhanced insulin secretion 
and lowered blood glucose levels. This research indicated that a 
ghrelin blockade increases insulin release to help maintain normal 
glucose concentrations (Yada, et al. 2008). Experiments done with 
gastrectomized mice, that lack stomach-derived ghrelin, show the 
role of pancreatic ghrelin in the insulin response. After GHS-R 
antagonist was administered, both groups of mice showed the 
same increased insulin response. This proves that the pancreatic 
ghrelin is responsible for these effects. Therefore, targeting the 
GHS-R can be a therapeutic approach in enhancing insulin secre-
tion (Dezaki, et al. 2006). Administering intra-peritoneal ghrelin 
antagonist to mice also decreased food consumption (Asakawa, 
et al. 2003). These findings can be beneficial in aiding obese indi-
viduals control their food intake. 
Additionally, an experiment done on mice implied ghrelin’s effects 
on body weight, insulin levels, and blood glucose concentrations. 
Injection of ghrelin twice a day for five days increased body 
weight in mice compared to the control. Depending on the diet 
and whether the mouse received ghrelin or saline, determined 
the increase in body weight. For example, one group of mice 
were fed a high fat diet and given saline. These mice exhibited a 
.60 g/day increase in body weight, while those fed a high fat diet 
with ghrelin had a .92 g/day increase. Serum cholesterol and insu-
lin levels increased and glucose concentration increased as well. 
The same experiment tested how ghrelin antagonist, [D-Lys3]-
GHRP-6, affected the same factors. After 7 days of administra-
tion to obese mice, weight gain, fat pad mass, and blood glucose 
concentrations decreased (Asakawa, et al. 2003). This study does 
not seem to be consistent with other research that has linked 
elevated ghrelin to decreased plasma insulin secretion; but a 
moderate increase in glucose concentration was observed. This 
can indicate a case of insulin resistance instigated by an increase 
in free fatty acids (FFA) that are known to contribute to insulin 
resistance. GHS-R antagonists increased insulin sensitivity and 
reduced glucose levels. In addition, it simultaneously decreased 
FFA concentration aiding in fostering insulin sensitivity (Asakawa, 
et al. 2003).
One class of drugs that is being studied as possible ghrelin recep-
tor antagonists are quinazolinone derivatives. In the lab, quinazoli-
none derivative 1 was discovered to have affinity to GHS-R1a. Yet, 
it was found that the molecule had agonistic binding to the recep-
tor rather than the desired antagonistic affect. Alkylation of the N 
group on the molecule altered its functionality by transforming 
it into a GHS-Rla antagonist. Piperdine-substituted quinazolinone 
derivatives that are phenyl or phenoxy substituted were found to 
act as GHS-R antagonists (Del-porte, 2011).
In a structure-activity relationship study, many derivatives of the 
compound were tested for their effects in vivo. Two quinazoli-
none compounds that were used for study were compounds 
26 and 43. These antagonists were administered at doses 3, 10, 
and 30 mg/kg. While compound 26 lowered body weight at the 
10 mg/kg dose, compound 43 only was effective at 30 mg/kg. 
Compound 26 at 30 mg/kg is known as the first orally adminis-
tered GHS-R antagonist possible to induce weight loss in animals. 
This renders it a feasible way to treat obesity, a leading cause of 
diabetes. Compound 26 administered at the highest dose had 
similar effects to an anti-obesity drug that is still under evaluation 
by the FDA, CB1 antagonist rimonabant, 5-(4-choophenyl-1-(2,4-
dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-car-
boxamide. This study also tested glucose tolerance. Both com-
pounds decreased glucose excursion by around 20%. However, 
the cause be-hind these decreased blood glucose levels, was 
not tested for. The study would like to go further in confirming 
that this result from the GHS-R antagonist stemmed from an 
enhanced insulin secretion (Rudolph, et al. 2007). This research 
1 2
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brings practical application of a drug that may be available to help 
treat obesity and diabetes. As a receptor antagonist, it minimizes 
ghrelin’s insulinostatic effects and enhances glucose metabolism. 
Immunoneutralization
Immunoneutralization of ghrelin also is a potential method of 
enhancing insulin secretion. Creating a vaccine to stimulate an-
tibody production against acylated ghrelin may be a viable treat-
ment for obese individuals. However, when a trial was conducted 
using a CYT-009 Ghr Qb vaccine, antibodies were developed, but 
weight stayed the same (Delporte, 2011). In another instance, 
mice were immunized against ghrelin to produce an antibody 
response. After being fed identical diets, the rats with more 
ghrelin-specific antibodies gained less weight per calorie ingested. 
Since their food intake did not vary from other control mice, 
this experiment shows that ghrelin produces a metabolic change 
rather than feeding changes. However, ghrelin has been known 
to increase feeding in a high-fat diet, these mice were given low-
fat, less appetizing meals. This could be a factor that might have 
influenced the ghrelin-vaccinated mice’s feeding habits, so the re-
liability of their conclusion is questionable. Additionally, there can 
be possible draw-backs to this course of treatment. Long-term 
or other side effects of eliminating ghrelin are unclear. It may 
have possible ramifications on energy balance that is regulated by 
ghrelin. The absoluteness of inactivating ghrelin by use of antibod-
ies is also irreversible, unlike ghrelin receptor antagonism that 
can be stopped when undesired effects occur. Another obstacle 
that we may be facing with immunoneutralization is the negative 
feedback loop of the body producing more ghrelin to compen-
sate for lack of ghrelin signals. Although the immediate results of 
an anti-ghrelin vaccine may look promising, further research is 
needed to con-firm the safety and reliability of this method to 
reduce body weight. Controlling the immune response can keep 
ghrelin antibodies from getting out of hand (Carl-son, Cummings, 
2006). However, until research can safely develop and monitor 
such a vaccine, it would be best to put this method on hold. 
Ghrelin Knockout
An alternative to a ghrelin vaccine is the ghrelin knockout model. 
The ghrelin gene is deleted from rats and they are then mon-
itored for feeding habits, metabolism, weight gain, and glucose 
concentration. One point to remember is the unknown effects 
of ghrelin’s complete absence from the body. In one experiment, 
ghrelin’s effects on insulin secretion were tested using ghrelin 
knockout mice. In particular, glucose-induced insulin release was 
higher in knockout mice. On the contrary, basal insulin levels 
remained the same in knockout and wild-type mice. Therefore, 
ghrelin knockout mice had improved insulin responses to glu-
cose. Afterwards, an insulin tolerance test (ITT) was given to both 
groups of mice. No significant differences were found between 
them. The experiment advanced to testing the effects of a high-fat 
diet, known to increase glucose concentrations. When fed a high 
fat diet, blood glucose levels increased in wild-type mice, and no 
in-crease was identified in the knockout mice. This can be at-
tributed to enhanced insulin secretion in response to elevated 
glucose levels. After the wild-type mice did a glucose tolerance 
test (GTT), mice with a high-fat diet showed higher glucose con-
centration levels compared to a control diet, implicating glucose 
intolerance. On the other hand, the ghrelin knockout mice exhib-
ited no difference in glucose tolerance between the high-fat diet 
and the control group. However, there was an increased insulin 
response in the mice fed a high-fat diet (Dezaki, et al. 2006). This 
research shows ghrelin’s role in glucose-insulin metabolism. In 
the ab-sence of ghrelin, increased insulin levels and improved glu-
cose tolerance were found. Although ghrelin knockout cannot be 
done to humans, it serves as an indication of ghrelin’s metabolic 
effects. Regulating ghrelin levels in obese people can possibly im-
prove their body weight and glucose tolerance.  
GOAT
Ghrelin O-acyltransferase is a membrane-bound O-acyltransferace. 
It catalyzes the octanoylation of ghrelin allowing it to be acylated 
and able to connect with the GHS-R1a receptor. Since it catalyz-
es ghrelin to be in its active form, one idea is to target GOAT 
to slow the process of the body producing acylated ghrelin. In 
GOAT knockout models, there is no acylated ghrelin found circu-
lating (Pulk-kinen, et al. 2010). As discussed earlier, studies show 
that unacylated ghrelin counteracts acylated ghrelin’s effect on 
insulin, and did nothing to insulin metabolism when administered 
on its own (Kiewiet, et al. 2009). So, inhibiting GOAT action can 
minimize the effects that acylated ghrelin has on insulin and glu-
cose metabolism. 
One method studied to inhibit GOAT is the administration of 
GO-CoA-Tat in mice. The GHS-R binding property of ghrelin 
is determined by the octanoylation on serine 3, making it acyl 
ghrelin. This inhibitor was found to be most active in binding to 
GOAT. After administering GO-CoA-Tat to mice at a 40 mg/kg 
dose, acyl ghrelin levels decreased while des acyl ghrelin levels 
remained unchanged. Additionally, after 1 month, weight gain 
due to decreased fat mass was assessed in the treated mice. 
Interestingly, no difference in weight was found compared to 
ghrelin knockout mice. This indicates that GOAT inhibition may 
have similar effects to ghrelin knockout. The mice’s response to 
glucose was measured to observe the effects of GO-CoA-Tat. 
The insulin response was in-creased and blood glucose levels 
subsequently decreased. This did not occur in ghrelin knockout 
mice thereby reinforcing the mechanism of GOAT inhibition to 
prevent ghrelin’s acylation (Taylor, et al. 2012). Additionally, use of 
this GOAT inhibitor may be a better option than using a ghrelin 
antagonist. Some advantages that a study done by Barnett et al. 
in 2010 explains  that GO-CoA-Tat does not need to cross the 
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blood brain barrier unlike the GHS-R antagonist which targets 
receptors in the brain as well. Additionally, there is no feedback 
of the body trying to compensate by producing extra acylated 
ghrelin to bind to the receptors. Another reason given is that 
targeting an enzyme like GOAT may be safer than targeting a 
widespread receptor (Barnett, et al. 2010). However, GOAT is 
still being studied and its use in treatment is not yet confirmed. 
Further experimentation would need to be done to examine the 
viability of such a method of treatment in humans, and the possi-
ble negative side effects of a drug using this mechanism. 
In conclusion, currently research is in the process of determin-
ing the possibilities of using the ghrelin system to treat or cure 
diabetes and obesity. No definite answer can be given about its 
viability in human subjects as most experimentation is done in 
mice. However, the facts have been proven. Ghrelin’s influences 
on insulin secretion, blood glucose concentration, weight-gain, 
and fat mass have been assessed in various studies. The regulation 
of ghrelin by reducing its impact on pancreatic islets or by elimi-
nating it altogether have been found to enhance insulin secretion 
and lead to less weight gain. Therefore, further research on the 
pharmacological effects of drugs used to regulate ghrelin’s effects 
may lead to a more certain conclusion.
Legend
AG: Acylated ghrelin UAG: Unacylated ghrelin
GHS-R: Growth hormone secretagogue recep-tor
GOAT: Ghrelin O-acyltransferace
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Introduction
The molecular basis for cancer is now well understood to in-
volve the genetic control of multiple genes that control cell cycle 
and tissue growth. The random mutations that activate dominant 
oncogenes or inactivate tumor suppression genes result in a cell 
cloning itself with an abnormal pattern of growth control forming 
a tumor. Traditional cancer therapies aim to destroy or remove 
the tumor by chemotherapy, radiation or surgery. The problem 
with both radiation and surgery is the ability of tumors to metas-
tasize and spread cancerous cells to areas inaccessible to these 
treatments or may not be noticeable at the time of treatment 
allowing a secondary tumor to appear. The trouble with chemo-
therapy is its low therapeutic index for many cancers and the 
rapid development of drug resistance in cancerous cells.
Gene therapy is a fundamentally different approach to the treat-
ment of diseases. Originally proposed as treatment for inherited 
autosomal recessive Mendelian disorders, such as hemophilia, 
gene therapy is now being used to treat multiple acquired condi-
tions including infections, degenerative diseases and cancer. Gene 
therapy is the use of genetic material (genes) to express a specific 
protein in a cell or to reduce the amount of protein by interfering 
with its synthesis. Replacing a defective gene with a functional 
one is the essence of gene therapy. 
Cancer is widely believed to arise from mutations to the cell’s 
DNA by either carcinogens or random mutations during cell 
division. This genetic basis coupled with the limitations of the 
traditional treatments, makes cancer a great candidate for gene 
therapies. More than 60 percent of all gene targeted therapy clin-
ical trials since 1989 aimed to treat cancer (Ginn et al, 2013). 
Strategies for Gene Therapy for Cancer
Cancer is a disease that involves multiple genetic changes to on-
cogenes, tumor-suppressor genes and modifier genes. There is 
also the intracellular interactions with multiple cells that regulate 
the body’s immune response and the interaction with other can-
cer cells to maintain a solid tumor. Gene therapy can be used 
alone or together with conventional treatments. It can be used 
to sensitize cancerous cells to radiation or chemotherapy. It can 
increase the body’s overall resistance to chemotherapy so larger 
doses can be used. Gene therapy can declump or shrink tumors 
to allow for surgical removal.  Various approaches are being ex-
amined both in preclinical studies and in clinical trials for gene 
therapy for cancer.
Downregulation of Genetic Targets
To downregulate the expression of protein coded by oncogenes, 
antisense molecules are used. Antisense molecules are synthet-
ic oligodeoxynucliotides (ODN) that hybridize with the coding 
(sense) mRNA of a specific gene. The antisense and sense mol-
ecules form double stranded RNA which cannot be translated 
destroying the mRNA. ODNs are designed to be highly resistant 
to nucleases which will destroy the mRNA (Stein et al., 1988). In 
a phase I–II clinical study using antisense ODNs to target BCL2 
(an anti-apoptotic oncogene) mRNA combined with chemother-
apy in patients with advanced malignant melanomas, the antisense 
ODN was found to successfully downregulate the target protein 
and has shown anti-tumor effects in 6 of the 14 patients (Jansen 
et al., 2000).
Immunomodulation by Gene Therapy
Because cancer cells originate from “self” cells, they generally do 
not cause a strong immune response. However, the immune sys-
tem can be augmented by gene therapy to increase their function. 
Therapeutic genes can be introduced into tumor cells or into 
effector cells such as T lymphocytes.
To elicit a greater immune response, tumor cells have been mod-
ified with the insertion of cytokine genes. Cytokines are small 
cell signaling polypeptides involved in immunity and inflammation. 
Systemic and local administration of cytokines from the interleu-
kin (IL) family has shown significant reduction in tumor size but 
have systemic side effects and short half-lives, making injection 
of interleukins deficient in long term tumor control. However, 
tumor cells modified to express IL-12 or IL-2 have shown the 
same size reduction as well as long term remission and metasta-
sis control (Gao et al., 2005, Tahara et al., 1995).
The receptors on T lymphocytes can be modified to target tu-
mor-associated antigens. The most common method of creating an 
artificial T cell receptor (TCR) is by protein fusion of single-chain 
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variable fragments derived from monoclonal antibodies that 
acts as the TCR ectodomain with the CD3-zetatransmembrane 
and endodomain. The endodomain can be further modified 
with co-stimulatory receptors to increase immunologic activity. 
Leukemias from B cell linages are suitable targets for this therapy. 
The CD19 antigen is expressed in differentiated cells with B cell 
linages and is rarely lost in cancerous cells. Anti-CD19 T cells can 
safely target and destroy cells expressing CD19 including can-
cerous cells, and they will later be replenished with healthy cells 
(Scheuermann & Racila, 1995).
For effective activation of T cells, non-specific signals are needed 
as well as the antigen-specific signal received by the T cell recep-
tor. Co-stimulatory molecules interact with receptors, such as 
CD28, on the T cell to provide the non-specific signals. Martinet 
et al. (2000) has shown that transfection of both IL-12 and 4-1BB 
ligand genes into tumor cells resulted in long-term remission 
of liver metastases in mice. The 4-1BB ligand, a co-stimulatory 
molecule that binds with the 4-1BB receptor on T cells, syner-
gizes with the CD28 pathway to increase the immune response 
(Melero et al., 1998). 
‘Suicide’ Gene Therapy
A commonly used idea for gene treatment of solid tumors is 
‘suicide’ gene therapy, where the cells expressing the therapeutic 
gene are killed. Suicide genes code for enzymes that can acti-
vate a drug with an otherwise low toxicity. When suicide genes 
are expressed only in the targeted cancer cells, the healthy cells 
avoid the drugs toxic effect. One enzyme commonly used is her-
pes simplex thymidine kinase, which converts the nontoxic drug 
Ganciclovir, into a toxic form by phosphorylation (Song et al., 
2009). The suicide gene can be placed under the control of tumor 
specific promoters such as c-erbB2 in breast cancer, ensuring spe-
cific drug activation in the tumor (Pandha et al., 1999). Because 
the enzyme can bleed into and kill neighboring non-transduced 
cells in what is termed the bystander effect, suicide genes can 
be optimized to only require ten percent transduction in a solid 
tumor greatly increasing its efficiency (Xiong et al., 2012). 
Apoptosis-inducing genes One of the problems involved in treat-
ing solid tumors by conventional therapies is that cancerous cells 
are often resistant to apoptosis and will not die with chemo-
therapy or radiation therapy alone. The gene that codes for the 
anti-tumor protein p53 is either mutated or deleted in more than 
50 percent of human tumors (Hollstein et al, 1991). Inserting a 
copy of wild type p53 into cancerous cells has been shown to 
induce apoptosis and make the cells more susceptible to chemo-
therapy and radiation therapy.
Anti-angiogenesis 
Tumors, just like any tissue, require a constant supply of nutrients, 
oxygen, hormones and growth factors for their growth and pro-
gression. This is provided by the formation of new blood ves-
sels or angiogenesis. Therefore, inhibition of angiogenesis would 
stunt tumor growth. Patients with glioblastoma multiforme, a 
highly vascularized form of brain cancer that does not respond 
well to conventional treatments, would benefit greatly from an 
anti-angiogenic treatment. Even poorly vascularized tumors can 
be reduced by anti-angiogenic treatment (Beecken et al., 2001). 
Clinical trials involving systemic administration of angiogenic in-
hibitors such as angiostatin and endostatin showed no dose-lim-
iting toxicity. However, they did not show marked signs of tumor 
regression due to the continuous release of pro-angiogenic 
factors released by the tumor (Ohlfest et al., 2005, Shepherd & 
Sridhar, 2003). Therefore, the delivery of angiogenic inhibitors by 
gene transfer is favored over systemic administration. 
Gene Transfer Techniques
The success of gene therapy lies in the efficient delivery of the 
gene of interest to the target cell. The therapeutic gene is cloned 
into a vector together with appropriate regulatory regions (pro-
moters/enhancers) as well as any supporting proteins needed. 
Selecting the right vector is a crucial part of gene therapy. The 
ideal vector will protect and easily deliver the genetic informa-
tion across the cell membrane and into the nucleus. It should 
have the ability to regulate the expression of the gene of interest 
and be able to successfully target specific cells to minimize toxic-
ity. It should be easy and inexpensive to produce in large quanti-
ties. Once the gene is cloned into the vector it can be introduced 
to the target cell. The gene can be delivered in vitro or in vivo. 
In in vitro transfer, cells from a specific tissue are removed from 
the patient and exposed to the gene-carrying vector. The trans-
formed cells are selected by biomarkers and are reintroduced 
into the patient’s body. In in vivo transfer, the vector is injected 
into the patient’s body directly, usually into the target tissue or 
the tumor if a tumor is the target.
Viral Vectors
Currently, the most effective method of gene transfer is though 
viral vectors. Viruses have evolved over the years to enter the cell 
and efficiently hijack the cell’s machinery to produce its own viral 
proteins. An ideal viral vector uses the viral infection pathway but 
avoids the expression of the viral genes that facilitate replication 
and the subsequent host cell death. This is achieved by deleting 
most of the viral genome, leaving intact the sequences (usually 
the long terminal repeats) required for capsid packaging and in-
tegration of the vector DNA into the host’s chromatin. The most 
commonly used viruses for gene therapy are retrovirus, lentivirus 
and adenovirus.
Retroviruses carry their genetic material as RNA and integrate 
their genome into host DNA using the viral enzymes reverse 
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transcriptase and integrase. The integrated DNA acts as a pro-
virus which replicates to make multiple copies of the virus and 
is released outside the cell. Therapeutic retroviral vectors are 
made replication-deficient by replacing the structural genes with 
the therapeutic gene. Since retroviruses only gain access to the 
host’s DNA when the nuclear membrane is broken down, they 
only infect actively dividing cells and integrate the gene of interest 
into the target cell.
Lentiviruses, a subclass of retroviruses, have recently been adapt-
ed to be used as gene transmission vectors. Lentivirus vectors 
can naturally enter an intact nuclear membrane and integrate 
their genome into non-dividing cells, which a retrovirus vector 
cannot do. HIV-1 is the most common lentivirus used in gene 
transfer. Because of its dangerous nature, lentivirus vectors do 
not carry the gene required for replication. As an added precau-
tion, self-inactivating (SIN) lentivirus vectors are being developed 
which contain deletions in the downstream LTR.
Adenoviruses carry their genetic material as double stranded 
DNA, but as opposed to the other viruses mentioned, the DNA 
is not integrated into the host’s genome. However, adenovirus 
can successfully infect broad range of cell type and is not limited 
to dividing cells. In 2003 the first gene therapy to be approved for 
commercial production was a recombinant adenovirus-p53 gene 
therapy for head and neck squamous cell carcinoma approved by 
China’s State Food and Drug Administration and is sold under 
the name Gendicine (Pearson et al., 2004).
Limitations of Viral Vectors
The obvious concern regarding the use of viral vectors is the 
possibility of the virus eliciting a strong immune response. In 
1999, an 18-year-old male died due to an extreme immune re-
sponse triggered by the administration of an adenoviral vector. 
He was participating in a phase I clinical trial to determine the 
safety of a gene therapy for ornithine transcarbamylase deficien-
cy, an X-linked genetic disease of the liver (Raper et al., 2003). 
Since then most work with adenovirus vectors used genetically 
crippled constructs which would minimize the likelihood of an 
immune response. 
The integration of the therapeutic gene when using retroviral 
or lentiviral vectors carries a possibility of oncogene activation. 
Since the point of insertion is mostly random, the transgene can 
insert into the upstream regulatory region of an existing gene 
and activate or upregulate the existing gene due to the proximity 
to the promoters in the downstream LTR of the transgene. The 
transgene can also insert itself into a transcriptional unit of an 
existing gene causing a loss of function in that gene. This was 
shown to be a real threat when four patients in a clinical trial that 
successfully treated X-linked severe combined immunodeficiency 
disease developed a form of leukemia. The cause in at least two 
of the patients appeared to be the integration of the therapeutic 
murine leukemia virus retroviral vector close to the LMO2 on-
cogene (Kohn et al., 2003). 
Adenovirus vectors, since they do not integrate the gene into the 
host’s genome, carry no risk of insertional mutagenesis. However, 
since adenovirus vectors to not integrate the gene into the cell’s 
DNA they are only expressed transiently and require multiple 
administrations to be effective and repeated delivery may com-
promise efficacy and might induce a severe immune response 
(Hartman et al, 2008). 
While self-inactivating (SIN) retroviral vectors may reduce the 
risk of insertional mutagenesis (Ellis, 2005), the clinical use of ret-
roviral vectors is curtailed due the limited packaging capacity of 
viral vectors. Most retroviral vectors can carry a transgene of up 
to 8 kb, as larger genes would compromise the efficiency of viral 
reverse transcription (Thomas et al,. 2003). This excludes the 
transport of multiple or large transgenes. Finally, the high costs 
involved in the manufacture of clinical-grade retroviral vector and 
regulatory issues keep viral vectors from widespread translation 
into clinical practice.
Non-viral Methods 
The simplest method of gene delivery is injecting naked DNA 
directly into the target tissue. Since naked DNA lacks any mode 
of transport through the cell membrane, there have been various 
methods developed to increase the efficiency of cellular uptake.
In smaller animals, hydrodynamic injection can overcome the low 
efficiency of cellular uptake. This procedure involves the injection 
of a large volume, about 10% the weight of the mouse, of DNA/
saline solution through the tail vein in less than 10 seconds, with 
most of the protein being expressed and accumulating in the liver 
(Liu et al., 1999). In larger animals, the volumes required for hy-
drodynamic injection become prohibitive. This limitation can be 
overcome by isolating an organ’s blood flow using catheters or 
part of a limb using external tourniquets.
The efficiency of delivery can be enhanced by physical methods 
such as microinjection directly into the cell, electroporation, so-
noporation and the use of microparticle in gene guns and mag-
netofection. Most of these methods are only feasible in in vitro 
gene delivery. Electroporation has been used successfully in gene 
delivery to mice skeletal muscle in vivo (Miyazaki et al., 2002), but 
the larger energy required to increase the permeability of the 
cell membrane across a human limb risks destroying too many 
cells. Sonoporation is limited to acoustically accessible organs. 
Although these methods are efficient, they require expensive 
specialized equipment reducing their benefit over viral vectors.
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The efficiency of delivery can also be increased by chemical 
methods. The negatively charged phosphate on DNA can bind 
to a variety of cationic polymers to form a DNA-polymer com-
plex called a polyplex. The polyplex interacts with the cell mem-
brane and is absorbed into the cell by phagocytosis where the 
polyplex is released and the DNA can migrate into the nucleus. 
Polyethylenimine (PEI) is one of the most commonly used non-vi-
ral vectors based on polycations for DNA delivery both in vitro 
and in vivo. PEI is a polymer with repeating units composed of an 
amine group and two carbon spacers. PEI can be linear, branched 
or as a highly branched dendrimer, though linear PEI is more 
commonly used. The exact mechanism my which the DNA-PEI 
polyplex escapes the endosome is unknown but is thought to 
be a result of the increased influx of protons, chloride ions, and 
water during endosome acidification causing it to rupture from 
the high osmotic pressure. Using confocal laser scanning micros-
copy, Merdan et al. (2002) observed the dispersal of the genetic 
cargo soon after the rupture of the endosomes  on living cells. 
Cationic lipids are also used to condense the DNA into a lipo-
some. These liposomes can protect the DNA from damage during 
transport, something that the other non-viral delivery methods 
fail to do.  Suzuki et al. (2010) successfully transfected murine 
ovarian tumors in vivo with IL-12 using self-prepared bubble lipo-
somes combined with ultrasound applied to the tumor. The bub-
ble liposome protocol was more effective than using the more 
expense commercially available transfection agent, Lipofectamine 
2000. However, the Lipofectamine control in the study was not 
conducted together with ultrasound.
Non-viral methods present many advantages over viral vectors. 
Most non-viral methods are simpler and cheaper to produce 
and elicit a smaller host immune response. The transfer capac-
ity of non-viral methods is functionally unlimited compared to 
viral capacity. Low levels of transfection used to be the limiting 
disadvantage, but advances have resulted in methods with trans-
fection rates that are clinically viable and can compete with viral 
vectors. However, the efficient delivery of DNA to the nucleus is 
not enough for long-term transgene expression if it cannot inte-
grate into the host genome. Transposable elements (transposons) 
could potentially offer such an alternative.
Transposon Systems for Gene Therapy
Transposons or transposable elements (TE) are mobile regions 
of DNA that can change their position in the genome. DNA 
transposons rely on a transposase enzyme to cut the TE from 
the donor site and insert it at the receiving site in a ‘cut-and-
paste’ like manner. The transposase gene is the trans-acting ele-
ment of the transposon system. The cis-acting element is a pair 
of inverted repeats at either end of the gene which are the target 
sites for the transposase as well as associated enhancers and 
promoters. Most regions coding for transposase also contain the 
cis-acting elements and are considered autonomous TEs. While 
transposons seem to have played a large role in evolution with 
close to fifty percent of the human genome made up of TEs, most 
species have accumulated mutations in the transposase genes.
One family of transposons, the mariner/tc1-like superfamily, has 
members in a wide range of species including nematodes, insects, 
fish, and humans with analogs reported in prokaryotes. This is a 
result of horizontal gene transfer between species. Unfortunately, 
not a single autonomous element has been isolated from verte-
brates. Ivics et al. (1997) reconstructed the first man-made trans-
poson system called the Sleeping Beauty (SB) transposon system 
based on the consensus sequence of members of the mariner/tc1 
family isolated from fish. The reconstructed SB transposase was 
successfully able to transfer elements not only in fish but also in 
other species including human cells. The use of a SB transposon 
based system of gene transfer was proposed in 2000 when suc-
cessful integration and long tern expression using SB was shown 
in mice (Yant et al., 2000).  
Because transposons have to survive along with the host cell, 
traits that posed less of a threat to the cell were selected evolu-
tionarily. A transposase with a high activity increases the chance 
of insertional mutagenesis. Therefore, early iterations of the SB 
tranposase had lower activity that could not compete with the 
fast acting retroviral enzymes. It was known early on that ex-
changing certain amino acids in SB transposase could increase its 
efficiency, but guessing the right combination of changes needed 
to construct a hyperactive transposase would be near impossible. 
Mates et al. (2009) conducted a large scale genetic screen of SB 
mutants and yielded a transposase (SB100X) that was ~100 times 
more efficient than first generation SB transposases. This hyper-
active transposase allows the SB transposon system to compete 
with viral vectors and was awarded the title of “Molecule of the 
Year, 2009. ”
Since SB transposon based vectors integrate the transgene into 
the host’s DNA, just as retroviral and lentiviral vectors do, they 
also pose the risk of insertional mutagenesis. Statistical analysis 
of the integration sites of both viral integrase and SB transposase 
suggests the SB vectors are safer. SB transposons integrate at 
TA dinucleotides and shows a preference (p<0.01) for a short 
TA palindromic consensus sequence. This preference can be 
explained by the greater bendability at TA sites that is possibly 
required to allow the transposase access, but with ~108 TA sites 
in the human genome this can still be considered random on a 
genomic level. A study mapping over 1,300 SB integration sites 
found 39 percent (p=0.02) integrated into known genes with a 
weak preference for regions slightly upstream or within 5kb of 
the start site (Yant et al., 2005). These results were compared to 
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10,000 computer-simulated insertions that showed truly random 
insertions would only result in 33 percent of genes. It is hard 
to avoid any preference for transcriptionally active genes since 
those are accessible due to chromatin modification such CpG 
islands. Even though SB transposon shows a statistically signifi-
cant preference for genes, the percentages are low compared to 
viral vector insertions.  Schröder et al. (2002) reported 69 per-
cent (p<0.0001) of in vivo integration sites using HIV-1 vectors 
were in known genes. Adding insulator sequences to the ends of 
transposable element can further reduce the risk of unwanted 
activation of neighboring genes (Walisko et al., 2007).
Long term expression of the transposase gene can result in the 
transposon being excised and reinserted in a different location in 
what is known as “re-hopping”, increasing the risk of insertional 
mutagenesis. To limit the amount of time in which transposase 
will be produced the transposase gene can transported on a sec-
ond plasmid that will be transcribed ectopically and destroyed. 
The use of mRNA as a source of transposase in also being ex-
plored (Wilber et al., 2006). 
The greatest weakness of the SB transposon system is its inability 
to infect cells. Any of the non-viral delivery methods mentioned 
above can be used to transport the SB-containing plasmid. There 
is also the possibility of using hybrid vectors that transport the 
transposon packaged into virions. These hybrid vectors may prove 
more effective than either method alone. The integration sites 
of an HIV-1/SB hybrid was shown to be closer to truly random 
integration profile with only 30 percent inserting into known 
genes (Staunstrup et al., 2009), and a herpes simplex virus/SB hy-
brid has successfully increased the capacity of the SB transposon 
(de Silva et al., 2009). SB transposon have also been successfully 
delivered to target tissue using modified liposomes that used 
Asialoglycoprotein receptor (ASGPR)-mediated endocytosis to 
target hepatocytes in vivo (Wang et al., 2009) and hybrid vectors 
may be employ similar targeting techniques being researched for 
viral vectors (Waehler et al., 2007).
Since transposons simply ‘cut-and-paste’, they do not have to rely 
on reverse transcriptase which has a tendency to incorporate 
mutations. The transposase can possibly be modified in the future 
to target a specific region of DNA using a synthetic zinc finger 
domain (Yant et al., 2007). SB transposons are easier and cheaper 
to manufacture than replication-incompetent viral vectors, allow-
ing researchers without the resources required to produce viral 
vectors to continue exploring transposon based systems.
Conclusion
Non-viral vectors with the ability to integrate the transgene are 
far more efficient than viral vectors or non-integrating DNA 
plasmids. The increase safety risks associated with viral vectors 
and resultant bureaucracy has limited the widespread use of 
commercially licensed gene therapy treatments. There are only 
two approved gene therapies worldwide in over 25 years of 
clinical trials, mostly due to safety and toxicity concern and not 
effectiveness. There is a need for a safer delivery system and the 
SB transposon system may be it. Most of its early limitations have 
been resolved to the point that it can compete with viral vectors. 
SB-mediated gene transfer has been shown to be effective in a va-
riety of treatment strategies including anti-angiogenesis (Ohlfest 
et al., 2005), suicide therapy (Song et al., 2009), and others. 
The first human clinical trial using SB transposons is under way. 
The trial will attempt to transfect T cells ex vivo with engineered 
receptors against the CD19 antigen as described above (Williams, 
2008). Regardless of what the results of this trial will be in terms 
of efficacy, the trial will prove the safety of this method and pro-
vide the data necessary for further improvement in future trials.  
References
Beecken, W. D. C., Fernandez, A., Joussen, A. M., Achilles, E. G., Flynn, E., 
Lo, K. M., ... & Shing, Y. (2001). Effect of antiangiogenic therapy on slowly 
growing, poorly vascularized tumors in mice. Journal of the National 
Cancer Institute, 93(5), 382-387.
de Silva, S., Mastrangelo, M. A., Lotta, L. T., Burris, C. A., Federoff, H. J., & 
Bowers, W. J. (2009). Extending the transposable payload limit of Sleeping 
Beauty (SB) using the herpes simplex virus (HSV)/SB amplicon-vector 
platform. Gene therapy, 17(3), 424-431.
Ellis, J. (2005). Silencing and variegation of gammaretrovirus and lentivi-
rus vectors. Human gene therapy, 16(11), 1241-1246.
Gao, J. Q., Sugita, T., Kanagawa, N., Iida, K., Eto, Y., Motomura, Y., ... & 
Nakagawa, S. (2005). A single intratumoral injection of a fiber-mu-
tant adenoviral vector encoding interleukin 12 induces remarkable 
anti-tumor and anti-metastatic activity in mice with Meth-A fibrosar-
coma. Biochemical and biophysical research communications, 328(4), 
1043-1050.
Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013). 
Gene therapy clinical trials worldwide to 2012–an update. The journal of 
gene medicine, 15(2), 65-77.
Hartman, Z. C., Appledorn, D. M., & Amalfitano, A. (2008). Adenovirus 
vector induced innate immune responses: impact upon efficacy and 
toxicity in gene therapy and vaccine applications. Virus research, 132(1), 
1-14.
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991). p53 
mutations in human cancers. Science, 253(5015), 49-53.
60
Jacob Stauber
Ivics, Z., Hackett, P. B., Plasterk, R. H., & Izsvák, Z. (1997). Molecular 
Reconstruction ofSleeping BeautyaTc1like Transposon from Fish, and Its 
Transposition in Human Cells. Cell, 91(4), 501-510.
Jansen, B., Wacheck, V., Heere-Ress, E., Schlagbauer-Wadl, H., Hoeller, C., 
Lucas, T., ... & Pehamberger, H. (2000). Chemosensitisation of malignant 
melanoma by BCL2 antisense therapy. The Lancet, 356(9243), 1728-1733.
Kohn, D. B., Sadelain, M., Dunbar, C., Bodine, D., Kiem, H. P., Candotti, F., ... 
& Glorioso, J. (2003). American Society of Gene Therapy (ASGT) ad hoc 
subcommittee on retroviral-mediated gene transfer to hematopoietic 
stem cells.Molecular Therapy, 8(2), 180-187.
Liu, F., Song, Y., & Liu, D. (1999). Hydrodynamics-based transfection in 
animals by systemic administration of plasmid DNA. Gene therapy, 6(7), 
1258-1266.
Martinet, O., Ermekova, V., Qiao, J. Q., Sauter, B., Mandeli, J., Chen, L., & 
Chen, S. H. (2000). Immunomodulatory gene therapy with interleukin 
12 and 4-1BB ligand: long-term remission of liver metastases in a mouse 
model. Journal of the National Cancer Institute, 92(11), 931-936.
Mátés, L., Chuah, M. K., Belay, E., Jerchow, B., Manoj, N., Acosta-Sanchez, 
A., ... & Izsvák, Z. (2009). Molecular evolution of a novel hyperactive 
Sleeping Beauty transposase enables robust stable gene transfer in 
vertebrates. Nature genetics, 41(6), 753-761.
Melero, I., Bach, N., Hellström, K. E., Aruffo, A., Mittler, R. S., & Chen, L. 
(1998). Amplification of tumor immunity by gene transfer of the co-stim-
ulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. 
European journal of immunology, 28(3), 1116-1121.
Merdan, T., Kunath, K., Fischer, D., Kopecek, J., & Kissel, T. (2002). 
Intracellular processing of poly (ethylene imine)/ribozyme complexes 
can be observed in living cells by using confocal laser scanning micros-
copy and inhibitor experiments. Pharmaceutical research, 19(2), 140-146.
Miyazaki, J. I., & Aihara, H. (2002). Gene transfer into muscle by electro-
poration in vivo. Gene therapy protocols, 49-62.
Ohlfest, J. R., Demorest, Z. L., Motooka, Y., Vengco, I., Oh, S., Chen, E., ... 
& Largaespada, D. A. (2005). Combinatorial antiangiogenic gene therapy 
by nonviral gene transfer using the sleeping beauty transposon causes 
tumor regression and improves survival in mice bearing intracranial 
human glioblastoma. Molecular Therapy, 12(5), 778-788.
Pandha, H. S., Martin, L. A., Rigg, A., Hurst, H. C., Stamp, G. W., Sikora, K., 
& Lemoine, N. R. (1999). Genetic prodrug activation therapy for breast 
cancer: A phase I clinical trial of erbB-2–directed suicide gene expres-
sion. Journal of clinical oncology, 17(7), 2180-2180.
Pearson, S., Jia, H., & Kandachi, K. (2004). China approves first gene 
therapy.Nature biotechnology, 22(1), 3-4.
Raper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G. P., ... & 
Batshaw, M. L. (2003). Fatal systemic inflammatory response syndrome in 
a ornithine transcarbamylase deficient patient following adenoviral gene 
transfer.Molecular genetics and metabolism, 80(1), 148-158.
Scheuermann, R. H., & Racila, E. (1995). CD19 antigen in leukemia and 
lymphoma diagnosis and immunotherapy. Leukemia & lymphoma, 18(5-
6), 385-397.
Schröder, A. R., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. 
(2002). HIV-1 integration in the human genome favors active genes and 
local hotspots. Cell, 110(4), 521-529.
Shepherd, F. A., & Sridhar, S. S. (2003). Angiogenesis inhibitors under 
study for the treatment of lung cancer. Lung Cancer, 41, 63-72.
Song, J. S., Kim, C. W., & Ochoa, E. R. (2009). Sleeping Beauty-mediated 
suicide gene therapy of hepatocellular carcinoma. Bioscience, biotech-
nology, and biochemistry, 73(1), 165-168.
Staunstrup, N. H., Moldt, B., Mátés, L., Villesen, P., Jakobsen, M., Ivics, Z., 
... & Mikkelsen, J. G. (2009). Hybrid lentivirus-transposon vectors with 
a random integration profile in human cells. Molecular Therapy, 17(7), 
1205-1214.
Stein, C. A., Subasinghe, C., Shinozuka, K., & Cohen, J. S. (1988). 
Physicochemical properties of phospborothioate oligodeoxynucleotides. 
Nucleic Acids Research, 16(8), 3209-3221.
Suzuki, R., Namai, E., Oda, Y., Nishiie, N., Otake, S., Koshima, R., ... & 
Maruyama, K. (2010). Cancer gene therapy by IL-12 gene delivery 
using liposomal bubbles and tumoral ultrasound exposure. Journal of 
Controlled Release, 142(2), 245-250.
Tahara, H., Zitvogel, L., Storkus, W. J., Zeh, H. J., McKinney, T. G., Schreiber, 
R. D., ... & Lotze, M. T. (1995). Effective eradication of established murine 
tumors with IL-12 gene therapy using a polycistronic retroviral vector.
The Journal of Immunology, 154(12), 6466-6474.
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003). Progress and problems 
with the use of viral vectors for gene therapy. Nature Reviews Genetics, 
4(5), 346-358.
Waehler, R., Russell, S. J., & Curiel, D. T. (2007). Engineering targeted viral 
vectors for gene therapy. Nature Reviews Genetics, 8(8), 573-587.
Walisko, O., Schorn, A., Rolfs, F., Devaraj, A., Miskey, C., Izsvák, Z., & Ivics, 
Z. (2007). Transcriptional activities of the Sleeping Beauty transposon 
61
Transposon Based Gene Therapy for Cancer
and shielding its genetic cargo with insulators. Molecular Therapy, 16(2), 
359-369.
Wang, X., Sarkar, D. P., Mani, P., Steer, C. J., Chen, Y., Guha, C., ... & 
Roy-Chowdhury, J. (2009). Long-term reduction of jaundice in Gunn 
rats by nonviral liver-targeted delivery of Sleeping Beauty transposon. 
Hepatology, 50(3), 815-824.
Wilber, A., Frandsen, J. L., Geurts, J. L., Largaespada, D. A., Hackett, P. B., 
& McIvor, R. S. (2006). RNA as a source of transposase for Sleeping 
Beauty-mediated gene insertion and expression in somatic cells and 
tissues. Molecular Therapy, 13(3), 625-630.
Williams, D. A. (2008). Sleeping beauty vector system moves toward 
human trials in the United States. Molecular Therapy, 16(9), 1515-1516.
Xiong, T., Li, Y., Ni, F., & Zhang, F. (2012). Monitoring of bystander effect of 
herpes simplex virus thymidine kinase/acyclovir system using fluo-
rescence resonance energy transfer technique. Journal of biomedical 
nanotechnology,8(1), 74-79.
Yant, S. R., Huang, Y., Akache, B., & Kay, M. A. (2007). Site-directed trans-
poson integration in human cells. Nucleic acids research, 35(7), e50.
Yant, S. R., Meuse, L., Chiu, W., Ivics, Z., Izsvak, Z., & Kay, M. A. (2000). 
Somatic integration and long-term transgene expression in normal and 
haemophilic mice using a DNA transposon system. Nature genetics, 
25(1), 35-41.
Yant, S. R., Wu, X., Huang, Y., Garrison, B., Burgess, S. M., & Kay, M. A. 
(2005). High-resolution genome-wide mapping of transposon integration 
in mammals. Molecular and cellular biology, 25(6), 2085-2094.
62
Introduction
The immune system is a continuously adapting organ system 
with many defense mechanisms in place to prevent infection. 
Thousands of microbes are constantly trying to find a way to 
infiltrate and take residence in the body and the components of 
the immune system together find a way to prevent infection from 
penetrating, or killing it once it does pierce the initial barrier.
Throughout history, the persistence of different infections has 
constantly evolved to reflect our continually changing ecosystem. 
As we learn to adapt to a specific disease, a new one will fill the 
void that was left. Yersinia pestis, the bacteria responsible for kill-
ing hundreds of millions of people throughout the 14th century is 
now almost completely eradicated (Haensch, et. al., 2010). 
Many methods have been discovered which successfully wiped out 
several illnesses plaguing the globe for many years. Vaccinations, 
healthier diets, and personal hygiene have all had a positive effect 
in reducing the number of bacterial and viral infections through-
out the past century. Mumps, measles, polio, and diphtheria are 
all examples of sicknesses that have practically been eliminated 
in most developed countries resulting in a healthier environment.
Despite the decreased incidence of microbial infections, many 
other disorders have quickly filled the void left by these infec-
tions. Crohn’s disease, type 1 diabetes, and allergies have seen 
exponential growth over the past seventy years, indicating an 
increase in hypersensitivity reactions. This paper explores the 
recent increase in hypersensitivity reactions, specifically atopy, to 
see if it is a direct result of the decreased number of microbial 
infections.
Materials and Methods
Materials for this paper were mined using Touro College’s li-
brary to access databases such as Proquest, Pubmed, and Ebsco. 
Additionally, some research was done using Google Scholar as 
well.
Discussion
The number of cases of autoimmune disorders skyrocketed over 
the past half century. Asthma, diabetes, and Crohn’s disease are 
all examples of hypersensitivity disorders which have increased 
exponentially in recent years while bacterial infections have 
steadily decreased.
Bacterial infections and autoimmune disorders are believed to 
be inversely related. Evidence for this theory first appeared in 
1989, in a paper written by David Strachan who conducted a 
study showing the relationship between the number of children 
born and the likelihood of receiving hay fever. Strachan found 
that children born into large families were less likely to contract 
the disease. He suggested the reason was that children born into 
large families were more susceptible to bacterial infections being 
transmitted by older siblings, preventing them from contracting 
allergies (Strachan, 1989). He did not provide an explanation for 
this correlation.
Strachan’s hypothesis opened a door for many others who fol-
lowed in his footsteps trying to explain the relationship between 
autoimmune disorders and bacterial infections. This theory 
later became known as the “hygiene hypothesis,” and scientists 
today are still trying to find the mechanism which causes this 
correlation.
In order for scientists to properly study the mechanisms of in-
fections leading to these disorders, it is important to understand 
what causes autoimmunity. Is a person’s genetic makeup the pri-
mary factor causing the disease, or do socioeconomic factors 
determine if a person will develop the disorder?
Genetic Factors
It seems that there definitely are genetic factors that contribute 
to an individual’s susceptibility to contract the diseases. Many 
human autoimmune diseases have a tendency for familial cluster-
ing. Familial clustering, represented by λs in Table 1 (Vyse & Todd, 
1996), gives the ratio of clustering in families relative to the rest 
of the world.  A λs  of 15 means that a sibling is at 15 times great-
er risk of developing the disease than a member of the general 
population (Vyse & Todd, 1996).  All of the autoimmune diseases 
listed contain a high rate of clustering, indicating that genes do 
play a role in autoimmune disorders. For type 1 diabetes, the 
MHC linked locus IDDM1 was the primary allele affecting the 
disorder, although other alleles played a smaller role as well. 
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Crohn’s disease, another autoimmune disease affecting different 
areas of the gastrointestinal tract, is the result of many single 
nucleotide polymorphism (SNPs) throughout a person’s genome 
(Mao & Jeonghwa, 2008).
Such evidence would disprove Strachan’s hypothesis. If autoim-
munity is solely a genetic disorder, it is impossible that environ-
mental factors would be able to change an individual’s chances of 
getting infected. 
However, there are numerous studies that counter the notion 
that autoimmunity is affected exclusively through genetics. Firstly, 
evidence from observing distinct groups of individuals as they 
migrated from one region to another shows that the rate of 
developing diabetes is directly related to the location. A study 
regarding Jews emigrating from Yemen to Israel showed that the 
number of cases of type 1 diabetes sharply increased with the 
duration of their stay in Israel. In fact, the numbers were higher 
than any other ethnic group in Israel (Airaghi & Tedeschi, 2006). 
Additionally, many studies have indicated that autoimmune 
disorders are not evenly distributed amongst the continents. 
Geographic data concerning Crohn’s disease, multiple sclerosis, 
and type 1 diabetes demostrates that a north-south gradient 
exists (Bach, 2002). In the northern hemisphere, the incidence 
of autoimmune disease decreases towards the equator. One ex-
ample of this is seen with the incidence of Crohn’s disease in 
the US which shows a clear geographic pattern of occurrence. 
Data collected from hospital discharges suggests that Crohn’s 
disease clearly occurs more often in northern parts of the coun-
try (Sonnenberg, et. al., 1991). Data exists showing similar results 
regarding type 1 diabetes, multiple sclerosis, and atopy as well 
(Bach, 2002). Genetic factors alone would not be enough to ex-
plain all of these phenomena.
Socioeconomic Status
Many studies have indicated that environmental factors, as well 
as socioeconomic status play an even greater role in determining 
one’s chances in developing autoimmune disorders (du Prel, et. 
al., 2007). We already stated that autoimmunity is not evenly dis-
tributed among the continents. Developed countries usually have 
a higher rate of autoimmunity than developing ones (Corvalan, et. 
al., 2005). Even in developed countries, there are several factors 
that will determine an individual’s chances of developing such a 
disorder. Socioeconomic factors can include a number of differ-
ent variables. A study regarding type 1 diabetes in Germany went 
into greater detail to determine which factors will have a greater 
influence. The results indicated that some aspects have a great-
er effect than others. Income level, education, and other similar 
trends had a small effect while living space per person was a 
much larger influence in determining a child’s risk of developing 
type 1 diabetes (du Prel, et. al., 2007). This study would support 
Strachan’s theory that infections play a direct role on autoimmu-
nity. Less living space would explain a child’s susceptibility to get 
an infection which would inhibit his chances of developing type 1 
diabetes. A similar study was done in Chile pertaining to asthma. 
The results supported the belief that overcrowding was associat-
ed with less asthma symptoms (Corvalan, et. al., 2005).
The general consensus is that although there are genetic vari-
ables in an individual that will determine if he is prone to develop 
an autoimmune disorder, these can be triggered based on so-
cioeconomic conditions. A child raised in an environment that 
was exposed to infections was more prone to develop infectious 
diseases which in turn provided a sense of protection from de-
veloping autoimmune disorders.
Hypersensitivity
Although asthma and allergy are both subsets of hypersensitivity 
reactions, they are caused by very different mechanisms. Allergy is 
an immediate hypersensitivity reaction (Type 1 Hypersensitivity) 
caused by activation of Th2 cells (a subset of T cells) which re-
lease cytokines to produces IgE antibody. When atopic individuals 
encounter certain foods or pollen, they produce a dominant Th2 
response which stimulates unchecked IgE production leading to 
an allergic response.
Autoimmunity is a delayed type (or Type 2) hypersensitivity re-
action resulting from the immune system acting on self tissue. 
Although the direct cause for this disorder is still unknown, it is 
believed Th1 activity, normally responsible for activating this path-
way, may be involved in causing this disorder (Lohoff, et. al., 1998).
Most of this paper focuses on allergy, because this is where most 
of the research on the hygiene hypothesis occurred, though some 
of the information may shed light on autoimmunity as well.
A simple explanation regarding why less infections are correlat-
ed with a higher rate of autoimmune disorders is that the more 
infections an individual undergoes in his lifetime causes a certain 
amount of pressure on the immune system, which has to fight off 
the antigen. Fewer infections means a delayed pressure on the 
immune system, which is free to mount inappropriate respons-
es against self antigens as occurs in type 1 diabetes (Airaghi & 
Tedeschi, 2006).
This explanation would not fit into any of the mechanisms pre-
viously explained in triggering autoimmunity. Just because the 
immune system is not pressured to fight off antigens, this doesn’t 
explain why it would fight self antigens. The hypothesis would be 
consistent if the immune system was weakened against foreign 
microbes but not for an entirely new disorder. Nothing in this 
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theory explains the inverse relationship between bacterial infec-
tions and autoimmunity.
Th1/Th2 balance
The immune system consists of T cells and B cells. T cells can be 
either CD8+, cytotoxic, which are responsible for killing viruses, 
or CD4+ helper T cells which assist in other immune functions. 
The CD4+ T cells can be either a subset of Th1 or Th2. Each sub-
set helps the adaptive immune system in its own way. 
Th1 cells are primarily instrumental in killing intracellular infec-
tions. Neutrophils are the immediate response to the body’s 
defense against an attack. However, under some circumstances, 
these neutrophils are not successful in phagocytosis of the patho-
gen. Either the pathogen has evolved to evade the neutrophil, or 
the neutrophil has not been activated properly. These situations 
require help from Th1 activated T cells. These T cells recruit 
macrophages to kill the microbe through ROS (Reactive Oxygen 
Species). Although this is an effective way of destroying a patho-
gen, there are certain drawbacks. One issue is that the agent that 
kills the microbes may harm healthy tissue as well. Macrophages 
do not discriminate which species they attack so tissue damage 
is usually accompanied with hypersensitivity to an infection. One 
way of inhibiting this response is through Th2 activation.
The Th2 subset of T cells has an entirely different role than Th1. 
While Th1 is effective in activating macrophages, Th2 cells are pri-
marily responsible for producing cytokines that signal antibodies 
such as IgE and activate eosinophils, which are responsible for 
killing Helminthic parasites (Abbas & Lichtman, 2009).
Th2 cells also secrete cytokines that activate the alternative mac-
rophage pathway, which inhibits the classical macrophage pathway. 
When Th1 cells activate macrophages to kill a pathogen, they kill 
host tissue as well. Th2 cells are responsible for inhibiting this 
pathway, as well as producing cytokines to express mannose re-
ceptors to aid in tissue repair to the host.
A proper immune response to an infection requires Th1 cells 
to activate macrophages to fend off the infection and Th2 cells 
to slow down this response. Different organisms have different 
amounts of Th1 and Th2 which will directly affect how they re-
spond to infections (Cohn, et. al., 2004).
An overabundance in Th2 response is what causes an allergic 
reaction. When a person is exposed to certain pathogens, name-
ly Helminth parasites, Th2 cells secrete cytokines to bring IgE 
and mast cells to the area to kill the infection. Atopic individuals 
mount an especially strong immune response to these antigens 
causing an allergic response, known as type 1 hypersensitivity.
Th1 and Th2 develop from a common precursor termed Thp. 
Development into mature Th cell depends on the conditions 
present during maturation. Several cytokines such as IL2 and 
TGF-β have a tendency to cause Th2 proliferation. However in 
the presence of a normal amount of antigen in the host, antigen 
presenting cells produced IL-12 which caused Th1 proliferation 
(Lohoff, et. al., 1998).
Thus, a healthy balance of Th1 and Th2 is necessary for a proper 
immune response. Th1 is necessary to fend off pathogenic mi-
crobes at the site of infection while a proper Th2 response is 
necessary to prevent too much tissue from getting affected by 
the macrophages. Different amount of Th1 and Th2 in the body 
determines the outcome of an infection. An experiment with 
different strains of mice with different amounts of Th1 or Th2 
helps determine the outcome of an infection. Leishmania major, 
an infection normally killed by activated macrophages, was placed 
in a strain of mice that had effective Th1 cells. The infection was 
successfully eradicated. However, when placed in a strain of mice 
that has a dominant Th2 presence, the mice succumbed to the 
infection (Elso, et. al., 2004). Mycobacterium leprae as well, if 
dominated by a Th2 response will lead to a much more severe 
form of leprosy. 
This imbalance of Th1/Th2 might explain why less infection may 
cause more allergic hypersensitivity. Developed countries are 
certainly more hygienic and individuals are less prone to develop 
infections. The body has less of a need for Th1 cells and may sup-
press Th1 production. Once an imbalance is formed, Th2 secretes 
cytokines which further inhibits Th1 and cause an overabundance 
of Th2 production (Holt, 2000). 
Regulatory T cells
In healthy individuals, regulatory T cells (Tregs) are responsible 
in suppressing dominant T cell activity. In response to infection, T 
cells often cause heavy responses that can cause serious harm to 
the individual if left unchecked. Activation of these Tregs, such as 
CD4+CD25+, were shown to suppress the Th2 response leading 
to a decrease of atopic responses in individuals exposed to pollen. 
Studies show that individuals who experience atopic symptoms do 
not express sufficient amounts of CD4+CD25+ (Ling, et. al., 2004). 
Additionally, lack of Tregs are also responsible for several disorders 
such as type 1 diabetes, multiple sclerosis, and inflammatory bowel 
disease.
Tregs utilize different mechanisms of control in response to different 
infections. In response to airway hypersensitivity reaction (AHR), 
Tregs secrete IL-10 along with TGF-β which controls the Th2 re-
sponse. In NOD mice, evidence showed that Tregs were instrumen-
tal in preventing type 1 diabetes through activation of CTLA-4 (a 
cell surface molecule) together with TGF-β (Workman, et. al., 2009).
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Table 3
Changes in human ecology that might affect microbiota composition
Change Consequence
Clean water Reduced faceal transmission
Increase in Caesarean section Reduced vaginal transmission
Increase use of pre-term antibiotics Reduced vaginal transmission
Reduced breastfeeding Reduced cutaneous transmission and a 
changed immunological environment
Smaller family size Reduced early life transmission
Widespread antibiotic use Selection for a changing composition
Increased bathing, showering and use of antibacterial soaps Selection for a changing composition
Increased use of mercury-amalgam dental filling Selection for a changing composition
Alternatively, there are a number of factors that lead to healthy 
Treg development. FoxP3 is the transcription factor that devel-
ops immature T cells into regulatory cells. A mutation in this may 
lead to several autoimmune diseases such as diabetes, anemia, 
and eczema. Another cell necessary for healthy Treg development 
is IL-2. IL-2 is not secreted by Tregs but it is necessary for Treg 
survival. IL-2 is secreted by activated T cells and a healthy balance 
of is needed to maintain homeostasis. Effector T cells compete 
with Tregs for IL-2 so Tregs can upregulate CD25 production to 
suppress effector T cells, providing a healthy feedback mechanism 
between responder T cells and Tregs (Goleva, et. al., 2005).
The mechanism leading to this deficiency in Tregs is unclear. One 
theory suggests that the effector T cells in individuals with asth-
ma may be toxic towards Tregs in these individuals (Thorburn & 
Hansbro, 2010). 
Another theory is that Tregs may actually be induced by patho-
genic infections as indicated in Table 2 (Thorburn & Hansbro, 
2010). Antigen presentation by the lungs was shown to promote 
TGF-β dependent induction of Foxp3 expression. Lack of in-
fection may lead to an uncontrolled immune response. Several 
infections are known to have a direct link to regulatory cells so 
by inhibiting these cells; it would lead to an increase in allergic 
response.
One particular study tried to find if there is a direct correlation 
between asthmatic infection and H. pylori- a common bacteria 
found in the gut. Experimentally induced asthma in mice had 
fewer symptoms when the mice were previously infected with 
H. pylori. The study also showed that these mice had significantly 
higher numbers of Tregs leading to the belief that Tregs is one 
of the underlying mechanisms controlling an asthmatic response 
(Arnold, et. al., 2011).
Microbiota Theory
Although this study definitely supports the theory that Tregs are 
one of the most influential factors in developing asthma, it also 
supports a different belief entirely in what causes the hygiene 
hypothesis.
In an essay concerning the diminishing numbers of microbiota in 
the body, Blaser and Falkow postulated that the main cause in the 
increased numbers of autoimmune disorders is related to the 
number of microbiota in body, rather than the number of patho-
genic infections a person encounters throughout life. For the 
past several centuries, humans have adapted to allow a diverse 
subset of microbial organisms to live inside the mucosal surfac-
es of the intestines and lungs, forming a symbiotic relationship 
between host and microbe. Humans provide a home for these 
microbes while they are helpful in digestion and metabolism. A 
change in human behavior may have a direct effect on how peo-
ple develop certain microbiota as shown in Table 3. The chang-
es in the conditions listed have had a direct effect on many of 
the known microbes that reside in the human body. Although 
reduced colonization of H. pylori from the gastrointestinal tract 
is beneficial in the sense that reduces susceptibility to gastric 
cancer, it is also shown to contribute to many metabolic disorder 
as well as childhood asthma. Blaser and Falkow (2009) maintain 
that the recent epidemic of autoimmune disorders is not due 
to the lack of pathogenic infection as much as it is due to the 
human microbiome as a whole (Blaser & Falkow, 2009). Other 
research supports this premise by saying the hygiene hypothesis 
may not a product of less exposure to pathogenic infections itself, 
as much as it is caused by lack of exposure to all microorganisms 
(Bloomfield, et. al., 2006)
Conclusion
Despite all the evidence supporting the hygiene hypothesis, there 
still is a fierce debate whether less hygiene will in fact cause a 
downward trend in autoimmune diseases. The direct mechanism 
remains elusive, and without definitive evidence demonstrating 
what causes the rise in allergic diseases, the microbial exposure 
hypothesis may be just as plausible in explaining the rise in atopy. 
And considering the many benefits our modern ecosystem pro-
vides for us on a daily basis, the pros of less microbial exposure 
far outweigh the cons. Clean drinking water and Cesarean sec-
tions are just a few examples that have saved many lives over the 
past few decades. So although decreasing the number of allergy 
cases is a priority, the current evidence should not support ex-
posing oneself to additional microorganism than those already 
prevalent in society. 
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Introduction
Alzheimer’s Disease (AD) and Creutzfeldt-Jacob Disease (CJD) 
are two disorders characterized by their neurodegenerative 
symptoms. These ailments are both considered forms of demen-
tia consisting of phenotypes portraying a patient’s loss of mem-
ory, mood irregularities, paranoia, and several other neurological 
symptoms. Physiologically, AD is characterized by its Amyloid-β 
and Tau protein plaques while CJD is characterized by its prev-
alence of misfolded prion proteins throughout the brain.  Albeit 
these two diseases are believed to have different modes of phys-
iological symptoms, they share many similarities with each other 
and other neurodegenerative disorders causing many scientists 
to theorize a possible correlation between their mechanisms. It is 
partly due to these similarities that physicians often misdiagnose 
various dementia relating disorders as either CJD or AD.  In a 
study of 304 autopsies that showed no prion disease prevalence, 
71 (23%) of the patients had Sporadic CJD (a variant form of CJD 
characterized by unknown cause) as a possible diagnosis in their 
medical records (Chitravas, et al., 2011). Another study showed 
that “between 12% and 23% of patients diagnosed with AD do 
not have sufficient AD pathology at autopsy to account for the 
presence of dementia (“misdiagnosed”) (Gaugler, et al., 2013).” 
Due to the vast likeness between many dementias, there has not 
been a definitive noninvasive procedure to precisely diagnose dis-
orders such as CJD and AD (Mayo Clinic Staff, 2014). 
Although AD and CJD share similarities, their prevalence in 
American society is far dissimilar. AD is the 6th leading cause 
of death with an estimated 5.5 million people over the age of 
65 who are afflicted with this neurodegenerative disorder in the 
United States (Sultana, et al., 2013). CJD on the other hand, dis-
plays a prevalence of a mere 4.6 cases per million people over the 
age of 60 ( Centers for Disease Control and Prevention , 2014). 
This is far fewer than the thousands of people who are diagnosed 
each year with AD. 
Despite the rarity of CJD, numerous research endeavors have 
been conducted in understanding this prion disease. One expla-
nation for this attention is due to the unique properties of a 
prion; a protein which acts as an infectious pathogen misfolding 
other proteins into additional prions (Wadsworth, et al., 2008). 
What is more surprising is that prions have been found in pa-
tients diagnosed with AD (Armstrong, et al., 2005). This would 
further suggest a possible correlation between pathogenic mech-
anisms of AD and CJD. Today various treatments for AD and CJD 
are currently in clinical trials to try to treat these incurable dis-
eases. If there is a correlation between pathological mechanisms, 
further research into one of these neurodegenerative disorders 
can help scientists better understand and treat the other. 
The purpose of this research article will be to define and explain 
the physical and physiological symptoms and mechanisms of AD 
and CJD, suggest possible correlations between the two, discuss 
current treatments, and lastly, the different forms of possible 
treatments will be compared to postulate a possible venue to 
determine if they would be effective to treat the other illness. 
Methods
Several online databases were used such as: Google Scholar, 
PubMed, and Jstor which were accessed through Touro College’s 
online library. Additional references were gleaned from papers 
found in these databases
Discussion
CJD Pathophysiology
CJD is quite unique due to its pathophysiological mechanism. 
While most infectious diseases are viral or bacterial based, CJD 
uses a prion to spread its illness. In actuality, every individual con-
tains Prion Proteins (PrPc) which are believed to be necessary 
for normal synaptic function (Collinge, et al., 1994). It is when 
this human-coded PrPc is post-translated and converted into 
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an abnormal isoform (PrPsc) that it starts to exhibit patholog-
ical tendencies. Data suggests that this abnormal protein is the 
main, if not the solitary, component of the transmissible disease 
(Wadsworth, et al., 2008). Once the PrPsc comes into contact 
with a normal PrPc, it causes a transmutation of residue 129 
turning it into a pathological agent.  This replaces the amino acid 
by residue 129 on the protein into either valine or methionine. 
Whereas many scientists agree that the prion protein is the main 
constituent of CJD, there is debate over the validity of this claim. 
Manuelidis, et al (2007), argue that the abnormal PrPsc form of 
the prion protein is a result, not the cause, of CJD. They claim 
that a 25 nm virus is the cause of the abnormal prion isoform. 
They discredit the long accepted hypothesis, that prions are the 
sole pathological constituents of CJD, for several reasons. Studies 
show, “high PrP-expressing transgenic brains, as well as abnormal 
recombinant PrPs, have failed to show significant or reproducible 
infectivity”. Additionally, the authors claim that after several de-
cades of research, scientists found no “infectious conformation” 
of PrPsc. Furthermore, sheep with scrapie showed signs of these 
25 nm viruses while uninfected controls showed no prevalence 
of these particles. These facts caused many researches to share 
doubt on the prion-only hypothesis.
Another theory with tangible evidence suggests a different mode 
of pathological mechanism. Several studies suggest that non-pro-
teinaceous cofactors are needed to facilitate the infectious prop-
erties of PrPsc, hypothesizing that prions work via multiple com-
ponents in order to function (Deleault, et al., 2012). While there 
are studies that show that purified PrPcs which were folded 
chemically into amyloid fibrils showed little infectivity, a combina-
tion of PrPc, liver RNA, and synthetic 1-palmitoyl-2-oleoyl-phos-
phatidylglycerol (POPG) lipid molecules facilitated the produc-
tion of authentic infectious prions. The contrasts between the 
infectivity of PrPc obtained from amyloid fibrils and from PrPc 
combined with lipids and RNA support this theory (see figure 
1). However, further study should be conducted to determine 
whether the cofactors are required for pathology or are merely 
a catalyst for a slow progressive disorder (Supattapone, 2010). 
These experiments cast doubt on the viral hypothesis of prion 
disease. If viruses were the cause of prion pathology, why were 
scientists able to reproduce CJD symptoms with only PrPc and 
various cofactors?
There are several ways for an individual to contract CJD. Factors 
include ingestion of prion-infected tissue, contamination during a 
procedure (most commonly a contaminated tissue transplant or 
equipment), inheritance of a mutation in the PrPc gene (PRNP), 
or sporadically (no apparent cause). When tissue infected with 
abnormal prions is ingested, such as meat from a cow infected 
with Bovine Spongiform Encephalopathy (BSE, also known as Mad 
Cow Disease), a variant form of CJD is contracted named vari-
ant CJD (vCJD). Contamination via a procedure causes a form 
of CJD termed Iatrogenic CJD while a genetic mutation that is 
inherited is called Genetic CJD. CJD that is acquired sporadically 
is referred to as Sporadic CJD (sCJD) (Wadsworth, et al., 2008). 
According to Wadsworth et al (2008), approximately 85% of cases 
with CJD occur as the sporadic variant (sCJD) while 15% are as-
sociated with a pathogenic mutation in the PRNP gene (Genetic 
CJD). Wadsworth further explains that the rare iatrogenic form 
of CJD occurs most frequently due to the transmission of prions 
via contaminated growth hormones from cadavers or by imple-
mentation of contaminated dura mater grafts. Additionally, it has 
been speculated that iatrogenic CJD can be transmitted via blood 
transfusions although it is extremely rare (Ricketts, et al., 1997). 
Prion disease prevalence has been tied to vCJD in the United 
Kingdom by the consumption of cattle with BSE. Another unique 
variant of CJD, named Kuru, is found in the Eastern Highlands of 
Papua New Guinea where members of the community would 
feast on the deceased relatives as a sign of respect and grief. From 
the community in Papua, scientist discovered that the incubation 
period of individuals infected with PrPsc could exceed 50 years 
(Wadsworth, et al., 2008).
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(urea and 
guanidine)
Amyloid fibrils
Protein 
misfolding 
cyclic
Amplification 
of mixture
? Structure
Highly infectiousMinimal infectivity
Total liver RNA
Phosphatidylglycerol
Extra ingredients: Two different biochemical protocols yield recombinant PrPc 
with different infectivity. (Left) Minimally infectious amyloid fibrils are formed 
by incubating recombinant PrPc with chemical denaturants� (Right) Mixing 
recombinant PrPc with phospholipid and RNA produces highly infectious prions� 
(Supattapone, 2010)
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Individuals with CJD often exhibit phenotypical signs of demen-
tia and various other neurodegenerative symptoms. The pri-
mary indication of CJD is the observation of sponge-like holes 
in a person’s brain giving the appearance of a sponge; for this 
reason, many scientists refer to prion diseases as transmissible 
spongiform encephalopathies (TSEs). Additionally, patients have 
been known to portray feelings of anxiety, depression as well 
difficulties of cognition such as impaired thinking, memory loss, 
personality changes, insomnia and difficulty speaking. Blurred vi-
sion, difficulty swallowing and sudden jerky movements are also 
typical signs of CJD. As the progression of the illness takes its 
course, cognitive phenotypical symptoms worsen. A majority of 
individuals lapse into a coma and eventually die due to cardiac 
arrest, respiratory failure, or an infectious pathogen. The dura-
tion of duress is typically 7 months for classical CJD and 12-14 
months for variant CJD; however, patients have been known to 
live up to 2 years after diagnosis (Mayo Clinic Staff, 2012).
Currently, the only way to verify the diagnosis of CJD is via an 
autopsy to confirm the presence of PrPsc plaques and to observe 
the formation of spongy-like holes and structures within the pa-
tient’s brain; however, doctors can accurately identify this disease 
via several diagnostics. First, a physician might asses the patient 
to determine if he/she portrays any of the symptoms of CJD. 
Additionally, doctors may administer an Electroencephalogram 
(EEG) to measure the individual’s brain’s activity. People with 
CJD typically portray an abnormal pattern. Magnetic resonance 
imaging (MRI) may be used to produce a high resolution image 
of a person’s brain in order to determine a signs of abnormal-
ity. Another known method of testing is a spinal tap where a 
physician withdraws a small amount of cerebral spinal fluid that 
surrounds an individual’s brain and spinal cord. The presence of 
several proteins in the CSF may be an indication of illness (Mayo 
Clinic Staff, 2012). A simple blood test to detect trace amounts 
of PrPsc may be an additional venue to test for CJD, but fur-
ther testing is needed to determine if this is a viable method of 
diagnosis (Castilla, Saa, & Soto, 2005). Furthermore, in a study 
conducted by Moda et al (2014), 13 out of 14 patients with vCJD 
showed signs of PrPsc in their urine samples suggesting a future 
possible diagnostic for vCJD.
AD Pathophysiology 
AD is a form of dementia characterized by the formation of 
Amyloid-β protein (Aβ) plaques or the hyperphosphorylation of 
Tau proteins along with neuron degradation in the brain. This is 
accompanied with numerous cognitive relating symptoms. While 
the symptoms of AD are well documented, there is much debate 
over the exact mechanism in which the disease carriers out its 
pathology. 
One suggested mechanism is through the formation of Amyloid-β 
proteins which in turn form amyloid-β plaques. The Aβ is formed 
from a far larger protein called the β-Amyloid Protein Precursor 
(APP). The cleavage to the Aβ form is catalyzed by the enzyme 
β-CITE APP cleaving enzyme-1 (BACE1) (Small & Cappai, 2006). It 
is believed that when there is an overproduction of Aβ, either via 
a faulty Aβ production mechanism or a failure of the body’s clear-
ance of the protein, Amyloid plaques are formed (Verkhratsky, et 
al., 2014). These aggregations of Aβ are believed to be toxic and 
are the main cause of AD. The conclusion that Aβ is involved with 
the pathogenesis of AD is strongly supported by an experiment 
involving APP transgenic mice. These mice contained human APP 
and when induced with an amyloid disease, showed very simi-
lar pathophysiological symptoms as AD. However, within recent 
years, studies have shown that Aβ plaques are not the most toxic 
form of Aβ. Experiments have shown that a low molecular weight 
diffusable form (non-plaque forming) of Aβ is more toxic. This 
would explain why in APP transgenic mice, abnormal cognitive 
symptoms are seen before Aβ plaque formation (Small & Cappai, 
2006). 
Another well-known hypothesis to the pathological mechanism 
of AD is the formation of toxic hyperphosphorylated tau proteins. 
Normal or dephosphorylated microtubule-associated protein 
(MAP) tau aid in the assembly and stability of microtubule net-
works in neurons. If an abnormality in the MAP tau arises, there 
are two other MAPs (MAP1A/B and MAP2) that can compensate; 
however, when the dephosphorylated tau turns into the hyper-
phosphorylated form, it turns toxic. This pathological form of tau 
sequesters normal tau (MAP1A/B and MAP2) while inhibiting 
and disrupting microtubule structure. The neuron that has been 
afflicted with this pathogenic MAP tries to dispose of the toxic 
substance by synthesizing additional normal tau and by turning 
the hyperphosphorylated form into an inert polymer. Eventually, 
this afflicted neuron begins to degenerate at a progressively slow 
pace. Aggregation of this abnormally hyperphophorylated tau has 
been linked to dementia and neurofibrillary degradation. This 
abnormal MAP tau appears to be the main contributor to tau 
pathologies, or tauopathies, for dephosphorylation returns the 
protein back to its normal functioning state. One possible rea-
son for this abnormality may be due to a conformational change 
in the MAP tau. This causes it to be a better substrate to be 
phosphorylated or a worse substrate for dephosphorylation. In 
either case, these conformational changes appear to cause the 
pathology of AD (Iqbal, et al., 2005).
AD is typically defined via 3 diverse categories: early-onset AD 
(EOAD), late-onset AD (LOAD), or early-onset familial AD 
(EOFAD). With increasing age as a known risk factor, patients 
who contract the disorder past the age of 65 are said to have 
LOAD which resembles the majority of all AD cases. People who 
are diagnosed with AD before the age of 65 is said to have EOAD 
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which encompasses up to 5 percent of all cases (WebMd, 2014). 
EOFAD is a form of the disorder where the onset of duress 
is under 65 years of age and where the individual has one or 
more of the genes associated with AD. These genes are believed 
to cause the person to attain a genetic disposition towards AD 
(Bird, 1999).
Genetic linkage studies have identified three different genes 
associated with EOFAD. The first gene identified was the APP 
gene (the gene that is responsible for APP production). It is be-
lieved that a missense mutation within this gene is a risk factor 
for EOFAD. Another gene found to be correlated with AD is 
PSEN1. Family studies have shown that mutations in this gene are 
pathogenic. The third gene found injunction with AD is PSEN2. 
Although it is far rarer than the PSEN1 mutation, it is believed 
that mutations in this strand of the gene are a precursor for 
pathogenesis of EOFAD. It is believed that the PSEN1 and PSEN2 
genes are involved with γ-secretase, an enzyme involved with the 
cleavage of APP, and a mutation in these genes cause pathology 
via this pathway. The majority of EOFAD cases (81%) can be ac-
counted for by a mutation in the PSEN1 gene, the second most 
(14%) by a mutation in the APP gene, and the least (6%) associat-
ed with the PSEN2 gene (Ertekin-Taner, 2007). 
Similar to EOFAD, a gene has been found to be associated with 
LOAD. The Apolipoprotein (ApoE) gene codes for a protein that 
transports cholesterol in the bloodstream. It is found as different 
forms named ApoE ε2, ε3, and ε4. The ApoE ε3 form is the most 
common form of the gene while ApoE ε2 and ε4 are less preva-
lent. It is believed that ApoE ε2 reduces the risks of AD and ApoE 
ε4 has the contrasting effect of increasing AD pathogenesis. If 
an individual attains two sets of the ApoE ε4, it greatly increases 
his/her chances of AD. Unlike other known genetic mutations, 
inheriting both sets of the ApoE ε4 gene does not guarantee AD 
pathology (Alzheimer’s Association, 2014). 
While there is no definitive method of ascertaining if an individ-
ual will contract AD, there are several disease-modifying factors 
that decrease or risk factors which increase one’s probabilities of 
pathology. Nam Hu et al (2013) characterizes a list of nutrients 
and their risks towards AD. Antioxidants obtained in an individ-
ual’s diet were shown to reduce the risks of AD. Studies show 
that maintaining a healthy level of vitamin C in a person’s diet can 
have a protective effect towards AD. In regards to metals, Iron is 
believed to be a risk factor for dementia while Zinc is believed 
to be a cause in the delay in AD pathology. In regards to fats and 
carbohydrates, while there is an assumption that these can pose 
as risk factors for AD, not enough reliable evidence is available to 
make a firm conclusion. Hu et al made a graph (figure 2) illustrat-
ing the effects of various everyday foods if whether or not they 
increase or decrease a person’s risk towards AD. 
Various other theories about the pathophysiology of AD con-
tribute to our understanding of the disease. One proposed hy-
pothesis is the degradation of the blood brain barrier (BBB). The 
BBB protects the brain from various pathogens and unwanted 
particles within the bloodstream. The deterioration of the BBB 
can cause various proteins in the blood to enter the cerebral 
spinal fluid and form plaques (Sardi, et al., 2011). Another theory 
involves the metal aluminum. While the correlation is not entirely 
known, it is believed that a high level of aluminum in the brain is 
a cause for AD (Shcherbatykh, 2007). Further research suggests, 
as mentioned by Moulton and Yang (2012), that air pollution too 
plays a role in AD. While the pathogenesis of AD is multifacto-
rial, air pollution can accelerate “age-related oxidative changes 
observed in the brain”, increasing one’s risk of contracting the 
disorder.
Analogous to CJD, patients who suffer from AD share many sim-
ilar phenotypical symptoms. Patients have been known to exhib-
it emotional symptoms such as depression, anxiety, and mood 
swings and cognitive symptoms such as loss of memory, difficulty 
speaking, and difficulty thinking. Additionally, those who contract 
AD are known to have delusions, such as paranoia, change in 
sleeping patterns, and loss of inhibitions. Towards the late pro-
gression of the disorder, important skills such as reading, hobbies, 
and reminiscing are lost (Mayo Clinic Staff, 2014).
Currently, there is no specific diagnostic to confirm the presence 
of AD. A physician determines whether you meet the criteria of 
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Figure 2
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Foods and beverages that influence the incidence of AD. Fish, vegetables, 
fruits, coffee, and light-to-moderate alcohol intake are reported to 
reduce AD incidence. Milk and tea are reported to influence cognition, 
but their influence on AD is not clear. (Hu, et al., 2013)
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dementia and often they can determine if it is due to AD. Doctors 
have an arsenal of diagnostic tests that they can perform to assist 
in narrowing the diagnosis. One possible test is a neuropsycho-
logical test where they can identify cognitive changes. Different 
types of dementia can have different cognitive patterns. A blood 
test can be administered to rule out other causes of memory 
loss such as vitamin deficiencies. Frequently, brain imaging is used 
to identify any abnormalities within the brain. An MRI can be 
used to produce a high resolution image of the brain for further 
study. A computerized tomography (CT) scan uses x-rays and a 
computer to generate cross-sectional images of the brain. This 
can help rule out head injuries and tumors. A positron emission 
tomography (PET) scan is used in conjunction with an isotope 
tracer which is injected into an individual. With this machine, a 
doctor can track the movement of this tracer and determine 
which areas of the body are dysfunctional. All of these diagnostics 
aid in the identification of AD; however, similar to CJD, the only 
way to confirm illness is to perform an autopsy and to observe 
plaque buildup within the brain (Mayo Clinic Staff, 2014). 
Pathophysiological Comparison of AD and CJD
AD and CJD are diagnosed via their dissimilar pathological mech-
anism and symptoms. AD is associated with Aβ plaques and Tau 
proteins and CJD with abnormal PrPsc. AD is a slow progressive 
disorder with an extremely high prevalence, afflicting a third of 
octogenarians, while CJD is rapidly progressing with an extreme-
ly low prevalence, afflicting one per million per year. However, no 
matter the dissimilar characteristics between the two disorders, 
there is evidence that there is an analogous mechanism between 
the two. 
It was shown in a study that PrPc prevalence affects the func-
tion of BACE1. BACE1 is a cleaving enzyme which catalyzes the 
cleavage of APP to either Aβ-40 or Aβ-42, two versions of the 
Aβ differing in residue length. A high expression of PrPc reduces 
the severing of the APP into peptide fragments by more than 95. 
This in turn reduces the secretion of Aβ-40 by 92% and Aβ-42 to 
undetectable levels. The support for this conclusion arises from 
the study that showed that reduced PrPc prevalence showed an 
increase in Aβ-40 and Aβ-42 production. This provides strong 
evidence between the correlation between AD and CJD mecha-
nisms (Hooper & Turner, 2008). 
These findings increase the probability that a slight reduction in 
PrPc at a young age could cause an inconsequential accumulation 
of Aβ-40 and Aβ-42 over many years, furthering the accumulation 
of Aβ plaques and the onset of AD. Patients with AD showed 
lower levels of PrPc in their occipital lobes with an increased 
activity of BACE1. Additionally, studies show that a polymorphism 
in codon 129 of the PrPc gene is a risk factor for early-onset AD. 
This polymorphism changes the peptide coded in that location 
to a valine or methionine causing the transconformational alter-
ation to the PrPsc pathogenic form. This is consistent with our 
assumed PrPc-BACE1 relationship. Hooper and Turner (2008) 
suggest that if PrPc affects Aβ production, we can assume that 
the absence of PrPc would lead to early-onset AD. 
If prion proteins regulate Aβ accumulation thus preventing AD, 
does Aβ regulate and/or prevent prion pathology? In an experi-
ment involving mice infected with scrapie, a form of prion disease 
in animals, it was found that in the terminal stages of the disease 
there was a considerable increase in the concentration of Aβ. 
Hooper and Turner comments on this that, “[i]nterestingly, the 
amounts of Aβ peptides were high in scrapie-infected mice, with 
a shorter disease incubation time raising the possibility that the 
higher levels of Aβ might exacerbate the disease process.”  If this 
theory is correct that high Aβ levels contribute to the rate of 
prion pathology, then this can be used as a way to slow down 
the progression of these ailments. However, they point out that 
we cannot rule out that the increased levels of Aβ are perhaps 
a result of the scrapie pathology, as stated before, and that fur-
ther study is necessary to confirm this hypothesis (Hooper & 
Turner, 2008). Furthermore, Debatin et al (2008) point out that 
the increased levels of Aβ could be the result of the saturation of 
clearance mechanisms; since the body is preoccupied with PrPsc 
maintenance, the same mechanism that also deals with Aβ accu-
mulation becomes saturated leading to a buildup of the AD asso-
ciated protein. This theory is supported by evidence that suggests 
a common pathway for protein degradation of PrPsc and Aβ.
Alternatively, there are those that argue that overexpression of 
PrPc increase Aβ plaque production. Lara Ordonez-Gutierrez et 
al (2013) disregard the evidence that suggest that PrPc directly in-
hibits Aβ production by altering the activity of BACE1. They state 
that most of these tests were performed in cell cultures while 
studies involving older animals showed no change in the expres-
sion of BACE1 in regards to PrPc concentrations. Furthermore, 
in vivo experimentation conducted by Ordonez-Gutierrez et al 
(2013) discovered that older animals that expressed a high level 
of PrPc expression also illustrated a high level of Aβ deposits 
with no significant consequence on BACE1 levels. They speculate 
that since BACE1 levels stay the same while Aβ deposit levels 
increase, perhaps this surge in plaque formation is a result of 
increased protein degradation and/or production via an alternate 
pathway involving PrPc.
Its been suggested that a divergent reasoning for the accumu-
lation of Aβ deposits in patients with a high PrPc expression. 
They explain, given the fact an unaltered expression of PrPc is 
observed during the pathology of prion disease, it is unlikely pri-
ons are the cause for Aβ accumulation in specific sCJD patients. 
Being that the aggregation of misprocessed proteins is caused by 
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the differences between de novo generation and its elimination, it 
is a possibility that the increased levels of Aβ deposits in sCJD are 
a result of a saturation of common clearance mechanisms. This 
is validated by studies that show a similar clearance mechanism 
is in place for both PrPsc and Aβ. Furthermore, in a group study 
of sCJD patients, individuals who exhibited high levels of Aβ-42 
showed little deposits of PrPsc while individuals with high levels 
of PrPsc had low amounts of Aβ-42. The correlation between 
Aβ-42 and PrPsc concentrations clearly indicates a shared mech-
anism between the two (Debatin, et al., 2008).
There are also reports discussing a few intriguing similarities 
between AD and CJD. Both AD and CJD are characterized by 
their peptide aggregations resulting in plaques; Aβ in AD and 
PrPsc in CJD. Additionally, the authors explain how AD and CJD 
can coexist in the same individual and that the Aβ and PrPsc 
plaques in sporadic AD and sCJD share a similar spatial distri-
bution throughout the brain, “suggesting a consistent pattern of 
cortical degradation of the two disorders (Armstrong, Lantos, & 
Cairns, 2005).” With all of these similarities, including the ones 
mentioned earlier, it is hard to deny the correlation between 
these two neurodegenerative diseases.
Possible Treatments for CJD
In persons with vCJD, it was observed that when ingested orally, 
infectious prions aggregated towards gut-assisted lymphatic tis-
sue and the spleen (Cashman & Caughey, 2004). From this loca-
tion, the prions are transported via splanchnic 
innervation to the spinal cord and brain (Figure 3). Cashman and 
Caughey point out that replication of these prions occur in loca-
tions accessible to immunotherapy and antibody neutralization. 
Due to the pathogenic pathway observed in vCJD, it is a possibil-
ity to artificially induce an autoimmune response against prions 
affecting its replication.  This can effectively slow down or block 
pathogenesis of the disease. It has been illustrated in studies that 
Possible spread of scrapie infectivity from the gut lumen to the nervous system following oral infection (route indicated by dotted line)� Soon after ingestion, 
the abnormal prion isoform (PrPSc) is detected readily within Peyer’s patches on follicular dendritic cells (FDCs), within macrophages, within cells with 
morphology consistent with that of M cells and within ganglia of the enteric nervous system (ENS)� These observations indicate that, following uptake of 
scrapie infectivity from the gut lumen, infectivity accumulates on FDCs in Peyer’s patches and subsequently spreads via the ENS to the central nervous 
system� FAE, follicle-associated epithelium� © Elsevier Ltd (2000)� (Cashman & Caughey, 2004)
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antibodies targeted against PrPc, cleared cells that were scra-
pie-infected with PrPsc in vitro. However, in vivo, antibodies tar-
geted against normal PrPc can have adverse effects since these 
cells in their non-pathogenic configuration are detrimental to 
normal neurological function. The autoimmune response to PrPc 
can prompt complement-dependent lysis in many cells disrupting 
normal function leading to apoptosis in the brain. It is entirely 
possible for an induced antibody response to reduce the immu-
nological tolerance of PrPc with the subsequent induction of an 
autoimmune disease (Cashman & Caughey, 2004). 
Often when a protein misfolds causing pathology, a sidechain 
of peptides that originally was sequestered within the molecule 
becomes exposed providing a means of distinguishing between 
pathogenic and non-pathogenic conformational isotopes. This 
specificity can aid in devising a means of targeting PrPsc alone 
without affecting the normal PrPc. The therapeutic potential of 
this approach is immense with the benefit of leaving non-patho-
genic proteins unharmed (Paramithiotis, et al., 2003).
There are several chemical inhibitors of CJD progression in vitro. 
Cyclic tetrapyrroles have been shown to slow the progression of 
scrapie in mice; however, this was only if treatment began imme-
diately after infection due to its inability to cross the BBB. Other 
tetrapyrroles that do cross the BBB could prove to be efficacious 
further in the stages of infection. It is believed that cyclic tet-
rapyrroles inhibit PrPsc by direct interaction with the protein. 
Polyene antibiotics and dimethlysulphoxide are also thought to 
inhibit PrPsc pathology. Polyene antibiotics target prions while 
dimethlysulphoxide helps reduce accumulations and excretion of 
PrPsc. Unfortunately, no chemotherapeutic drug has been shown 
to significantly alleviate the pathology of CJD once clinical symp-
toms are present (Cashman & Caughey, 2004).
Several other therapies have been suggested for CJD treatment. 
One is through gene therapy via a lentiviral vector-mediated 
RNA interference (RNAi). A lentivirus is a genus of viruses that 
can be modified to implement specific genes within a host’s ge-
nome or silence others. This is achieved through short hairpin 
RNAs (shRNAs) that can silence select genes. A study conducted 
with scrapie-infected neuronal cells that involved shRNAs that 
suppressed the PrPc gene, PRNP, showed an efficient suppression 
of PrPsc aggregation. Mice infected with lentivirues with shRNAs 
showed a reduced expression of PrPc and an extended lifespan 
of those infected with scrapie. Although further testing needs to 
be done, a lentiviral vector-mediated RNAi appears to be a valid 
approach for the treatment of CJD (Pfeifer, et al., 2006). However, 
reducing PrPc expression may hinder CJD pathogenesis but it 
may also contribute to various adverse effects. additional re-
search will need to be conducted to attain a viable solution to 
these concerns.
Another suggested therapy is by the use of antihistamines, specif-
ically astemizole. Experiments involving astemizole indicated that 
it prolonged the lifespan of scrapie-infected mice. Additionally, 
astemizole has the capabilities of crossing the BBB making it a 
favorable drug for the treatment of CJD. Except for a rare case of 
heart arrhythmia, astemizole is an over-the-counter drug that is 
relatively safe in recommended doses. It is theorized that astem-
izole’s antiprion properties arises from its activity on autophagy, 
which is the degradation and recycling of cells and proteins. It 
is suggested that individuals containing mutations in the PRNP 
gene and who are genetically susceptible to CJD should take as-
temizole regularly as a preventative measure against disease. The 
effects of astemizole on autophagy could provide new methods 
for treating other neurodegenerative diseases (Karapetyan, et al., 
2013).
CJD treatments vs AD pathology
Can several potential treatments for CJD be administered or 
modified to treat AD? AD is associated with the accumulation of 
abnormal proteins (Aβ and/or Tau proteins). It is possible to tar-
get these molecules via an induced autoimmune response such 
as that observed in CJD treatments (Cashman & Caughey, 2004). 
However, this can initiate a negative cascade in which the body 
targets normal functioning Aβ or Tau proteins resulting in cell 
lysis and the reduced immunological tolerance towards normal 
cells causing autoimmune disease. 
Abnormal proteins are often accompanied by the exposure of a 
previously sequestered side chain. This side chain can be used to 
target pathogenic proteins alone without interfering with nor-
mal function. These findings can be applied to AD in treating Aβ 
and Tau fibril accumulations. Although further experimentation is 
needed to produce a safe autoimmune induced treatment, this 
can be a viable method to combat AD pathology (Paramithiotis, 
et al., 2003).
Lentivector-mediated RNAi can be used to treat AD as well. 
ShRNAs that repress specific gene expression could be used to 
suppress a faulty gene that causes pathology. For instance, if an 
individual has two genes coding for a molecule involved in the 
pathogenic AD pathway with one of the genes corrupted and the 
other in its normal function, shRNAs can be utilized to silence 
the faulty gene’s expression without affecting the normal one. 
However, Lentivector-mediated RNAis can suppress the function 
of both normal and faulty genes causing unwanted adverse effects 
(Pfeifer, et al., 2006). This prototype treatment for CJD can ulti-
mately be utilized to treat other disorders such as AD. 
Direct modification of PrPsc/PrPc levels is another option for 
AD treatment. With a theorized mechanism correlation between 
PrPc and Aβ proteins, it is possible to indirectly treat AD by 
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inducing prion production. For instance, Hooper and Turner be-
lieve that PrPc regulates Aβ levels by inhibiting enzyme catalyzed 
cleavage of APP to Aβ-40 and Aβ-42. The greater the PrPc levels, 
the lower the levels of Aβ in the body. If a patient has AD due 
to high levels of Aβ, according to Hooper and Turner (2008), it 
should be possible to reduce these levels by increasing expres-
sion of PrPc production (see figure 4). Ordonez-Gutierrez et al 
(2013) argue that increased levels of PrPc increase Aβ plaque 
formation. This suggests that reducing PrPc concentrations is the 
viable method in treating Aβ aggregations in AD. More data has 
to be obtained to procure the exact mechanism between PrPc 
and Aβ. It seems that both Hooper and Turner and Ordonez-
Guiterrez et al agree that a related mechanism exists between 
the two proteins, it is the effect one has on the either that is 
in question. Either way, understanding how these two molecules 
interact can be important in treating either of these two neu-
rodegenerative disorders. Prion diseases can offer scientists a 
prototype on the processes of other neurological disorders such 
as AD (Cashman & Caughey, 2004).
Possible treatments for AD
Currently, AD patients are treated with two different types of 
drugs, either acetylcholinesterase inhibitors or memantine. 
Acetylcholinesterase inhibitors act by increasing cell-to-cell 
communication chemical levels that were diminished during AD 
onset. This is accomplished by inhibiting enzymes that facilitate 
the breakdown of acetylcholine, a neurotransmitter found with-
in the brain. Progression of symptoms is usually maintained for 
a time before AD pathology continues to worsen. Memantine 
works via a different pathway within the brain, slowing the de-
velopment of symptoms relating to AD. The mode of action for 
memantine is to target and inhibit NMDA receptors which has 
shown to improve cognitive function compared to a placebo. 
Unfortunately, medication only forestalls pathology since there is 
no cure for AD (Gotz, Ittner, & Ittner, 2012) (Eubanks, et al., 2006) 
(Mayo Clinic Staff, 2014). 
Research into the immunization against Aβ showed promising 
results. Mice immunized with Aβ-42 showed reduced Aβ burden 
and preserved cognitive function. In an interrupted clinical trial, 
patients who were injected with one, two, or three immuniza-
tions of Aβ-42 showed decreased levels of tau proteins with 
postmortem reports of diminished Aβ in the neocortex. The trial 
was interrupted because 6% of the patients developed meningo-
encephalitis (Gilman, et al., 2005). Using natural anti- Aβ antibod-
ies derived from healthy humans may provide a better method 
in reducing adverse effects such as encephalitis in patients (Sardi, 
et al., 2011). Although the clinical trial was suspended, immuno-
therapy seems to be a viable method in treating AD (Gilman, et 
al., 2005). 
In a recent pharmaceutical study, a monoclonal antibody aimed 
at Aβ named Bapineuzumab was intravenously administered for 
78 weeks. It was found that there was a diminished phosphory-
lated tau along with a reduced accumulation of Aβ in the brain 
of AD individuals carrying the pro-pathological gene, ApoE ε4. 
These findings show promise in the treatment of AD through re-
ductions of plaque buildup. Interestingly, these reductions of the 
disease-inducing molecules were not able to forestall the rate of 
pathological progression in the disorder. One suggested hypoth-
esis is that Bapineuzumab was administered too far along in the 
AD pathology. To remedy this concern, the drug would have to 
be administered before the appearance of clinical symptoms. This 
poses an issue since it is extremely difficult to diagnose a patient 
before symptoms appear; however, it may be able aid those who 
are high risk for AD. Another hypothesis is the actual pharma-
ceutical mechanism of the drug. As of yet, Bapineuzumab does 
not target phosphorylated tau that aggregated into neurofibril-
lary tangles, another hallmark of AD (Cedernaes, et al., 2014). 
While further study is needed to improve the efficaciousness of 
antibodies against AD, immunotherapies are strong contenders in 
discovering a feasible treatment for neurodegenerative diseases. 
Non-steroidal anti-inflammatory drugs (NSAIDs) have been 
shown to be a preventative measure for AD. There are reports 
that suggest that BBB degradation plays a central role in AD. 
As the BBB degrades, many previously unwanted molecules 
cross into the fluid surrounding the brain possibly eliciting a re-
sponse of inflammation. Inflammation can further increase the 
The role of the prion protein in Alzheimer’s disease prevention: In the amyloid 
cascade hypothesis of AD, a genetic mutation (for example, in the genes 
encoding APP or the presenilins), ageing or some other environmental trigger 
(e�g� oxidative stress) causes an accumulation of the neurotoxic Ab peptide, 
which aggregates to form the characteristic amyloid (senile) plaques found 
post-mortem in the brains of AD patients� Through mechanisms that are 
poorly understood, the increased levels of Ab peptides, particularly oligomeric 
and fibrillar forms, cause neuronal cell death and dementia. The normal 
cellular form of the prion protein, through inhibiting the production of the 
Ab peptide, might help to prevent the development of AD (Hooper & Turner, 
2008)�
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permeability of the BBB allowing circulating Aβ to enter the brain 
where it can start a degenerative and inflammatory process. 
NSAIDs are drugs that reduce pro-inflammatory responses in 
the body. Studies have shown that patients who were medicated 
with NSAIDs over a long period of time exhibited a reduced 
incidence of AD. This indicates the presence of pro-inflammatory 
molecules in the pathology of AD (Sardi, et al., 2011).
Many therapies for AD focus on ameliorating Aβ levels in the 
brain without much focus on tau proteins concentrations. 
Treatments aimed at pathogenic tau proteins produced reason-
able results. Abnormal tau proteins are phosphorylated versions 
of the normal tau form. One method of treatment is to inhibit 
this phosphorylation. Administered lithium chloride inhibited gly-
cogen synthase kinase-3, an enzyme that catalyzes the transfer 
of a phosphate group onto other molecules, and reduces the 
levels of hyperphosphorylated tau, insoluble tau, and behavioral 
impairment in various mice models. Inhibition of other kinases 
also showed promising results. Furthermore, immunization with a 
tau phospho-peptide prevented pathology in tau transgenic mod-
els with no apparent adverse effects (Gotz, et al,, 2012). With the 
promise of tau directed therapies, it is worthwhile to formulate 
treatments involving both Aβ in conjunction with tau proteins. 
The active component of marijuana, ∆9-tetrahydrocannabinol 
(THC), appears to also be an efficacious and viable method in 
the treatment of AD. THC competitively inhibits the enzymat-
ic protein acetylcholinesterase which catalyses the breakdown 
of acetylcholine. It is believed that acetylcholinesterase is a key 
component in the pathological progression of AD by inducing 
Aβ plaque formation. THC effectively inhibits this enzyme, re-
ducing the degradation of acetylcholine transmitters in the brain 
while simultaneously diminishing Aβ plaque formation. This treats 
both the progression and the symptoms of the disease. THC is 
a superior inhibitor of acetylcholinesterase as opposed to other 
acetylcholinesterase inhibiters that are currently used to treat 
AD. Additionally, THC appeared more effective with only half the 
dosage compared to these other medications.  (Eubanks, et al., 
2006). 
The treatment of metabolic deficiency is another suggested al-
ternative in treating AD. An abnormality in the energy metab-
olism, calcium metabolism, or free radical pathways showed to 
contribute to deficiency within the other two metabolic routes 
creating a “mitochondrial spiral”. This spiral forms a negative cas-
cade effect where the defects of one metabolic pathway continue 
to degrade other pathways which in turn further damage the 
original faulty pathway (see figure 5).  It is thought that mito-
chondrial spiral causes abnormities in the metabolism of the APP 
and the segments of Aβ it produces. It may also be a proximate 
reason for clinical debilities found in AD. Ameliorating the spiral 
may be an alternative route in AD treatment. Studies involving 
an induced increase in metabolic activity by administering a con-
coction of glucose and several Krebs cycle intermediates into 
patients showed an increase in cognitive function with less neu-
rodegeneration. Improving a deficient mitochondrial spiral may 
prove to be effective in treating AD (Blass, 2001).
AD treatments vs CJD pathology
With AD and CJD sharing many pathological pathways, it seems it 
may be possible to treat CJD via techniques previously reserved 
for AD. Acetylcholinesterase inhibitors that reduce the enzymat-
ic degradation of acetylcholine perhaps can be used to alleviate 
symptoms of dementia found in patients with CJD (Cummings, 
2000). With the increased levels of the neurotransmitter ace-
tylcholine in vivo, there can be an increased level of cell-to-cell 
communications within the brain possibly easing several cognitive 
symptoms. However, inhibition of this enzyme is most likely not a 
viable method of treatment for there is little research conducted 
on the effects of acetylcholinesterase inhibitors on CJD. There is 
some evidence that memamtine, another drug used to treat AD, 
has some inhibitory effects towards PrPsc (Muller, et al., 1993).
Immunizations for CJD have been thought of as a method of 
treatment as well. Similar to AD, antibodies targeted against pro-
teins associated with CJD have showed some promising results. 
However, being that adverse effects were found with immuniza-
tions, research has to be done before it is safe for public use as 
a treatment for CJD (Cashman & Caughey, 2004). NSIADs have 
been suggested as a treatment for CJD. Inflammation has been 
associated with both AD and CJD. In contrast to AD, there is 
little data available on the effectiveness of NSAIDs on CJD. In 
vivo studies showed that NSAIDs may have some effect on prion 
pathology, nevertheless, experiments using patients showed 
ROS
Ca++
Energy 
insufficiency
The mitochondrial spiral� Impairments of energy metabolism, alterations in 
cellular calcium homeostasis, and excess free radicals (ROS) interact with 
each other in mitochondria; inducing any one of them leads to abnormalities 
in the other two� The interaction can set up a deleterious, downward cycle 
(Blass, 2001)�
Figure 5
76
David Rotblat
disappointing results. It is possible that the NSAIDs were given 
too late in the disease pathogenesis. Further study is needed to 
determine if antiinflammatory drugs are a suitable treatment for 
CJD (Eikelenboom, et al., 2002). 
Treatment of the “mitochondrial spiral” may play a role with indi-
viduals with CJD. In regards to AD, it was found that a deficiency 
in one of three different metabolic pathways can cause deficits 
in the other two creating a mitochondrial spiral. Attempts to 
alleviate the stress on this spiral showed to improve cognitive 
symptoms in patients (Blass, 2001). In CJD, some studies show 
oxidative abnormalities plays a role in pathogenesis (Petersen, et 
al.). This can cause defects in one of the three metabolic pathways 
mentioned earlier. Alleviating these deficiencies may be a viable 
venue of treatment. It should be mentioned that other studies 
found no role of oxidative stress in CJD (Bleich, et al., 2000). 
Further study is needed on the topic to fully understand the 
effects of the mitochondrial spiral on disease pathogenesis.
It was suggested that it is possible that Aβ contributes to CJD 
pathology. It has been hypothesized that Aβ exacerbated the dis-
ease process by possibly accelerating the pathology (Hooper & 
Turner, 2008). If this hypothesis proved to be correct, any treat-
ment formulated towards AD can in turn be prescribed for the 
mitigation and delaying of symptoms in CJD. Additionally, it was 
found that the other protein linked with AD, tau proteins, were 
associated with prion pathology (Han, et al., 2006). As additional 
experimentation is required to determine the exact impact of 
one protein on the other, treatments made to diminish tau pa-
thology may ameliorate symptoms of CJD. These hypothesized 
venues of remedy will not cure prion pathology but can most 
likely hinder CJD neurodegenerative impacts on the brain. The 
correlation between these two diseases is too strong to suggest 
otherwise. Furthering research into understanding CJD is a via-
ble method of ascertaining a feasible treatment for the growing 
epidemic that is AD.
Conclusion
AD and CJD are both neurodegenerative disorders that share a 
common pathophysiological mechanism. PrPc and Aβ, proteins as-
sociated with pathology in CJD and AD respectively, are believed 
to interact with each other. There is a slight debate whether they 
interact directly by contact or indirectly by affecting enzymatic 
proteins, such as BACE1. Additionally, there is an argument how 
they influence each other in regards to inhibiting/promoting pa-
thology; for example, does PrPc induce or inhibit Aβ aggregations 
that cause pathology? Either way, there is a strong correlation of 
pathologies that most scientists agree with. It is this connection 
that helped researchers discover new and creative treatments 
for AD and CJD. Treatments that were previously reserved for 
either disease are now being tested against the other. This is 
enhancing the understanding of the mechanisms of each ailment, 
bringing researchers one step closer to discovering a cure for 
both neurodegenerative diseases. Perhaps, discovering the means 
of pathologies for AD and CJD will lead to cures for many other 
forms of dementia. 
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Introduction 
Baseball, America’s Pastime, is a sport enjoyed by men and women 
of all ages. The look of joy on a young child’s face when receiv-
ing his first baseball glove is testament to the love of the game. 
Who doesn’t remember going to their first baseball game? The 
glamour of the game as well as the part time relaxation of lazing 
around in the field allows for baseball and softball to be among 
the most popular sports for adolescents in the United States. 
A survey from the National Federation of High School Athletes 
(NFHS handbook) found in the 2013-2014 academic year, that 
a total of 15,789 schools listed baseball as a sport of choice for 
men (behind basketball and track), with 541,054 students par-
ticipating (behind football as well). Fast pitch softball for females 
was listed as the fourth most popular sport as 15,225 schools 
list it as a sport (behind basketball, track, and volleyball), with 
364,297 students participating (behind soccer as well).  However, 
contrary to popular belief, as well as studies classifying baseball 
as a safe sport, baseball and softball are not without their fair 
share of injuries. Although not as prevalent or life threatening as 
football injuries can be, the results can be season ending, or at 
times, even career ending. A study done by Conte et al. (2001) 
on Major League pitchers has shown that 57% of pitchers suffer 
from a shoulder injury during a season. The study also showed a 
growth in injury occurrences over an 11 year period from 1989 
to 1999. Estimates of injury rates for youth (ages 9-14) are a 5% 
risk of serious arm injury (shoulder or elbow) within 10 years 
(Littleleague.org). 
Pitch-count Recommendations
As a result of such injury rates there has been an increasing em-
phasis on the pitch count during a game, as well as cumulative 
pitch count throughout the season. Pitch count is more strongly 
enforced in younger populations due to concern over how the 
repetitive stress that occurs with pitching alters both structural 
as well as functional mechanics of the young shoulder complex. 
Arm pain is common in youth pitchers with studies showing that 
risk of pain increases after 75-80 pitches per game (Lyman et al 
2002). This has led to recommendations by little-league baseball 
for the following daily pitch maximums: ages 7-8, 50; 9-10, 75; 11-
12, 85; 13-16, 95; and 17-18, 105
Methods 
Journal articles were found by searching the terms “pitcher 
fatigue causes”, “pitch-count”, and “fatigue related injuries”. 
Articles were accessed using the Touro Library databases of 
EBSCO, ProQuest, and Sage Premier Collection. As the topic is a 
sports medicine related issue, the index of The American Journal 
of Sports Medicine was utilized as well. Search terms were later 
refined to specify shoulder injuries and pitching biomechanics. A 
final method of research was an interview with a biomechanical 
shoulder researcher at the Hospital for Special Surgery (HSS).
Pitching Biomechanics
Biomechanical studies have determined that the arm is not the 
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Figure 1
Sequence of Motion in Pitching (Dillman et al 1993)
(a)
(f)
(i) (j) (k)
(g) (h)
(b) (c) (d) (e)
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only body part involved in pitching. A pitch can be split into 6 
separate sections: wind-up, stride, arm-cocking, arm acceleration, 
arm deceleration, and the follow through (Dillman et al 1993), 
with the upper and lower limbs working in tandem for a proper 
pitch.
For purposes of this paper the focus will be on the shoulder, but 
details from other locations are needed in moderation. During 
the windup stage the pitcher takes a step backward with the 
front foot, or stride foot. As the pitcher begins, he rotates 90° and 
slowly lifts, elevates, and flexes the stride leg. The stride stage fol-
lows with the other leg slightly flexing, and the stride leg moving 
toward the catcher. This phase is most important to a safe pitch, 
as a key element is to control proper trunk location to contrib-
ute to a pitch. If the trunk is not as back as possible it would affect 
the pitch velocity. Additionally, the landing spot of the stride leg 
contributes to hip rotation which will interfere with the contri-
bution of the trunk to the pitch. As the hips start to rotate, the 
arm is flexed at the elbow, and the shoulder undergoes maximum 
external rotation (arm-cocking stage). The humerus then inter-
nally rotates along the glenoid as the arm accelerates toward the 
plate. During the release of a pitch the scapula rotation goes from 
a maximum of 178° to 105° in approximately 0.029 seconds. It is 
important to note that a decrease in lower extremity force will 
often result in either a decrease in momentum or an increase in 
upper extremity force leading to injury.
To date there have been three studies that compared ball velocity 
and shoulder kinematics over the duration of a game. Murray et 
al (2001) studied major league pitchers, Escamilla et al (2007) col-
legiate, and a recent yet to be published study from HSS, studied 
high school pitchers. Each study has advantages over the other, 
with specific revelations into pitch-count related injuries.
Major League Pitchers
Murray et al (2001) was the first attempt to compare pitch velocity 
and pitcher kinematics over a period of time. They studied 7 pitch-
ers (mean age 26) during spring training. 5 pitchers pitched for 5 
innings with 2 pitching for 7. Cameras were placed in three different 
locations of the stadium to capture different angles of the pitcher. A 
computer program was used to manually digitize 20 different land-
marks to compare over time. The program compared a fastball from 
the first inning as well as one from the last inning pitched. 
They observed significant changes in the maximum external rotation 
angle of the shoulder as well as a decrease in ball velocity. A decrease 
of an average of 9° was noted with a 5 mph drop in velocity. Although 
fatigue is the probable cause for these discrepancies, the possibility 
of protective measures taken by the pitchers cannot be ruled out.    
Collegiate Level Pitchers
Escamilla et al (2007) chose a slightly different approach to study 
fatigue. They studied 10 Division I collegiate baseball pitchers with 
a mean age of 20. Each pitcher threw 15 pitches per “inning” with 
a rest period in between to simulate an actual baseball game. Five 
pitchers pitched the entire 9 innings (135 pitches), 2 pitchers pitched 
8 innings (120 pitches), and 3 pitchers pitched 7 innings (105 pitches). 
Along the lines of a simulated game, the catcher called for a variety 
of pitches-not just fastballs. At the end of each inning pitchers were 
asked to scale their level of fatigue. Kinematic data were recorded 
using reflective markers on the pitcher to be studied using mo-
tion analysis software (more accurate than video markers used by 
Murray et. al). (2001)). 
Although pitch velocity decreased from the first inning to the last, 
the only significant kinematic difference was trunk position, as the 
trunk was more vertical at the end than the beginning. This led 
Escamilla et al. to conclude that there cannot be a specific amount 
of pitches that determine fatigue and therefore injury. They hypoth-
esized that in real game scenarios there are more than 15 pitches 
during some innings, as well as an increased level of motivation that 
may lead to harder throws. 
High School Pitchers
A recent study from HSS (unpublished data) focused on young 
adults (average age was 15) during a simulated game. Participants 
were initially tested for range of motion in three different positions: 
45° internal rotation, 0°, and 45° external rotation. After the average 
peak torque was determined the pitching sequences began. Once 
warmed up, the pitchers threw 90 fastballs in 6 sets (1 set = 15 pitch-
es) with five-minute breaks between sets to simulate a game length 
situation. After the completion of the innings, participants were re-
tested for range of motion. Kinematic data was recorded using the 
same method as Escamilla et al but with one major addition. They 
used a specialized scapula marker for more exact scapula tracking.   
Figure 2
Average normalized pitching speeds across sets (unpublished data)�
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Although each pitcher threw with different velocities, normalized 
data showed that the second set of pitches were thrown the 
fastest, with the fifth and sixth being the slowest (Figure 2). 
Isometric strength tests demonstrated decreased internal (19%-
26%) and external strength (13% to 16%) for neutral and 45° 
internal rotation testing positions.  No significant differences in 
strength were detected when participants were tested in 45° of 
external rotation.
Kinematic measurements at five pitching events (foot contact, 
maximum external rotation, release, and maximum internal rota-
tion) revealed significant changes in scapulothoracic measures at 
maximum internal rotation. There was a 3.8° decrease in scapula 
backward tilt in set 6 compared to both sets 1 and 2 and scapula 
elevation increased by 3.6° in set 6 when compared to set 1. 
Abnormalities in scapula kinematics with increased scapula eleva-
tion are very common for symptomatic shoulders with possible 
rotator cuff tears.
This study shows that even before a pitcher feels fatigued, there 
is a drop in strength and velocity. Although no one complained 
about feeling fatigued when questioned, there were clear indi-
cations of muscular fatigue amongst the athletes, which was re-
flected in the reduction of the arm rotational strength and the 
decrease in ball speed between sets 2 and 6. 
Discussion 
There are only a few studies that have examined baseball during 
an extended number of pitches to investigate how fatigue affects 
upper extremity kinematics. Escamilla et. al. (2007) defined fa-
tigue as the point at which the athletes could no longer continue 
pitching due to a subjective perception of muscular fatigue. This 
resulted in a variable number of pitches for each athlete that 
ranged from 105 to 135 pitches (7 to 9 innings). Although the 
subjects in that study didn’t report fatigue, the rotational isomet-
ric strength post pitching in the HSS study clearly showed that 
the subjects experienced muscular fatigue during the simulated 
game of 90 pitches. The difference may be attributed to the high-
er age and level of competition of collegiate participants as stud-
ies have demonstrated that there are great differences in pitching 
kinematics between different levels of competition (high school, 
college, major league) (Fleisig 2009). An advantage in Escamilla’s 
study over previous research was the introduction of an artificial 
game, allowing researchers to more accurately measure shoulder 
kinematics. However, this also opens a possibility of lack of effort 
on behalf of the pitchers leading to inaccurate data.
The advantage for Escamilla is a disadvantage for Murray et. al 
(2001). Since Murray was analyzing major league pitchers in real 
game scenarios, (albeit spring training) the actual motion capture 
can be inaccurate. However, a major clinical advantage was the 
conclusion of minimal kinematic variability as changes in external 
rotation can be attributed to protective measures. This shows 
that there is hope for young pitchers. Proper strength and con-
ditioning, as well as being coached in proper mechanics can min-
imize injury risk to pitchers.
The study from HSS was advantageous in not letting pitchers 
wait until they felt fatigued, or let them complete a simulated 
game. Their research shows how fatigue affects strength and ve-
locity before the pitcher realizes it. Add the fact that the study 
was done in a meaningless simulated game, and one can see the 
probable effect during a game. However, a major disadvantage 
was the type of pitch allowed. They only allowed fastballs which 
does not accurately portray real-life scenarios.  
Muscular fatigue was also reflected in the ball speed results, as 
all three studies revealed a decrease in ball velocity from start to 
finish. This is to be expected as when one overworks any muscle 
there tends to be fatigue. However, the main implications are not 
just the ball velocity. Lyman et al (2001) surveyed a little league 
over the course of a season. Careful pitch counts were collected 
and players were interviewed at the end of each game, as well 
as the end of the season regarding pitch type and injuries. The 
results of the study led Lyman et al to recommend a maximum 
of 75 pitches per game as mentioned above. Interestingly enough, 
they also found that the more a person pitched the lower the 
risk of injury. This is due to lack of experience when it comes to 
pitchers, or possibly lack of conditioning. However, more than 
600 pitches a season led to elbow pain as well, so that should 
be avoided.  
Fleisig et al. (2011) added to this study by linking pitch type 
and amount to injury frequency. The American Sports Medicine 
Institute concluded that the players who pitched more than 100 
innings in at least 1 calendar year had about 3.5 times as much 
chance of serious injury as those who pitched less. They also 
recommended not starting to throw curve-balls before the age 
of 13, to take a break of 2-3 months annually, and not to pitch on 
consecutive days (American Institute of Sports Medicine, 2013). 
However, subsequent reports have found that a large percentage 
of youth pitchers do not follow these guidelines (Yang et al. 2014). 
Specific Injuries 
During the release of the ball the shoulder goes from 178° to 
105° in approximately 0.029 seconds. This quick motion can cause 
the greater tuberosity to come near the acromion. Unfortunately, 
the biceps tendon or supraspinatus (rotator cuff) can get caught 
in between. Impingement pain is easily treated with rest and phys-
ical therapy (Hawkins 1980).
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The sudden interior rotation of the humerus also leads to biceps 
tendinitis, or a frayed long head of the biceps tendon. Although 
this injury alone can be treated surgically, it is also treated with 
rest and therapy. However, a frayed biceps is the start of a cascade 
of injuries. If the biceps gets frayed or torn the shoulder loses 
some stability. When the shoulder loses some stability it applies 
stress on the labrum. This leads to tears in the superior part of 
the labrum an injury called a superior labrum anterior and pos-
terior, or SLAP, tear. Instability can also lead to torn rotator cuff 
muscles, specifically the supraspinatus. Both SLAP tears and torn 
rotator cuff  muscles require surgery to fix. 
Conclusion
Literature has shown a correlation between high pitch-counts 
and shoulder injuries. Although pitchers may think they are not 
fatigued, this has been shown to be false. Younger pitchers, who 
are not yet developed, both physically and in pitching mechanics, 
are at a higher risk for injury. This has led the American Sports 
Medicine Institute together with Major League Baseball to insti-
tute guidelines for young pitchers. 
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Introduction
Progressive muscular atrophy (PMA) was first described in 1848 by 
F. A. Aran, who reported 11 cases of weakness and paresis of the 
upper limbs (Bonduelle, 1989). However, it was not until 1869 that 
French neurologist Jean-Martin Charcot classified amyotrophic lat-
eral sclerosis (ALS) as a separate neurodegenerative motor neuron 
disorder (MND) from PMA. It was not until 1874 that ALS was given 
the name of amyotrophic lateral sclerosis in Dr. Charcot’s “Oeuvres 
Completes.” In his earliest studies, he noted that, “lesions within the 
lateral column in the spinal cord resulted in chronic progressive pa-
ralysis and contractures (no atrophy of muscles), while lesions of 
the anterior horn of the spinal cord resulted in paralysis without 
contractures (with atrophy of muscles)” (Goetz, 2000). ALS shares 
many clinical symptoms to other MNDs such as: spinal muscular 
atrophy, primary lateral sclerosis and bulbar palsy. The key to ALS’s 
understanding was due to Dr. Charcot’s unique method known as 
“anatomo-clinical method.” Using this technique he was able to de-
termine the correlation between clinical signs detected during life 
and anatomical lesions seen at death. Furthermore, post-mortem 
studies revealed both the anterior horn cell lesion typical of acute 
amyotrophy, and also the distinctive bilateral and symmetric sclerosis 
of the lateral spinal cord columns. Hence, he named the syndrome 
ALS, since it incorporated the two aspects of gray matter involve-
ment (amyotrophy) and white matter damage (lateral sclerosis). Dr. 
William Gowers, though, argued with Charcot’s terminology since 
it suggested that lateral sclerosis was primary and amyotrophy was 
secondary, and instead, postulated they are one event (Goetz, 2000). 
This is still debated over a century later.
ALS is an incurable disease that has an incidence of approximately 
2 in every 100,000 people. The mean age of onset for ALS is 55-60 
and affects men more than women. No diagnostic test exists for 
ALS. Physicians only diagnose ALS when both upper and lower 
motor neurons are affected and after ruling out all other causes 
. At first, one may notice weakness in an arm or leg, described as 
“limb onset” of ALS, or difficulty with speech production, known 
as “bulbar onset” ALS, which quickly spread to other parts of the 
body. Eventually, all limbs and movement cease, leading to com-
plete paralysis. Since ALS shares several common symptoms with 
spinal muscular atrophy and other neurological conditions, sev-
eral tests are required to diagnose. Presently, the only tests, aside 
from limited genetic testing, vary from electromyography (EMG) 
and nerve conduction study (NCS) to magnetic resonance imag-
ing (MRI). After all these tests are performed, physicians still may 
not know until later stages of the disease. 
Presently, the cause of ALS is unknown. Some research points 
out that ALS results from inaccurate protein formation. Other 
research demonstrates there is an excess of glutamate in the syn-
apses causing neurite toxicity. Still other research shows chang-
es to RNA processing. A fourth theory suggests environmental 
factors since U.S. military personnel in the Gulf War had higher 
incidence of developing ALS (Haley 2003).
Genetic mutations in ALS are numerous, for instance, superox-
ide dismutase 1 (SOD1), chromosome 9 open reading frame 72 
(C9orf72), TAR DNA-binding protein 43 (TDP-43), senataxin 
(SETX) and fused in sarcoma (FUS) are a few of the growing list 
of genetic mutations associated with ALS. In contrast, spinal mus-
cular atrophy (SMA) has only one genetic mutation in survival 
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motor neuron 1/2 (SMN1/2). SMA shares some common fea-
tures with ALS, such as lower motor neuron degeneration, gem 
depletion and possibly biomarkers.
ALS and SMA share a biochemical pathway in gem depletion re-
lated to each disease’s respective genetic mutation (TDP-43 and 
SMN) (Yamazaki, 2012; Groen et al., 2013; Turner, 2014, Rafałowska 
et al., 2014). Also, both selectively target motor neurons although 
SMN1, SMN2, TDP-43, SETX and FUS are ubiquitously expressed 
(Cauchi, 2014; Achsel et al., 2013; Tsuiji et al., 2013).  A project 
called: Biomarker identification for SMA (BforSMA) has yielded 
significant results for future clinical studies (Finkel et al., 2012). 
ALS biomarker identification would also accelerate future clinical 
trials. SMA has had much more success in diagnosis and progno-
sis than ALS due to its monogenic nature, while many of ALS’s 
genetic mutations are still being discovered (Keller et al., 2014). 
Nonetheless, there appears to be a strong relationship between 
these two disparate MNDs. By researching the overlap of these 
two MNDs a common therapeutic approach may be possible. 
As of yet, it remains unknown why ALS and SMA, which have 
genes that are ubiquitously expressed, selectively destroy motor 
neurons.
Methods
Peer-reviewed articles from PubMed and UptoDate (a division of 
Wolters Kluwer Health) using keywords “Amyotrophic Lateral 
Sclerosis” “ALS” “Genetic basis of ALS” “Biomarkers for ALS” 
“Spinal Muscular Atrophy” “SMA” “SMA and ALS” were utilized 
as background for this paper. Dr. Alex Pearlman and Dr. Harry 
Ostrer also provided guidance in developing this thesis.
Theories on Targeted Motor Neuron 
Degeneration in ALS
ALS is a heterogeneous disease with multiple pathogenic mech-
anisms and variable sites of disease onset and progression. 
Researchers currently are searching for the starting point of the 
disease and the reason why motor neurons are specifically tar-
geted. Present research focuses on aberrant protein formation in 
axons, excess glutamate activity in neuromuscular synapses and 
gem depletion in cells as being responsible for ALS pathology. 
The first hypothesis on ALS pathogenesis is faulty protein for-
mation in axons. According to Dr. Zhang, at the University of 
Madison-Wisconsin, misfolded protein in neurons causes a 
cascade of events (Chen et al., 2014). Eventually, the protein is 
shuttled to the distal part of the axon, but becomes tangled in 
transport and axonal degeneration occurs. This may also explain 
Alzheimer’s and Parkinson’s disease and their pathophysiology. 
Through use of induced pluripotent stem cells (iPSCs), Dr. Zhang 
formed new nerve cells in vitro and tested his hypothesis (Chen 
et al., 2014). Indeed, when patient iPSCs were used, neurofilament 
(NF) aggregation together with neurite swelling in spinal motor 
neurons (MN) resulted. “Such MN-selective NF changes were 
mimicked by expression of a single copy of mutant SOD1 (D90A) 
in human embryonic stem cells (hESCs) and prevented by genetic 
correction of the SOD1 mutation in patient iPSCs” (Chen et al., 
2014). “A4V is the most common SOD1 mutation in the US and 
D90A is most common in Europe” (Giannini et al., 2010; Saeed 
et al., 2009). In ALS MNs bead like structures form along neurites. 
These bead like structures have heavy immunostaining for plasma 
phosphorylated neurafilament-H. Plasma phosphorylated neura-
filament-H levels closely reflect disease progression in SOD1 
(G93A) mice and are regarded as an ALS biomarker (Calvo et 
al., 2012). Therefore, the bead like structures that were heavily 
phosphorylated with plasma phosphorylated neurafilament-H, 
indicated pathogenicity. As opposed to control MNs and non-
MNs that have an even staining pattern. This finding highlights the 
possibility of targeting NF regulation for therapeutic intervention.
A second hypothesis on the pathogenesis of ALS is excess 
glutamate accumulation, which causes neuro-degeneration. 
“Glutamate is generally acknowledged to be the most import-
ant transmitter for normal brain function” (Purves et al., 2001). 
Glutamate is an excitatory neurotransmitter. However, high 
extracellular glutamate can have toxic effects on neurons. It is 
synthesized in neurons from precursors. In a Human Molecular 
Genetics paper by Dr. Guo he explains that glial glutamate trans-
porter, excitatory amino acid transporter (EAAT2 also known as 
GLT1), is responsible for removing glutamate from the synaptic 
cleft (Guo et al., 2003). In ALS patients, the glutamate transporter 
EAAT2 has been found inactive. Defective glutamate transport 
and loss of EAAT2 protein have also been observed in affect-
ed brain regions of patients with Alzheimer’s disease (Masliah 
et al., 1996). Overactivation of glutamatergic neurons can result 
in a neurodegenerative process known as excitotoxicity i.e. cell 
death. (Guo et al., 2003). “However, it is still unknown whether 
it is a primary cause in the cascade leading to neuron degenera-
tion or a secondary event to cell death” (Guo et al., 2003). After 
experimentation with transgenic mice, containing increased ex-
pression of EAAT2 and SOD1 variation (G93A) degeneration of 
neurons was slowed, but did not cease. The results “suggest that 
the loss of EAAT2 may contribute to, but does not cause, motor 
neuron degeneration in ALS” (Guo et al., 2003). Transgenic mice 
with the common mutations of SOD1 exhibit neurodegenera-
tion comparable to ALS. The SOD1 mutation results in a toxic 
gain of function rather than a loss of enzymatic function (Wong 
et al., 1995). Furthermore, in a Nature paper by Dr. Rothstein 
he demonstrates β-lactam antibiotics, for example, ceftriaxone, 
a semi-synthetic, third generation cephalosporin antibiotic, has 
been used to treat bacterial infections (Rothstein et al., 2005). 
These antibiotics also show no substantial toxic CNS effects. 
Additionally, they have found it to increase gene expression 
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of GLT1. Leading to neuroprotection by increasing glutamate 
transporter expression. The mechanism of this overexpression 
appears to be activation of the genetic promoter for GLT1, al-
though the pathway for promoter activation is, as yet, unknown. 
(Rothstein et al., 2005). This too provides another possible inter-
vention of ALS, which is currently in phase 3 clinical trials (Berry 
et al., 2013). Note that the only drug currently available for ALS 
is Riluzole. It provides no relief of symptoms, but slows the prog-
ress of the syndrome by decreasing glutamate accumulation.
ALS and SMA Overlap
A third hypothesis for ALS disease onset is gem depletion. Gems 
or gemini of Cajal bodies are protein products of SMN, TDP-43, 
FUS and SETX located in nuclear foci and in the cell cytoplasm 
responsible for the assembly of small nuclear ribonucleoproteins 
(snRNPs) (Tsuiji et al., 2013; Achsel et al., 2013; Cauchi, 2014). In 
spinal motor neurons with TDP-43 mutations there are depleted 
gems, snRNPs and small nuclear ribonucleotides (snRNAs) (Tsuiji 
et al., 2013). TDP-43 and FUS localize within nuclear gems togeth-
er with the SMN complex and are involved in the maintenance 
of the spliceosome by controlling levels of snRNA (Tsuiji et al., 
2013). It was further shown that accumulation of spliceosomes 
cause aberrant splicing of mRNAs resulting in motor neuron 
death in ALS and SMA. To clarify what gems are, how they relate 
to SMN, TDP-43 and FUS and the link between spliceosomes and 
motor function, Dr. Ruben Cauchi explains succinctly the RNA 
processing pathway. The pathway starts with the SMN-Gemins 
complex consisting of a nine-membered union of diverse pro-
teins. More specifically, these are SMN, seven Gemin proteins 
(Gemin2-Gemin8) (Carissimi et al., 2006) and Unrip (Carissimi 
et al., 2005). The SMN-Gemins complex establishes the snRNP 
assemblyosome. “SnRNPs are composed of one or two short 
noncoding RNA molecules (snRNAs) bound to a set of seven 
Smith (SM or Sm-like (Lsm) proteins, and a unique set of sn-
RNP-specific proteins” (Matera, Terns, & Terns, 2007). 
Working together with numerous non-snRNP splicing factors, 
U1, U2, U4/U6 and U5 snRNPs form the more abundant spli-
ceosome that is responsible for splicing introns from pre-mRNA; 
as opposed to, U11, U12 U4atac/U6atac and U5 snRNPs that 
constitute the less available spliceosome (Patel & Steitz, 2003). 
The Lsm-class U6 and U6atac snRNPs, though, are synthesized 
in the nucleus while the core structure of the remaining Sm-
class snRNPs is assembled in the cytoplasm. The published work 
on these interactions is fairly recent, and it is still is not fully 
understood why in vivo requires the action of the SMN-Gemins 
complex (Otter et al., 2007) and involves the uploading of a hep-
tameric Sm D1/D2/E/F/G/D3/B ring-shaped core domain onto 
the “Sm site,” a conserved uridine-rich sequence motif intrinsic 
to snRNAs (Cauchi, 2014).
The snRNAs expelled from the nucleus following transcription 
are tagged by SMN-Gemins complex-independent Gemin5 pro-
tein. Once Gemin5 is charged with snRNAs it binds with SMN-
Gemin complex, proximate to Gemin2, to form the Sm core 
assembly. Gemin2 is essential for the majority of Sm proteins rec-
ognition to form the ring-shaped domain. It also blocks foreign 
RNA binding supposedly until bona fide RNA substrates, snRNAs, 
are identified. (Zhang et al., 2011) (Figure 1). SMN’s function in 
snRNP assembly, according to many, is the most decisive of all the 
SMN-Gemins complex members (Cauchi, 2014) and is probably 
linked to axonal mRNP trafficking (Fallini, Bassell, & Rossoll, 2012; 
Briese, Esmaeili, & Sattelle, 2005). Proper Sm core assembly is 
necessary not only for stability and function of snRNPs, but also 
for snRNP biogenesis, including cap hypermethylation, 3` terminal 
trimming and eventual import into the nucleus. Once in the nu-
cleus, snRNPs mature in Cajal Bodies (CBs) prior to pre-mRNA 
splicing. After multiple splicing procedures, snRNPs return to the 
CBs where they are regenerated or recycled (Staněk et al., 2008).
Mutations in the copy numbers of SMN1 and the identical gene of 
SMN2 are the principal etiologic basis of SMA cases. The number 
of copy numbers in SMN2 is inversely correlated with disease 
severity. One of the main theories explaining SMA is improper 
mRNA processing. According to the above, the fewer normal 
SMN proteins cause a lack of SMN-Gemins complex essential 
for pre-mRNA splicing (Borg & Cauchi, 2013; Briese et al., 2009). 
Phenotypic SMA effects have been modeled in fly, zebrafish and 
mouse models with insufficient levels of SNM protein (Burghes 
& Beattie, 2009; Briese et al., 2009). Gemins mutations, however, 
have not been associated with SMA. Investigators hypothesize 
SMN is unique in human genetics and a SMN2-like pseudogene in 
any of the Gemins would be incompatible with life. Dr. Cauci con-
ducted an experiment with organisms containing reduced levels 
of Gemins selectively in motor neurons. Organisms with this 
defect develop similar motor deficits found in the attenuation of 
SMN. Therefore, inadequate levels of any member in the SMN-
Gemins complex can cause motor deficits. Decreased capacity 
of the SMN-Gemins complex can account for neuromuscular 
selectivity, based on sequencing of RNA from microdissected 
motor neurons of presymptomatic SMA mice; there are specific 
transcriptome abnormalities that link SMN deficiency to motor 
neuron pathology in SMA (Zhang et al., 2013).
The function of Gems is thought to colocalize with CBs in later 
developmental stages. Gems are viewed as storage depots for 
supplementary SMN-Gemins complexes since upregulation of 
SMN or Gemins induces gem formation or increases gem num-
bers (Cauchi 2011, Turner et al., 2014). Additionally, when there 
is loss of SMN or Gemins there is substantial decrease in gems 
and CBs. 
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ALS and SMA phenotypes affect lower motor neurons in the 
anterior horn of the spinal tract. There is a common tract and 
biochemical pathway that both MNDs share. ALS can also affect 
the upper motor neurons. Two of the more common genetic mu-
tations found in ALS are TDP-43 and FUS. (Millecamps et al., 2010; 
Tsai et al., 2011). Surprisingly, these two genes engage in RNA 
processing. Under pathogenic conditions, the proteins of each 
are found concentrated in the cytoplasm and not in the nucleus 
in both neuronal and glial cells. This suggests there is a loss of 
proper nuclear function or toxic gain of function pertinent to 
ALS pathogenesis (Andersen & Al-Chalabi, 2011; Ferraiuolo et al., 
2011; Lagier-Tourenne, Polymenidou, & Cleveland, 2010).
SMN has been found in decreased levels in transgenic SOD1 mu-
rine models (Turner, 2009) and SMN protein levels were reduced 
in ALS patients (Turner, 2014). This agrees with previous evidence 
relating decreased copy numbers of SMN2 to increased severity 
of ALS. (Veldink, 2005). Furthermore, loss of the SMN2 protein 
caused gem depletion in motor neurons, and knockout mice of 
TDP-43 showed altered numbers of gems (Shan et al., 2010). In 
ALS patient derived cells with TDP-43 or FUS mutations, the gem 
numbers are significantly reduced too (Yamazaki et al., 2012). 
Also, biochemical experiments have shown that TDP-43 and FUS 
interact with the SMN-Gemins complex (Yamazaki et al., 2012, 
Tsuiji et al., 2013). 
Biomarker Identification
Since both ALS and SMA are swift and crippling diseases, early 
diagnosis is essential for prognosis and future treatment options. 
Although, genetic testing is a current diagnostic tool for SMA, 
it does not test for all mutations in SMA, and is a premium that 
most cannot afford. Additionally, it does not provide a test for 
treatment response. Previous clinical trials for both ALS and SMA 
have produced no complete treatments for humans. There is a 
need to develop biomarkers that can help deliver quicker results 
from research into practice. At the same time, biomarkers facili-
tate the discovery of novel targets and pathways in pathogenesis.
One of the most successful approaches for diagnosis is biomark-
er identification, incorporating: proteomics, metabolomics and 
transriptomics. Biomarker identification is not new to transla-
tional medicine. Biomarkers have been used tremendously in 
the cancer field and they are beginning to show promise in SMA 
too. After a recent cross-sectional study in Biomarkers for SMA 
(BforSMA), the top 5 biomarker candidates: CILP2, TNXB, COMP, 
ADAMTSL4 and CLEC3B may be used for diagnosis and testing 
response to treatment after further testing (Finkel (2012). A lon-
gitudinal study will be necessary to qualify the results of BforSMA. 
The BforSMA isolated the candidate plasma proteins, metabolites 
based on type of SMA presented since type I will produce pos-
sible differences than type II or III. Transcripts, though, did not 
provide significant candidates in the BforSMA. The potential from 
the BforSMA is tremendous for future clinical trials and reduc-
tion in patients and costs associated with studies. ALS would also 
benefit from biomarker identification.
All of the BforSMA are only from peripheral blood mononuclear 
cells. As a result, there was an absence of change in gene ex-
pression or splicing suggesting that the degree of reduction of 
the SMN protein in this tissue is not enough to cause dramatic 
changes. This would be consistent with the fact that blood and 
other tissues do not exhibit the change of cellular or organ func-
tion except in Type I SMA. Since SMN protein is known to have 
reduction concurrent with genetic mutations in ALS, some of the 
biomarkers not tested for in BforSMA may serve as an interest-
ing study for a common biomarker between these two seemingly 
disparate diseases.
Following the BforSMA study, a publication by Dr. Robert Bowser 
outlines biomarkers that have been discovered recently in trans-
genic models that may best represent ALS patients, along with 
prognostic determinants for ALS. Some of the biomarkers high-
lighted are SOD1 in the cerebrospinal fluid (CSF), increased 
levels of NF in blood/CSF, increased expression of CD4+ T 
cells (Bakkar, Boehringer, & Bowser, 2014). Some of the positive 
prognostic markers for ALS are low pNF-H, high sCD14 and low 
S100B in blood/CSF (Bakkar, Boehringer, & Bowser, 2014). A dis-
advantage of these biomarkers is that they are only tested from 
transgenic models unlike the BforSMA, which tested human SMA 
patients. As with the BforSMA, longitudinal studies are necessary 
to qualify these findings. 
There is significant evidence of genetic and mechanistic inter-
action between SMA and ALS. Unfortunately the low rate inci-
dence of ALS – approximately 2 in every 100,000 people – has 
limited the expenditure of resources into the understanding of 
the pathogenesis and treatment of this disease.   Thus any link-
age between ALS and the more common disorder of SMA may 
prove extremely beneficial.   With further research on the shared 
pathways and possible common biomarkers of ALS and SMA, 
therapies of MNDs may emerge that may combat the devastating 
consequences of both of these neurodegenerative disorders.  
Future Directions
To further clarify the potential linkage, between SMA and ALS, 
both the limb- and bulbar- onset types of ALS must be brought 
under a more uniform classification scheme that recognizes the 
homogeneity of these diseases which may then be applied to 
SMA. The elucidation of the genetic make-up of ALS may also lead 
to a common gene for multiple sites of origin.  Moreover, some 
genetic mutations in ALS may also be shown to augment symp-
toms common in SMA. The fact that both of these MNDs affect 
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lower motor neuron function and share a common biochemical 
pathway in pathogenesis may lead to other insights into the in-
teraction between these MNDs.   Biomarker identification will 
likely prove extremely useful in future clinical trials as a potential 
possible diagnostic tool.
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Introduction
The U.S. National Nanotechnology Initiative defines Nanomaterial 
as materials that have at least one dimension in the 1-100 nm 
range. Despite its size, you can see things with the effects of 
nanoparticles all around you. They give the sunset its red color, 
allow birds to navigate, and help geckos stick to trees. All around 
us, there are nano-sized materials present form volcanoes, forest 
fires, viral particles, biogenic magnetite and combustion prod-
ucts (Nano.gov). What has taken the scientific world by storm 
in the last few years is not the naturally existing nanoparticles, 
but rather, it is the newfound ability to create new materials on 
a nanoscale. The term “Nanotechnology” by the material science 
standard refers to the creation of these new particles and its 
usage. In the physical sciences, nanotechnology is associated 
with the quantum behavior of subatomic particles in nanoscale 
structures. In the biomedical sciences, nanotechnology is used 
in imaging, diagnosing, monitoring diseases, gene delivery, artifi-
cial implants, and targeted drug delivery (Nasimi, Haidari 2013). 
Engineered nanomaterials are useful, specifically in drug delivery, 
because of their large surface area to mass ratio (Oberdorster 
2004). When a drug is encapsulated in a nanoparticle, there is 
a more accurate delivery to the targeted tissue. Drug permea-
bility will also increase, thereby reducing the dosing frequency. 
For instance, an intravenously administered hydrophilic drug has 
poor reabsorption after glomerular filtration, often caused by the 
rapid renal clearance of the drug; whereas, encapsulating the drug 
in a nanoparticle reduces renal clearance and allows for better 
absorption. An orally administered drug has to endure enzymatic 
degradation in the gastrointestinal tract and a pass through the 
liver before it enters systemic circulation. By encapsulating the 
drug in a nanoparticle, the exposures to harsh conditions on the 
digestive tract are minimized (Kadam, et al 2012).
The key to using nanoparticles in drug delivery systems is ensur-
ing that the drug can be released at the proper time. In that vein, 
a biodegradable nanoparticle formulation would be needed, as it 
is the intention to transport and release the drug in order to be 
effective. However, model studies to the behavior of nanopar-
ticles have largely been conducted with non-degradable parti-
cles. Most data concerning the biological behavior and toxicity 
of particles comes from studies on inhaled nanoparticles. This is 
part of the unintended release of ultrafine or nanoparticles by 
combustion-derived processes such as diesel exhaust particles 
(Oberdörster, Oberdörster et al 2005). Research has demon-
strated that exposure to these combustion derived ultrafine par-
ticles/nanoparticles is associated with a wide variety of effects, 
including vascular thrombosis, peripheral thrombosis, increased 
plasma fibrinogen levels and cardiovascular effects (Radomski, 
Jurasz et al 2005; Oberdorster, Oberdörster et al 2005). Since 
the size for both ultrafine and nanoparticles (100 nm) is relative-
ly the same, many use both terms as equivalents. Based on the 
similarity of character and size between the two, researchers are 
speculating that the adverse effects of ultrafine particles, as part 
of environmental pollution, may be similar to the negative effects 
of engineered nanoparticles.
Methods
The NCBI PubMedCentral database, the Touro College library 
Database, Proquest, and Google Scholar were search en-
gines used to find information. The following key words were 
searched to obtain research related to this paper: nanotechnol-
ogy, nanoparticles, nano-medicine, nanotechnology and medical 
uses, nanotechnology and drug delivery, toxic effect of nanopar-
ticles, negative effects of engineered nanoparticles, toxicity and 
nanoparticles, applications of nanoparticles, and hazards of nan-
otechnology. Further sources were found by using appropriate 
references cited in various journals and reviews.
Nanoparticles and Drug Delivery
Nanoparticles are formed through natural or human facilitated 
degeneration of larger structures or by controlled assembly 
processes. These procedures occur either in the gas phase, in 
a plasma, in a vacuum phase or in the liquid phase (SCENHIR 
2006). Naturally occurring nanoparticles are found in the air 
in surprisingly high concentrations - approximately 106 to 108 
nanoparticles per liter of air depending on conditions. They orig-
inate from the oxidation of volatile compounds, diesel and car 
engines, and photo-oxidation. The most significant concentration 
of particles and smallest particle size are associated with high-
speed road traffic, apparently due to the subtle conditions during 
concomitant cooling and dilution of the exhaust gases (SCENHIR 
2006). Although there are many naturally occurring nanoparticles, 
the ones that are man-made and biodegradable are the ones that 
are used in drug delivery systems (Oberdorster 2004).
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Preparation of Nanoparticles
Before choosing a method to prepare nanoparticles for use in 
drug delivery, many factors have to be taken into account. Some 
of these factors are the size of the nanoparticle required, the 
inherent properties of the drug (ex. solubility, stability), surface 
characteristics and the degree of biodegradability, biocompati-
bility and toxicity (Mohanraj, Chen 2006). The following are the 
three main methods used to prepare nanoparticles for drug 
delivery:
Dispersion of preformed polymers: A polymer is dissolved in an 
organic solvent, which is also used as the solvent for the hy-
drophobic drug. This mixture is then emulsified in an aqueous 
solution containing a surfactant. After a stable emulsion is formed, 
the organic solvent is evaporated. Some of the polymers used in 
this method include poly- lactic acid, poly(D, L-glycolide), poly(D, 
L-lactide-co-glycolide) and poly(cyanoacrylate) (Mohanraj, Chen 
2006). 
Polymerization method: Monomers a polymerized and form 
nanoparticles in aqueous solution. The drug is encapsulated either 
by dissolving it in the polymerization medium or by absorption 
onto the nanoparticles post- polymerization. The nanoparticles 
are separated from the suspension by ultra-centrifugation (Reis, 
et al 2006).
Coacervation or ionic gelation method: A significant amount of 
research has been focused on the preparation of nanoparticles 
using hydrophilic, biodegradable polymers such as chitosan, gela-
tin and sodium alginate. A method was developed by P. Calvo, et 
al. for preparing hydrophilic chitosan nanoparticles by ionic gela-
tion. They mixed two aqueous solutions together- one was the 
polymer chitosan and the other was the polyanion sodium tri-
phosphate. The positively charged group of the chitosan interacts 
with the negatively charged triphosphate to form coacervates 
(an aggregate of colloidal droplets held together by electrostatic 
attractive forces) with a size in the range of a nanometer (Calvo, 
et al 1997).
Drug Loading and Release
The ideal nanoparticle for drug delivery should have a high 
drug loading capacity, thereby reducing the quantity of matrix 
materials (Mohanraj, Chen 2006). The two main ways to load 
a drug into a nanoparticle is by incorporating it at the time of 
nanoparticle production, or absorbing the drug after formation 
of the nanoparticles by incubating the nanoparticle carrier with 
a concentrated drug solution. The efficiency in loading the drug 
is very much dependent on the solubility of the drug in a solid 
state into the matrix material or polymer. The solubility is related 
to the polymer composition, molecular weight, the drug-polymer 
interactions and the type of functional group present (ester or 
carboxyl) (Govender, et al 1999). Once the drug is loaded, the 
next step is to ensure an opportune release. In general, the re-
lease of the drug is dependent on the solubility of the drug, drug 
diffusion through the nanoparticle matrix and nanoparticle ma-
trix degradation. (Mohanraj, Chen 2006). Very often, the drug is 
released by interactions between intracellular chemicals and the 
nanoparticle matrix. For example, the cationic surface of some 
nanoparticles allows penetration through the cell membrane 
and the drug is then released after the nanoparticle matrix is 
triggered by intracellular glutathione. Another example is the re-
duction of cadmium sulfate or ferric oxide (which are used to cap 
silica nanoparticles) by thiols that release the molecules inside 
the nanoparticle (Nasimi, Haidari 2013). An alternate mechanism 
for release is the use of pH-responsive nanomaterials. A further 
achievement in the area of drug release was reached when a 
method was developed to use multifunctional super-magnetic 
nanoparticles that can be released remotely (Derfus, et al. 2007).
Passing the Blood Brain Barrier (BBB)
From several standpoints the brain is a challenging organ for 
drug delivery. First, the occurrence of progressive diseases in 
the brain will increase with the aging population. Secondly, the 
blood brain barrier (BBB) is well known as the best gatekeeper 
in the body toward exogenous substances. Generally pharma-
ceuticals including most small molecules do not cross the BBB. 
The BBB is formed by tight junctions between the cerebral en-
dothelial cells, which abolish all aqueous diffusion pathways, and 
by biochemical systems consisting of enzymes, which specifically 
metabolize many drugs. However, the barrier properties may be 
compromised intentionally or unintentionally by allowing the 
passage of nanoparticles (Kreuter, et al. 2002). Many studies were 
done that show coating of the nanoparticles with the polysor-
bate (80) surfactants resulted in transport of drugs across the 
blood brain barrier (Schroder  1996). It is interesting to note that 
studies were first done using engineered nanoparticles to cross 
the BBB; however, with increased research it was discovered and 
published that natural ultrafine particles can cross the BBB and 
cause damage. 
Toxicological Hazards of Nanoparticles
General concepts
To effectively tap into the potential of Nanotechnology in 
Nanomedicine, full attention is needed to focus on safety and 
toxicological issues. For pharmaceuticals, precise drug delivery 
formulations may be used to increase the so called “therapeutic 
ratio” which is the margin between the dose needed for clini-
cal efficacy and the dose that would induce adverse side effects 
(toxicity). Also, for these specific formulations, a toxicological 
evaluation is needed. The US Food and Drug Administration ap-
proval is crucial for clinical applications of nanotechnology, but 
considerable problems come into account when it comes to 
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approving nanotechnology-based products. The Food and Drug 
Administration regulate pharmaceuticals and biological devices 
differently, and it is not yet clear how emerging nanotherapeutics 
will be evaluated.  It is important to have a safety guide particu-
larly in the applications of nanoparticles for drug delivery. In these 
applications, particles are brought intentionally into the human 
body and environment (Buxton, et al 2003). Opinions started to 
divert when toxicologists claimed that new science, methods and 
protocols are needed (Nel et al 2006). However, the need for 
a safety guide is now underlined by several expert reports and 
more importantly by the following concepts:
1) Nanomaterials are made for their unique surface properties 
as opposed to the similar properties of bulk materials. Since the 
surface is the layer that interacts with the body tissue, and an 
essential factor of particle response, these unique properties 
need to be investigated from a toxicological perspective. When 
nanoparticles are used for their distinctive reactive characteris-
tics, it may be probable that these same characteristics also have 
an impact on the toxicity of such particles. Although existing 
tests and procedures in drug and device assessment may work 
to detect many risks related to the use of these nanoparticles, 
it cannot be presumed that these assays will detect all potential 
risks. (SCENIHR 2006) The toxicity may differ depending on the 
type of particles used, i.e., biological versus non-biological origin.
2) Nanoparticles are recognized as having different physical and 
chemical characteristics from micron-sized particles. This may 
result in changed body distribution, passage of the blood brain 
barrier and triggering of blood coagulation pathways. In view 
of these characteristics, specific emphasis should be on testing 
and studying the distribution of nanoparticles. What is currently 
lacking is a basic comprehension of the biological behavior of 
nanoparticles in relation to the distribution in vivo both at the 
organ and cellular level.
Using nanoparticles as a drug carrier may reduce the toxicity of 
the incorporated drug. In general, research focuses on the toxici-
ty of the entire formulation. The results of the nanoparticles itself 
are not described, so differentiation between drug and nanopar-
ticle toxicity cannot be made. There should be a specific emphasis 
on the toxicity of the “empty” non-drug loaded particles. This is 
especially important when slow or non-degradable particles are 
used for drug delivery. (Oberdorster, Maynard, et al. 2005)
Evidence for Nanoparticle Toxicity
The largest database on the toxicity of nanoparticles comes from 
the PM10 literature (particulate matter with a size below 10 mm), 
where studies on inhalation and the ‘Nanoparticle hypothesis’ 
have proved to be a powerful drive for research (Oberdörster, 
Oberdörster et al 2005). Therefore it is relevant to discuss this 
Particle type Description
PM10, PM2.5
Particle mass fraction in ambient air with a mean diameter of 10 or 2.5 μm 
respectively. Basis of current standards for ambient particles in Europe and USA
Coarse particles The mass fraction of PM10, which is bigger than 2.5 μm
Ultrafine particles 
(PM0.1)
The fraction of PM10 with a size cut-off at 0.1 μm. Contains primary particles and 
agglomerates smaller than 100 nm
PSP
Poorly soluble particles with low specific toxicity. Maybe be fine or ultrafine. 
Terminology used in relation to bulk synthetic particles. Examples TiO2, carbon 
blacks, Amorphous silica, Iron oxides (Fe2O3), Zinc oxides (ZnO)
CDNP Combustion derived nanoparticles, such as diesel exhaust particles (DEP)
DEP Diesel exhaust particles
Table 1
Various denominations of particles in inhalation toxicology and drug delivery in relation to their source (ambient, bulk, engineered)
92
Zisi Hursarsky
evidence with the expectation that it will shed light on the tox-
icity of engineered nanoparticles.  The adverse health effects of 
particulate matter (PM) are measurable as causes of respiratory 
disease and deaths as well as hospitalizations and deaths from 
respiratory and cardiovascular disease. Many laboratory studies 
have been done to investigate the effects of ultrafine and PM par-
ticles.  It was found that some nanoparticles might have the extra 
potential of affecting cardiovascular disease directly. Vascular 
function was impaired after inhalation of diesel exhaust particles. 
However, data to date is limited and not all studies of nanoparti-
cles have shown significant translocation from lung to the blood. 
Understanding clearance kinetics of inhaled ambient air nanopar-
ticles will also be important in understanding the potential for 
adverse effects. (Oberdorster, Maynard, et al. 2005)
The current standard in particle toxicology is that ultrafine am-
bient air particles have the potential of affecting cardiovascular 
disease both indirectly via pulmonary inflammation and directly 
through particle distribution. Although significant, this property 
of redistribution has yet to be demonstrated for nanoparticles 
present in real PM10’s. It should be noted that there are several 
mechanisms whereby nanoparticles could lead to inflammatory 
effects, as is the case for larger particles. These mechanisms are 
either based on the large surface area of a particle core or on 
soluble components released by the nanoparticles (Schins, et 
al. 2004).  Several toxicological studies support the argument 
that nanoparticles in PM10’s could drive inflammatory effects. 
There are a number of components of PM10’s that contribute 
to the mass but have little toxicity, including salts such as sul-
fates, chlorides and ammonium salts and nitrates. In fact, within 
PM10’s there are only few components that toxicologists would 
identify as likely causes of adverse effects – i.e., particle surfaces, 
organics, metals and endotoxins. A large surface area, organics 
and metals are all characteristic of combustion–derived particles 
and so these have attracted considerable toxicological attention 
(Donaldson, et al. 2005).
Effects of Nanoparticle Toxicity
Many physicochemical factors can influence the potential biological 
interactions and toxicity of nanoparticles. Therefore, it is import-
ant to consider the extent to which the physicochemical proper-
ties of nanoparticles have been characterized in any given study. 
Without sufficient characterization, it is extremely challenging to 
interpret the results of individual studies and virtually impossible 
to compare the results of different studies, even in cases where 
the same nanoparticle has been investigated. As a result, the ability 
to identify parameters that might influence toxicity is hampered. 
Although there is not yet a universally accepted standard of pa-
rameters that is deemed necessary for nanoparticle characteri-
zation, recent reports have highlighted several key physicochem-
ical elements for which it is strongly recommended that data be 
reported (Oberdörster, Maynard, et al. 2005).  These limitations 
include method of synthesis, size, size distribution, shape, com-
position, crystal structure, aggregation and agglomeration status, 
dissolution, purity, surface area, and other surface characteristics. 
Classification of nanoparticles in the context of the experimental 
contact media (cell culture media, dosing solution, aerosol, etc.) is 
also of substantial importance, as some physicochemical parame-
ters are likely to differ depending on whether they are determined 
in the experimental media or in the bulk (i.e., “as received”) state. 
Unfortunately, the inclusion of all these parameters in publications 
describing nanoparticle toxicity studies appears to be rare. 
Nanoparticles in The Lungs
When nanoparticles enter the respiratory system, they are thought 
to cause damage that results primarily from lung particle overload. 
This is due to the inability of alveolar macrophages to recognize 
and/or clear particles of this size, resulting in a particle build up, 
chronic inflammation, fibrosis, and tumor-genesis. However, many 
studies have not shown a correlation between nanoparticles and 
inflammation (Card, et al, 2008). Many studies also track whether 
the particles translocate from the pulmonary system into sys-
temic circulation. One of the studies reported to date indicate 
that inhaled 99mtechnetium-labeled carbon nanoparticles, which 
are man-made, are not detected outside of the lungs in significant 
quantities after inhalation. However, as mentioned to by Mills et 
al., these findings do not indicate that other nanoparticles will be-
have in the same manner, nor do they rule out the possibility that 
nanoparticles may interact with and influence the vascular system 
in the lungs. Moreover, the studies conducted to date have used a 
single inhalation exposure protocol, and it is possible that repeat-
ed exposures may result in greater pulmonary accumulation and 
transfer of significant quantities of nanoparticles to the circulation 
(Mills, et al. 2006). 
Fibrosis is a condition that many researchers believe is caused by 
nanoparticle exposure. Many experiments were done using animals 
to test the effects of primarily carbon nanotubes, carbon black, 
fullerenes, silica, and metal-based nanoparticles including titanium 
dioxide, silver, and nickel. Though it is known that the pathogenic 
mechanisms underlying animal models of lung fibrosis and human 
lung fibrosis are not necessarily the same, increased collagen de-
posits and structural deviations to the lungs can result in changed 
respiratory mechanics that are common features of both. Fibrosis 
in animal models is defined by increased collagen content and/or 
histopathological evidence of structural alterations to the lung that 
are consistent with fibrosis (Card, et al, 2008). It was found that 
the type of carbon nanotubes, their length, and the way specific 
fibers interact, all have varying effects on pulmonary inflammation 
and fibrosis. Studies have found that the longer the nanotube fiber 
length, the greater the toxicity, and the more likely it is to cause 
fibrosis and cancer (Donaldson, et al. 2006).
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Effects on Blood and Cardiovascular System
In a study by Radomski, et al, (2005) the effects of various 
nanoparticles on platelet function were studied. In vitro studies 
were done using human blood samples, and then in vivo studies 
were done in rats to confirm the effects of platelet- aggrega-
tion found in the human blood. Engineered nanoparticles were 
found to cause activation and aggregation of human platelets. 
The efficacy of the nanoparticles in blood aggregation in vitro 
was matched by the same results in the rats. Treatment with 
nanoparticles caused rat vascular thrombosis. The data shows 
that not all nanomaterials act similar in this test, and that sur-
face area is not the only factor playing a role here. The data also 
validates the idea that mainly cationic species have an effect on 
blood clotting. Interestingly, this was the first study that allows 
bridging of data, since a PM10 sample (SRM1648) was included in 
the test-series, in combination with nanoparticles. The PM sample 
actually showed a lower effect on platelet aggregation compared 
to the carbon nanotubes (Radomski, Jurasz et al 2005). Another 
study shows that repeated exposure to PM10’s causes a systemic 
inflammatory response, including bone marrow stimulation, and 
is related to the progression of atherosclerosis in the coronary 
arteries and aorta (Suwa, et al. 2002).
Uptake and Effects of Nanoparticles in The Brain
Nanoparticles can gain access to the brain by two different 
mechanisms. (1) Trans-synaptic transport after inhalation through 
the olfactory epithelium. (2) Uptake through the blood-brain 
barrier. The first pathway has been studied primarily with model 
particles such as carbon, Au and MnO2 in experimental inha-
lation models in rats (Oberdörster et al 2004; Oberdörster, 
Oberdörster et al 2005). The pathway via the BBB has been the 
topic of research for a while, especially for drug delivery. Studies 
suggest that the physiological barrier may hinder the distribution 
of some proteins and viral particles after trans-vascular delivery 
to the brain, suggesting that the healthy BBB contains defense 
mechanisms protecting it from blood-borne nanoparticle expo-
sure. When nanoparticles with different surface characteristics 
were evaluated, neutral nanoparticles and low concentrations 
of anionic nanoparticles were found to have no effect on the 
BBB, whereas high concentrations of anionic nanoparticles and 
cationic nanoparticles were toxic for the BBB (Nel et al 2006). 
Fullerenes and C60 nanoparticles have been shown to induce 
the production of reactive oxygen species, oxidative stress, and 
rapid brain lipid peroxidation in marine species. Because of all the 
negative effects on the brain by nanoparticles, further tests would 
need to be done before using fullerenes and C60 for human and 
industrial use (Oberdorster 2004).
Conclusion
Although there is a considerable amount of data on the toxicity 
of nanoparticles, this data is mainly based on a small sampling 
and the assumption that a lot of effects by particulate matter 
are driven by the ultrafine particle fraction in it (Oberdörtster, 
Oberdörster et al 2005). This small sampling doesn’t really give 
enough information to adequately determine the potential haz-
ards. Although hazard identification is the general approach for 
safety evaluation of healthcare products, it is recommended to 
add testing driven by the anticipated application and classification 
by risk. Some engineered nanoparticles that are airborne will 
pose inhalation and cardiovascular hazards, while cosmetics with 
nanoparticles provide dermal exposures. Each nanoparticle for-
mulation should be tested on a case-by-case basis in the requisite 
ways focusing on their method of entry. In this respect the poten-
tial adverse effects of empty particles should also be considered. 
In developing testing procedures and protocols a number of basic 
issues need to be considered:
1) It needs to be determined whether noticed effects are caused 
only by nanoparticles, or are the adverse effects caused by some-
thing else and only aggravated by nanoparticles. It is clear from 
research that both PM and ultrafine particles can cause inflam-
mation, cancer, etc., but these new and smaller nanoparticles may 
cause different effects. 
2) Most of the conclusions drawn about nanoparticles are based 
on correlations made between the behavior of ultrafine particles 
and PM’s to that of nanoparticles. The question is how much of 
a correlation is permitted to be drawn, how many assumptions 
can be made, as manufactured nanoparticles and ultrafine/ PM 
particles are not identical.
3) The scientific world is dealing with a increasingly growing num-
ber of nanomaterials. All have the potential to create a new toxic 
effect that has never been studied before. The current testing and 
classification system for nanoparticles does not seem sufficient 
to fully identify and quantify the toxicological effects of these new 
nanoparticles. 
For years pharmaceutical sciences have been using nanoparticles 
to reduce toxicity and the side effects of drugs. Up to recently it 
was not realized that these drug carrier systems themselves may 
cause risks to the patient. The type of hazards that are introduced 
by using nanoparticles for drug delivery are beyond what is posed 
by conventional hazards imposed by chemicals. However, as of 
current data, the scientific example for the possible toxic and ad-
verse reactivity of nanoparticles is lacking and we have little un-
derstanding of the basics of the interaction of nanoparticles with 
living cells, organs and organisms. A conceptual understanding of 
biological responses to nanomaterials is needed in order to de-
velop and apply safe nanomaterials in drug delivery in the future. 
Furthermore, a close partnership between those working in drug 
delivery and those working in particle toxicology is necessary for 
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the exchange of concepts, methods and to establish a common 
system for identifying the potential dangers of nanoparticles. 
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Introduction
The Importance of Hydration
Water is an essential nutrient required for life. It is the most 
abundant compound found in the human body and is respon-
sible for moving nutrients along the body’s pathways. Water is 
also involved in biochemical reactions as a solvent and reagent; 
its physical properties affect reaction rates and mechanisms of 
various processes. Dehydration, an imbalance between water 
intake and body water loss, which can be caused by sweating, 
respiratory process, and/or urine production, is generally defined 
as a loss of 1-2% of body weight (Kliener, 1999). This level of 
dehydration increases the core body temperature (Ganio et al., 
2007), impairs aerobic capacity, decreases plasma volume, and 
increases cardiovascular strain (Hill et al., 2008). Furthermore, 
studies indicate a correlation between insufficient fluid intake and 
different forms of cancers (Kleiner, 1999). Even when the water 
concentration deficit is less than 1% there can be negative effects, 
such as headaches, digestive problems, lack of concentration, and 
dry skin (The Expert Group on Hydration, 2005). 
“Sports drinks are beverages that may contain carbohydrates, 
minerals, electrolytes, and flavoring and are intended to replenish 
water and electrolytes lost through sweating during exercise” 
(Pediatrics, 2011).
Children
The average daily total water recommendation for children aged 
6 to 11 is 1.5 liters for girls and 1.7 liters for boys (National 
Academy of Sciences, 2005). Children aged 11 and above should 
be drinking approximately 2 liters per day. Special care needs to 
be taken to ensure that children and adolescents are properly 
hydrated. They are less likely to take the time to drink regularly, 
especially when in school where decisions are made for them 
(The Expert Group on Hydration, 2005). Due to their smaller 
size, children are at greater risk of the effects of poor hydration 
(Pediatrics, 2000).  
Data from the U.K.’s National Diet and Nutrition Survey of 2000 
are cited to demonstrate that most children are not drinking 
enough and most parents are not aware of this issue. In the 
study, 40% of 11-18 year olds were consuming less than the 
Food Standards Agency’s minimum of 1.2 liters. In schools, 38% 
of students were not offered sufficient fluids even after physical 
education (The Expert Group on Hydration, 2005), despite the 
fact that the effects of dehydration can be especially severe when 
children exercise. They generate more metabolic heat per mass 
unit than adults do during exercise, even when just walking or 
running (Pediatrics, 2000). 
Due to the high risk of dehydration, should sports drinks be given 
to children and adolescents engaged in athletics as an effective 
source of hydration? 
Method
Critical analyses of research articles were utilized to gather this 
information. These articles were collected from online databases 
and journals, such as, Touro College’s online databases, PubMed, 
and Google Scholar.
Sport Drinks: A Source of Hydration
Many experts assert that sports drinks are an invaluable source 
of hydration, as they maintain body electrolyte concentrations 
and lead to greater fluid consumption.
Electrolytes
Excessive intake of sodium-free drinks, such as plain water, can 
lead to hyponatremia, a rapid fall in serum sodium concentration 
and serum osmolality (Maughan, et al., 1993). Even replacing large 
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fluid losses with equal amounts of pure water may dilute the plas-
ma sodium level (Ganio et al., 2007). Water alone cannot replace 
electrolytes lost through sweat. Therefore, it has been suggested 
that electrolytes and water should be replaced with sports drinks 
that contain the proper amounts and ratios of these elements 
(Maughan, et al., 1993, Pediatrics, 2000).
Water Absorption
Dr. R. J. Maughan, a Fellow of the American College of Sports 
Medicine, and his colleagues maintain that electrolytes contained 
in sports drinks enhance fluid absorption in the body. Sports 
drinks manufacturers frequently use this assertion when advanc-
ing their products and also claim that sports drinks are scien-
tifically formulated to tackle dehydration. Lucozade®, a drink 
manufacturer states, “Adding both carbohydrate and sodium to 
a sports drink, helps your body absorb fluids more effectively” 
(Lucozade, 2015).
Taste 
Naturally, people, especially children, tend to consume fluids that 
they enjoy. The effect of taste is found even within various sourc-
es of water. One survey found that out of 124 respondents, 43% 
said taste was the primary reason they chose bottled water over 
tap water (Kliener, 1999). Surely, the palatability of cool, pleas-
ant-tasting sports drinks greatly enhance fluid intake. More spe-
cifically, sodium chloride, commonly found in sports drinks, has 
been shown to increase voluntary fluid intake by 90% compared 
to unflavored drinks (Pediatrics, 2000). Additionally, the carbohy-
drates that sports drinks contain, to various degrees, may influ-
ence palatability (Maughan, et al., 1993). Therefore, while water 
is an easily available drink, flavored beverages, sports drinks, are 
often the beverage of choice to increase fluid intake, specifically, 
in the case of an exercising child, where the need for rehydration 
and sensitivity to flavor are especially significant. 
Thirst Inhibiter
The body’s natural reaction to dehydration is thirst. The hypo-
thalamus senses fluid loss when the concentration of sodium in 
the body rises. It responds by increasing renal sodium and water 
conservation, which stimulates the sensation of thirst (Noakes, 
2012). Drinking plain water could lead to a rapid fall in sodium 
concentration which could alter the chain of reaction, ultimately 
inhibiting thirst and causing a reduction of fluid intake. Sports 
drinks are preferred, since they have accurate water-sodium ra-
tios and do not inhibit thirst.
Refuting the Claims in Favor of Sports Drinks
Taste  
While tap water does not have a favorable taste and can lead to 
children not drinking enough fluids, palatability can be achieved 
in ways other than sports drinks. For example, parents and 
caregivers can supply children with filtered, purified, and/or bot-
tled water. If this does not supply the desired fluid intake, taste 
can be enhanced by adding a minimal amount of flavor, such as 
lemon slices, to the water (Ahmad, 2008).  
Electrolyte
Sweating is the most efficient method that the body uses to dissi-
pate excess heat, either a result of byproducts of muscular work 
or from a hot environment (Burke, 1997). The water contained in 
sweat decreases the core body temperature through evaporative 
cooling at the skin surface. Generally, the sweat produced by the 
average exercising child or adolescent is a relatively dilute plasma 
secretion containing far more water than electrolytes. Since the 
main fluid lost is water, the main replacement should be water, 
not sports drinks which contain electrolytes (Ahmad, 2008). 
Nevertheless, to avoid incorrect electrolyte/water ratios, care 
should be taken not to drink disproportionate amounts of water 
(Robert Wood Johnson Foundation, 2012, Pediatrics, 2011). Most 
children’s and adolescents’ daily electrolyte requirements are 
met sufficiently by a healthy balanced diet, while sports drinks 
offer little to no advantage over plain water. Furthermore, sports 
drinks can be harmful due to excess caloric, fat, and protein in-
take and the potential nutritional imbalance that can ensue.
In addition, hyponatremia has been observed in cases of dehy-
dration, maintained hydration, and over hydration. Therefore, ex-
cessive water intake cannot be correlated to hyponatremia; the 
cause may be multi-faceted and circumstantial and further studies 
need to be done before conclusions can be drawn (Ganio, Casa, 
Armstrong et al, 2007). 
Energy Source
Despite the above arguments, some maintain that sports drinks 
are still advantageous for energy resupply (Maughan, et al., 1993). 
However, since the average child athlete does not need quick 
energy supplements, there is little need for energy-containing 
beverages. The recommended daily intake of fruit juices, low fat 
milk and other daily diet food supply the appropriate amounts of 
carbohydrates and proteins that children need (Pediatrics, 2011).
Water Absorption
The advantage of increased total water absorption attributed 
to sports drinks is only under conditions where further bouts 
of exercise occur after short recovery periods. However, during 
rest or low intensity exercise, sports drinks do not improve the 
overall water absorption rate or the amount consumed by means 
of plain water. This assertion is maintained by an innovative ex-
periment using a deuterium dilution technique to compare the 
hydration ability of commercially available sports drinks versus 
water (Hill, 2008). Scientists provided three different sports 
drinks solutions, as well as plain water, ingested with an isotope 
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tracer, to exercising subjects (aged 18-35) at set intervals over 
the course of sixty minutes. The team then analyzed their sali-
va samples; the appearance of deuterium in saliva indicated the 
uptake of water in the body’s tissues and enabled the team to 
calculate the kinetics of the water absorption.  With the aid of 
proven mathematical modeling, the kinetics data provided the re-
searchers with estimates for the maximum absorption rate, the 
time at which absorption was complete, and the percentage of 
solution absorbed, at any given time. This innovative approach 
measured the gastric emptying rate and the intestinal absorp-
tion, two major factors that affect absorption of the solution’s 
water content. It is important to note that the exercise was not 
intensive, consisting of walking on a treadmill at 55% of heart 
rate maximum for an hour. The results of the experiment clearly 
indicated that for the speed of rehydration, the maximum rate 
of absorption was achieved with sports drinks rather than with 
water. Nonetheless, by half of the total time of absorption there 
was no difference in the rate of absorption between the sports 
drinks and water. Furthermore, by the end of the total time, the 
sports drinks and water solutions accomplished the same total 
absorption volumes. Therefore, the study determines, “under 
conditions where recovery periods occur between further bouts 
of exercise, sports drinks may be favored due to faster speed 
at which they reached their max absorption rate.” However, for 
normal, non-intensive, conditions, since there is no advantage in 
total water absorption and no need for quick rates of rehydra-
tion, there is no hydration advantage in providing sports drinks 
instead of plain water.
Sports Drinks – A Bad Choice For Hydration
Excessive Sports Drink Consumption
Sports drinks contain sugars and recent studies show that most 
children today consume far more added sugars than the maxi-
mum daily recommendation (Johnson RK et al., 2009). Beverage 
patterns and trends among school-aged children in the United 
States indicate that, between 1989 and 2008, the percentage 
of American children aged 6 to 11 consuming sports drinks 
increased from 2 percent to 12 percent (Lasater et al., 2011). 
A study by a group of nutritionists measured US children and 
adolescents per-capita daily caloric intake from sugar-sweetened 
beverages (SSB) and 100% fruit juice. The authors found that SSB 
consumption increased from 242 kcal/day in the years 1988-1994 
to 270 kcal/day in the years 1999-2004. One hundred percent 
fruit juice intake increased from 38 to 48 kcal/day. The largest 
increases occurred among children aged 6 to 11 years (Wang et 
al., 2008). In another study, researchers asked adolescents why 
they drank sports drinks. No one claimed they did so to maintain 
hydration (O’dea, 2003). 
Excessive sugar intake causes weight gain, poor nutrition, dis-
placement of healthy ingestion, obesity, and poor dental health. In 
addition, SSBs lead to type 2 diabetes and cardiovascular disease 
(Robert Wood Johnson Foundation, 2012). Additionally, the gra-
tuitous amounts of sodium found in sports drinks displace neces-
sary nutrients and results in excessive caloric intake (Pediatrics, 
2011). Therefore, to achieve optimal health, sports drinks should 
not be used as a source for hydration. 
The Value of Sports Drinks
In the event that the child is playing in a hot and/ or humid envi-
ronment maintaining hydration is even more crucial, as children 
do not adapt to extreme climatic changes as well as adults do. “A 
child may need as many as 8 to 10 exposures (30 to 45 minutes 
each) to the new climate to acclimate sufficiently.” Hot air tem-
peratures and high humidity levels, even with relatively normal 
air temperature, may lead to heat stress. Furthermore, children 
have a large area-to-body mass ratio which results in significant 
heat gain. Moreover, children’s sweating capacity is considerably 
lower than adults, which diminishes their ability to dissipate body 
heat via evaporation. Consequently, children exercising in hot 
and humid environments are at greater risk from the effects of 
dehydration (Pediatrics, 2000).  More specifically, children playing 
in hot and/or humid conditions for more than one hour lose 
excessive amounts of electrolytes, such as sodium, potassium, 
and chloride, which cannot be replaced sufficiently by plain water 
(Ahmad, 2008). Under these conditions, “[s]ports drinks have 
been shown to decrease fatigue and replace electrolytes lost in 
sweat” (Robert Wood Johnson Foundation, 2012). 
Likewise, sports drinks are appropriate for children and ado-
lescents who engage in prolonged vigorous physical activity, as 
the amount of energy and electrolytes lost cannot be regained 
through plain water alone (Robert Wood Johnson Foundation, 
2012). To prevent fatigue and maintain performance it is neces-
sary to resupply muscle glycogen stores through ongoing intake 
of carbohydrates. The carbohydrates and electrolytes contained 
in sports drinks restore the loss, and provide the necessary nu-
trients in the proper ratios. 
Discussion
In view of the above, for the average child, water is the best 
form of hydration. Sports drinks are detrimental, in large part 
because they provide children with excess sugars. Furthermore, 
their added ingredients can negatively affect the proper amount 
and relative proportion needed for a healthy diet.  Cohen (2012) 
affirms that after 38 years of research there is still no scientific 
proof for sports drinks providing higher fluid intake or better ab-
sorption than water. Sports drinks were designed for committed 
athletes, and they should be restricted to them.  
In addition, while sports drinks may be advantageous because of 
their greater palatability in comparison to tap water, which will 
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lead to children consuming more fluids, parents and caregivers 
should keep in mind that the bad health effects far outweigh these 
benefits. Therefore, water should be the beverage of choice, and 
if the child is not drinking enough, a parent should seek methods 
to encourage voluntary water consumption, such as by providing 
cool, filtered water and promoting the health benefits of water 
(Loughridge and Barratt, 2005).
Nutritionists offer water drinking guidelines to maintain hydra-
tion. In the case of a child participating in normal physical activity, 
for less than three hours and in normal air/humidity conditions, 
water intake should occur every 15-20 minutes (Ahmad, 2008). 
The main body fluid lost is water, therefore, water is the only 
substance needed to be replenished. Still, care should be taken to 
replace water at a rate equal to, not greater than, the sweat rate 
(Ganio et. al, 2007). In events of intensive physical activity, water 
and a balanced diet, for example, soup, fruits and vegetables, are 
enough to replace the water, carbohydrates and  electrolytes lost 
during exercise, provided the activity does not last more than an 
hour (Robert Wood Johnson Foundation, 2012). In the event of 
prolonged physical exercise, children should be well hydrated be-
fore and during the activity. Periodic drinking should be enforced 
throughout, even if the child does not feel thirsty (Pediatrics, 
2000). Also, children and adolescent athletes should drink water 
even after the activity is over (Pediatrics, 2011). 
In cases of hot or humid conditions and during intense exercise 
lasting over an hour, since there is a greater loss of electrolytes 
(sodium, potassium, and chloride) and energy, water alone is not 
enough to rehydrate and replenish energy, and sports drinks 
should be provided (Robert Wood Johnson Foundation, 2012). 
Ahmad (2008) advises that every 15-20 minutes the child and 
adolescent should be provided with five ounces of electrolyte-re-
placing fluids such as water mixed with juice or sports drinks. 
Also, sports drinks are commendable in situations where quick 
rehydration is critical. It is important to note that the various 
amounts of sodium, potassium, and magnesium, found in the dif-
ferent sports drinks all achieve quicker retention rates over a 
short period of time, in relation to plain water (Hill et al., 2008).
Thirst as an Indicator for Hydration
In general, as mentioned in the paper, exercise raises the core 
body temperature which causes the body to sweat out the heat 
and to replenish fluids lost in the process by the conscious feel-
ing of thirst (Noakes, 2012). Over the course of the research, 
however, it was evident that scholars debate whether thirst is a 
good indicator for fluid replacement in children and adolescents. 
Some argue that thirst is not a good indicator and relying on 
it for fluid intake may lead to severe dehydration. Firstly, thirst 
often-times lags behind changes in hydration (Ganio, et al., 2007). 
The threshold of the indication of thirst occurs at a point when 
a person is already dehydrated to a level of .8 % to 2% loss of 
body weight (Kliener, 2009). Secondly, drinking water creates a 
reduction in plasma osmolality and reduces the drive to drink, 
even before sufficient fluid has been consumed to replace loss 
(Maughan RJ et al., 1993).  Thirdly, children frequently do not 
feel the need to drink enough to replenish fluid loss during 
prolonged exercise, and if they find plain water non-appealing, 
they may not drink even if they are feeling thirsty (Pediatrics, 
2000). Lastly, environments may alter the thirst mechanism. For 
example, swimmers may have virtually no thirst response during 
immersion (Kliener, 2009). Therefore, these researchers conclude 
that children should be given to drink even if they are not thirsty. 
The risk of relying on just thirst to identify when to provide fluids 
is greater in hot/humid environments, where the potential for hy-
po-hydration in children and adolescent athletes is even greater. 
However, it can be argued that thirst is a reliable indicator; it is 
a natural biological response to dehydration and children rehy-
drate voluntarily when fluid is available (Kliener, 2009). Cohen 
(2012) questions the scientific validity of studies that claim thirst 
to be unreliable, calling it a “war on thirst”. The article states that 
scientists who invalidate thirst as an indicator of dehydration are 
associated with the sports drinks industry and their results are 
biased. Instead, Cohen’s article maintains that thirst is a good 
indicator of when to drink. In addition, humans do not need to 
immediately replace all the fluids lost during routine exercise; 
humans are delayed drinkers. Individuals can rely on the next 
meal for most fluid replacement. Thirst is a dependable indicator 
of water and electrolyte deficits that need to be imminently rec-
tified (Noakes, 2012). 
Conclusion
The negative effects of sports drinks render them unfit to prop-
erly hydrate children and adolescents; instead plain or flavored 
water should be the primary beverage. However, if an exercising 
child is not drinking enough, is playing for more than three hours 
in normal conditions, is engaging in repeated bouts of exercise 
interspersed with short breaks, or is exercising in hot, humid 
conditions for over one hour, then sports drinks would be the 
best source of hydration.
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Viability of SiRNA as a Clinical Treatment
The future of medicine is heading closer and closer to perfecting 
gene therapy. While research is bringing the option to alter genes 
closer to fruition, there is still a long way until it will be able to 
be implemented. Simpler therapies albeit with their own set of 
problems, seem to be a more realistic option for the foresee-
able future. One in particular that has seen some progress is 
the use of small interfering RNA (siRNA). ”Since its discovery 
by Fire and Mellow in 1998, siRNA has proven to be a powerful 
tool for modulating the expression of almost any gene in various 
species.” (Nechaev, et al, 2013) During Göran Hansson’s speech 
after receiving the noble prize for the discovery of a form of 
RNA silencing, he said, referring to RNAi (more general term for 
siRNA), that it “has added a new dimension to our understanding 
of life and provided new tools for medicine.” (Eggleston, 2009). 
It can have many applications and doesn’t necessarily require 
the alteration of DNA. It allows the DNA to remain in its state 
of disarray however it won’t allow the problematic gene to be 
translated. This allows for control of the gene without having to 
alter the DNA. The applications for this are countless. SiRNA 
can treat many otherwise untreatable diseases ranging from viral 
infections to complex genetic disorders (Endo-Takahashi. et al. 
2012). Although the concept of siRNA is not a new one, there are 
some kinks in how to use it as a treatment. One major setback 
is that although it is now possible to create this aforementioned 
silencing RNA (siRNA), its method of delivery is problematic. The 
siRNA, if delivered indiscriminately, can wreak havoc in cells it 
wasn’t intended for. It can stop crucial growth and functional ele-
ments of important life sustaining cells. It is therefore important 
to deliver these potentially harmful substances only to their in-
tended targets. This is just one of a few issues that can be a major 
hindrance in siRNAs future as a treatment. It is imperative to 
understand how siRNA works before an approach can be found 
to tackle the issues that can arise in using siRNA as a treatment. 
SiRNA silences the expression of specific genes allowing for par-
ticular cell functions to seize. SiRNA begins its life as a double 
stranded RNA molecule (dsRNA). The dsRNA is cleaved into 
shorter siRNAs. This process requires dicer to cleave the large 
dsRNA. The siRNA is incorporated into a protein complex re-
ferred to as RNA inducing silencing complex (RISC). The still 
double stranded siRNA is unwound by the protein complex via 
multiple steps. The now single strand of siRNA leads the RISC to 
the target RNA destroying it (Schwarz, et al, 2014). The destroyed 
mRNA is no longer able to perform the function it was coded for. 
This allows for a cell to continue with its other functions as long 
as the specified protein isn’t crucial for the cells normal function. 
The siRNA does not interact with the genome directly allowing 
for less risk of creating mutant cells. 
Possible Applications of siRNA
SiRNA has been studied largely for its application as a cancer 
suppressor. It has however, many applications beyond that. wheth-
er in its ability to lower circulating cholesterol (Tep, et al, 2012) 
by inhibiting the translation of a specific protein, or as a method 
of controlling HIV-1(Zhou, et al, 2008) as well as possibly reduc-
ing any other potentially harmful protein synthesis. SiRNA can 
have other non-clinical applications as well. Although the same 
basic ideas and methods are used for all potential treatments 
associated with siRNA the broad range of diseases it can poten-
tially treat allows for some unique applications. 
One study on the effects that siRNA can play in treating ovarian 
cancer used a pretty classical method of using siRNA. The surface 
protein cd44 is necessary in activating signal pathways necessary 
for cancer, specifically metastasized, to continue its growth and 
destruction. These pathways instruct the cell to continue tran-
scribing proteins necessary for cell growth, as well as other fac-
tors that allow the cancer cells to live and multiply. The cd44 
protein is also only found to be expressed by metastasized can-
cer cells, thus negating many of the issues associated with siRNA 
delivery that will be discussed later. The study used siRNA as well 
as an anticancer drug to see the combined effects they could 
have on metastasized ovarian cancer. The siRNA was specific to 
mRNA coding for cd44. It was carried out in vitro as well as in 
vivo with similarly successful outcomes; the cancer cells growth 
was slowed dramatically in both tests. Compared to just the use 
Abstract
The purpose of this paper is to better understand the methods problems and some solutions for siRNA treatments. 
The benefits of this novel medical treatment are explored and its benefits are expounded on by comparing it to other 
more complex and futuristic treatments. The exact process of siRNA silencing and down regulation is unknown. Some 
hypotheses of how it may work are discussed giving precedence to the most widely accepted hypothesis. Although siRNA 
treatments are not yet used on a major scale for many diseases, different possible treatment options are compared and 
explained. Particular care was taken to give a broad range of illnesses in order to show the vast possibilities of siRNA 
therapy. The common problems and some methods to overcome them are arranged in an orderly manner starting from 
the time the siRNA treatment is administered, through its delivery and subsequent potency, followed finally by its degrada-
tion. SiRNAs viability as a treatment is then analyzed primarily on its large interest in many fields, as well as the enormous 
progress it has made since its discovery just a short while ago.
Viability of SiRNA as a Clinical Treatment
Zev Blumenkranz
Zev will graduate in June 2015 with a B.S. degree in Biology.
102
Zev Blumenkranz
of the cancer drug and other chemotherapies, it was deemed 
more efficient and aggressive. This is a truly great step forward 
in finding a new cure with this rarely used method of treatment. 
(Shah, et al, 2013).
SiRNAs use as a treatment for HIV is also being considered. “HIV-
1 gene expression, during productive and chronic infection, is es-
sentially dependent upon the early regulatory genes tat and rav.” 
(Caputo, et al, 1997) If a method to stop these regulatory genes 
from being expressed can be found it can be used to virtually 
control HIV. Although there have been many improvements in 
controlling and preventing new outbreaks of HIV and the associ-
ated life altering conditions, HIV is still a still prolific disease(Cen-
ters for Disease Control, 2013) .
Working on this premise, researches created a siRNA delivery 
method that is specific to the HIV strain they were interested in 
controlling. The siRNA was manufactured to be specific to the 
genes that coded for tat and rav. In stopping the expression of 
these genes that are crucial for the viability of HIV-1 they were in 
essence stopping the disease. Through methods including quan-
titative real time pcr, they were able to confirm that the genes 
associated with  rav and tat were significantly down regulated 
(Zhou, et al, 2008).  
The extensive range of treatments that can be possible with a 
treatment involving siRNA doesn’t just apply to cases of cancer 
and the HIV virus. It is being evaluated for its potential as a meth-
od of treating conditions involving an increased level of low den-
sity lipoprotein (LDL) cholesterol. “In individuals with 5-year risk 
of major vascular events lower than 10%, each 1 mmol/L reduc-
tion in LDL cholesterol produced an absolute reduction in major 
vascular events of about 11 per 1000 over 5 years” (Cholesterol 
Treatment Trialists’ (CTT) Collaborators. 2012).  A reduction in 
ones LDL levels, specifically in the  amount found in one’s blood 
stream, has proven to reduce the risk of cardiovascular disease 
(Manninen, et al, 1992), and might be a factor in lowering the risk 
of those who have had a stroke previously from having another 
(Sacco, et al, 2006) .
SiRNA can be used indirectly as a way to lower LDL cholesterol 
levels. “ A novel therapeutic approach to lower LDL-c that is cur-
rently in clinical development involves blocking VLDL assembly 
and secretion by inhibiting the microsomal triglyceride transfer 
protein (Mtp)” (Tep, et al, 2012). By using siRNA to inhibit trans-
lation of the gene responsible for Mtp, they were able to reduce 
the levels of LDL cholesterol found in the blood stream. This is 
especially useful for those who don’t react well to the current 
protocol set to reduce LDL levels by prescribing statins.
The broad range of application in a clinical sense for the use of 
siRNAs is apparent from the few studies mentioned. There are 
many other applications that can be utilized, but those mentioned 
here show how broad its ability as a drug can be. Most of these 
studies however, are very theoretical. There are many hurdles 
that must be overcome before being able to use it as a treatment. 
The main hurdles being its delivery to a specific cell and stopping 
a specific protein without affecting others.      
Problems and Their Potential Answers
Delivery of SiRNA to cells has been a major problem for re-
searchers. There are quite a few reasons that it is difficult to 
deliver molecules of siRNA, or more specifically its precursor 
dsRNA, to cells. The first is its really short lifespan. Even if the 
dsRNA won’t degrade before reaching its desired location, the 
trouble of getting it into the cytoplasm of the cell is a hurdle in 
itself. However the biggest issue seems to be how to get these 
crucial siRNAs to a specific cell. Once in the correct cell, prob-
lems may still arise. SiRNA can be finicky at times and down 
regulate proteins that it wasn’t intended for. Basically the siRNA 
has major issues with its specificity on the cellular level as well 
as intercellular. 
“Unmodified, naked siRNAs are relatively unstable in blood 
and serum, as they are rapidly degraded by endo- and exonu-
cleases, meaning that they have short half-lives in vivo.” (Akhtar, 
Benter, 2007). This limits the ability to administer siRNAs in their 
“naked” already modified form. However, chemically modifying 
the siRNAs seems to prevent their untimely degradation. Studies 
were done comparing siRNA in its naked, already modified form, 
to siRNA that was chemically modified either by way of caging, 
nanoparticles, or PEGylation. When this comparison was done 
under conditions that simulated living in the blood stream, the 
siRNA that had been modified showed a significant increase in 
life span. Chemically modifying siRNA seems to be the way to 
allow for the siRNA to survive its journey to the cell. (Shah, et 
al 2013) 
Surviving its journey to the cell is just the first of many hurdles 
for this important new treatment. The next  major stumbling 
block to overcome is how to get it to the cell of choice. Although 
siRNA is selective for specific proteins it can cause havoc in a cell 
it wasn’t intended for. For example, even if a cell doesn’t have the 
specific protein that this siRNA codes for it can cause unwant-
ed mRNA degradation due to off targeting (B. Scaggiante, et al, 
2011), a complication that will be discussed in a more general 
sense in the coming paragraphs. 
Some methods are being studied as ways to allow the delivery 
to be more specific. The use of aptamers has been relatively suc-
cessful in allowing the siRNA to reach specific cells, although it 
has its own unique set of issues (Liu, Gao, 2013). Another method 
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that has been used is connecting the siRNA enclosed in nanopar-
ticles to an existing delivery system. This has shown promising 
results especially when the intended drug is also used (Shah, et al, 
2013). Other methods are showing promising results as well. This 
leads to the next problem of the siRNA being delivered across 
the cell membrane.
SiRNA can be especially difficult to deliver through the cell mem-
brane due to its charge. The cell membrane has an affinity to 
the siRNAs inherent charge causing it to be repelled. There are 
several methods being studied to find the most efficient way of 
allowing molecules of siRNA to penetrate the cell membrane. 
The first is the physical or mechanical method. Using electropo-
ration or ultrasound, for example, to allow for cellular uptake. 
Another method being looked at is the use of chemicals either 
to neutralize the negative charge of siRNA or deliver it through 
other methods. (Zhou, et al, 2008)
With passage of siRNA through the cell now possible, off tar-
geting, the last issue of delivery needs to be resolved. Although 
siRNA is coded uniquely to suppress the desired protein, it isn’t 
always so specific. If a similar protein is also produced in the cell 
that the siRNA is delivered to, it can occasionally down regulate 
that protein as well. A specific protein is one that has a similar 
genetic code even though it can serve a very different and some-
times crucial role in the viability of the specified cell.
A few methods have been used to negate this off target silencing. 
The methods mainly use modifications to the siRNA or dsRNA 
starting material. By modifying the backbone of the strand, im-
proved specificity was able to be reached. Although useful the 
modifications tend to make the siRNA less efficient against the 
target mRNA as well. There is one particularly successful option 
that doesn’t affect the down regulation of the target mRNA as 
much as many of the previous methods tried. This process re-
quires adding a one nucleotide bulge on the antisense strand spe-
cifically at the second positon. The modified siRNA was found to 
be more specific to the intended mRNA producing less mistaken 
down regulation while still properly down regulating its intended 
target. ( Dua, et al, 2011)
With its intended target found, the siRNA can now efficiently 
down regulate it. However, the stable dsRNA that the RISC now 
unwound to use as a mRNA inhibitor, is no longer as stable. 
Due to its less stable state when joining the RISC, “Transfected 
synthetic siRNA works for only a few days in mammalian cells.” 
(Sioud 2004) While multiple treatments may reduce the issue of 
short term effectiveness, a better solution may be available. Using 
retroviral drugs the siRNA can be integrated into the genome 
more specifically as hairpin RNA. This is like the naturally oc-
curring non synthetic siRNA. Using siRNA the cell can regulate 
itself post transcriptionally. By integrating the codons to produce 
siRNA the time frame for siRNA longevity becomes indefinite. 
This is not by it increasing in stability rather it allows for a con-
stant dose without further intervention. (Stewart, et al, 2003) 
Conclusion
The concept of using siRNA as a treatment for humans is one 
that excites and can open many previously unavailable options 
to those suffering many debilitating diseases. It is so promising 
that any stumbling block that has arisen along the way hasn’t 
deterred researchers from their final goal of using siRNA in the 
clinical setting. They have attacked it from every angle and found 
solutions for many problems and ideas for others. The main issue 
of delivery primarily affects reaching specific cells or tissues with 
specificity. There are clinical trials mainly focused on using siRNA 
as a topical treatment. Although this method of treatment has 
been proven successful, by eliminating many of the issues associ-
ated with delivery, it only works on areas that are able to react 
to topical treatments. Topical siRNA treatments have seen much 
progress and continue to pass multiple phases of their testing; 
some have even been approved for clinical use. These treatments 
bypass many of the issues discussed, and show the ability of 
siRNA as a potential treatment for other diseases that need a 
more complex delivery system. 
The extensive opportunities for siRNA use are driving many to 
discover new and improved methods. The way in which siRNA 
has turned from a discovery into clinical trials in a mere fifteen 
years attests to its great potential and likely future as a viable 
treatment. There are many areas that are still unclear especially 
regarding the methods in which siRNA works. With more discov-
ery and new technology the methods of delivery and treatments 
will likely improve and start the important work siRNA was in-
tended for.
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